<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0009.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0011.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h61" class="calibre7"></a><a id="page_5-1" class="calibre7"></a><a href="part0002.html#rh69" class="calibre7">ANEMIA</a></h2>
<p class="cst">↓ <i class="calibre3">in RBC mass: Hct</i> &lt;<i class="calibre3">41% or Hb</i> &lt;<i class="calibre3">13.5 g/dL (men); Hct</i> &lt;<i class="calibre3">36% or Hb</i> &lt;<i class="calibre3">12 g/dL (women)</i></p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Symptoms: ↓ O<sub class="calibre8">2</sub> delivery → fatigue, exertional dyspnea, angina (if CAD)</p>
<p class="bl"><span class="sbl">•</span> Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension</p>
<p class="bl"><span class="sbl">•</span> Other findings: <b class="calibre4">jaundice</b> (hemolysis), <b class="calibre4">splenomegaly</b> (thalassemia, neoplasm, chronic</p>
<p class="bl1">hemolysis), <b class="calibre4">petechiae/purpura</b> (bleeding disorder), <b class="calibre4">glossitis</b> (iron, folate, vitamin B<sub class="calibre8">12</sub></p>
<p class="bl1">defic.), <b class="calibre4">koilonychia</b> (iron defic.), <b class="calibre4">neurologic abnormalities</b> (B<sub class="calibre8">12</sub> defic.)</p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including <b class="calibre4">pica</b>), FHx</p>
<p class="bl"><span class="sbl">•</span> CBC w/ diff.; RBC params incl. retics, MCV (nb, mixed disorder can → nl MCV), RDW</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Reticulocyte index</b> (RI) = [reticulocyte count × (Pt’s Hct/nl Hct)]/maturation factor</p>
<p class="bl1">maturation factors for a given Hct: 45% = 1, 35% = 1.5, 25% = 2, 20% = 2.5</p>
<p class="bl1">RI &gt;2% → adequate marrow response; RI &lt;2% → hypoproliferation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peripheral smear:</b> select area where roughly ⅓ RBCs touch each other; ✔ RBC size, shape, inclusions (see “Appendix” &amp; “Peripheral Smear”), WBC morphology, plt count</p>
<p class="bl"><span class="sbl">•</span> Additional labs as indicated: hemolysis labs (if RI &gt;2%, see below), iron/TIBC, ferritin, folate, B<sub class="calibre8">12</sub>, LFTs, BUN &amp; Cr, TFTs, Hb electrophoresis, enzyme/gene mutation screens</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bone marrow (BM) aspirate and biopsy (bx)</b> with cytogenetics as indicated</p>
<p class="capf"><b class="calibre4">Figure 5-1</b> Approach to anemia and common causes</p>
<p class="image"><img src="../images/00080.jpeg" alt="" class="calibre2"/></p>
<p class="h">M<small class="calibre30">ICROCYTIC</small> A<small class="calibre30">NEMIAS</small></p>
<p class="capf"><b class="calibre4">Figure 5-2</b> Approach to microcytic anemias <span class="tfont1">(<i class="calibre3">NEJM</i> 2014;371:1324)</span></p>
<p class="image1"><img src="../images/00081.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Iron deficiency <span class="s">(<i class="calibre3">NEJM</i> 2015;372:1832; <i class="calibre3">Lancet</i> 2016;387:907)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ marrow iron &amp; depleted body iron stores → ↓ heme synthesis → microcytosis → anemia</p>
<p class="bl"><span class="sbl">•</span> Special clinical manifestations: angular cheilosis, atrophic glossitis, pica (consumption of nonnutritive substances such as ice, clay), koilonychia (nail spooning)</p>
<p class="bl1">Plummer-Vinson syndrome (iron deficiency anemia, esophageal web &amp; atrophic glossitis)</p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">chronic bleeding</b> (GI—incl. cancer, menstrual, parasites, NSAIDs, etc.), ↓ <b class="calibre4">supply</b> (malnutrition; ↓ absorp. due to celiac sprue, Crohn’s, ↑ gastric pH, subtotal gastrectomy), ↑ <b class="calibre4">demand</b> (preg; <i class="calibre3">Blood</i> 2017;129:940). Iron-refractory iron-defic. anemia (IRIDA; rare genetic disorder due to hepcidin dysregulation; <i class="calibre3">Nat Genet</i> 2008;40:569).</p>
<p class="bl"><span class="sbl">•</span> Diagnosis (eval ideally before Rx): ↓ <b class="calibre4">Fe</b>, ↑ <b class="calibre4">TIBC</b>, ↓ <b class="calibre4">ferritin</b> (esp. &lt;15), ↓ <b class="calibre4">transferrin sat</b> (Fe/TIBC; esp. &lt;15%), ↑ soluble transferrin receptor; ↑ plt. Unless hx c/w other etiology, <i class="calibre3">initiate workup for GIB</i>, incl. <i class="calibre3">H. pylori</i> serology. ? Celiac labs (<b class="calibre4">anti-TTG</b>, antigliadin, anti-endomysial Abs). Cytogenetics &amp; molecular testing as indicated.</p>
<p class="bl"><span class="sbl">•</span> Treatment: oral Fe tid (~6 wks to correct anemia; ~6 mo to replete Fe stores; nb, oral Fe does not give ⊕ Hemoccult). In excessive/persistent GI losses or dialysis, cancer, CHF, or prior to Epo Rx, <i class="calibre3">IV iron</i> (Fe-sucrose, -gluconate, -dextran) should be considered.</p>
<p class="h2a"><a id="page_5-2" class="calibre1"></a>Thalassemias <span class="s">(<i class="calibre3">Lancet</i> 2018;391:155)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ synthesis of α- or β-globin chains of Hb → <b class="calibre4">≠</b> subunits → destruction of RBCs and erythroid precursors; ∴ anemia from hemolysis <i class="calibre3">and</i> ineffective erythropoiesis</p>
<p class="bl"><span class="sbl">•</span> α<b class="calibre4">-thalassemia</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2014;371:1908)</span>: deletions in α-globin gene complex (nl 4 α genes), seen w/ Southeast Asian, Mediterranean, African, Middle East ancestry</p>
<p class="bl1">3 α → α-thal-2 trait = silent carrier; 2 α → α-thal-1 trait or α-thal minor = mild anemia</p>
<p class="bl1">1 α → HbH (β<sub class="calibre8">4</sub>) disease = severe anemia, hemolysis, and splenomegaly</p>
<p class="bl1">0 α genes → Hb Barts (γ<sub class="calibre8">4</sub>) = intrauterine hypoxia and hydrops fetalis</p>
<p class="bl"><span class="sbl">•</span> β<b class="calibre4">-thalassemia:</b> mutations in β-globin gene → absent or ↓ gene product seen w/ Mediterranean (espec. Greek or Italian), African, or Asian ancestry</p>
<p class="bl1">1 mutated β gene → thal minor (or trait) = mild anemia (no transfusions)</p>
<p class="bl1">2 mutated β genes → thal intermedia (occasional transfusions) or thal major (= Cooley’s anemia; transfusion dependent) depending on severity of mutations</p>
<p class="bl"><span class="sbl">•</span> Special clinical manifestations: chipmunk facies, pathologic fractures, hepatosplenomegaly (due to extramedullary hematopoiesis), high-output CHF, bilirubin gallstones, Fe overload</p>
<p class="bl"><span class="sbl">•</span> Dx: MCV &lt;70, <b class="calibre4">normal Fe, ferritin</b>, <b class="calibre4">MCV</b>/<b class="calibre4">RBC count</b> &lt;<b class="calibre4">13</b> [Mentzer Index, 60% Se, 98% Sp; <span class="s1r">(<i class="calibre3">Ann Hem</i> 2007;86:486)</span>], ± ↑ retics, basophilic stippling; <b class="calibre4">Hb electrophoresis:</b> ↑ HbA<sub class="calibre8">2</sub> (α<sub class="calibre8">2</sub>δ<sub class="calibre8">2</sub>) in β-thal; <i class="calibre3">normal</i> pattern in α-thal trait, ∴ PCR or supravital stain for dx</p>
<p class="bl"><span class="sbl">•</span> Treatment: folate; transfusions + Fe chelator [either deferoxamine (IV) or deferasirox (PO)]; ? splenectomy if ≥50% ↑ in transfusions; consider allo-HSCT in children w/ severe β-thal; gene therapy in development <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:1479)</span></p>
<p class="h2a">Anemia of chronic inflammation <span class="s">(see below)</span></p>
<p class="h2a">Sideroblastic anemia</p>
<p class="bl"><span class="sbl">•</span> Defective heme biosynthesis within RBC precursors</p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">hereditary/X-linked</b> <span class="s1r">(<i class="calibre3">ALAS2</i> mutations)</span>, <b class="calibre4">idiopathic</b>, <b class="calibre4">MDS-RARS</b>, <b class="calibre4">reversible</b> (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia)</p>
<p class="bl"><span class="sbl">•</span> Special clinical manifestations: hepatosplenomegaly, iron overload syndromes</p>
<p class="bl"><span class="sbl">•</span> Dx: social, work &amp; TB hx; can be micro-, normo-, or macrocytic; variable populations of hypochromic RBCs; ↑ Fe, nl TIBC, ↑ ferritin, basophilic stippling, RBC <b class="calibre4">Pappenheimer bodies</b> (Fe-containing inclusions), <b class="calibre4">ring sideroblasts</b> (w/ iron-laden mitochondria) in BM</p>
<p class="bl"><span class="sbl">•</span> Treatment: treat reversible causes; trial of pyridoxine, supportive transfusions for severe anemia with chelation therapy; high-dose pyridoxine for some hereditary cases</p>
<p class="h">N<small class="calibre30">ORMOCYTIC</small> A<small class="calibre30">NEMIAS</small></p>
<p class="h2a">Pancytopenia <span class="s">(see below)</span></p>
<p class="h2a">Anemia of chronic inflammation <span class="s">(ACI; <i class="calibre3">NEJM</i> 2012;366:4)</span></p>
<p class="bl"><span class="sbl">•</span> ↓ RBC production due to impaired iron utilization and functional iron deficiency from ↑ <b class="calibre4">hepcidin;</b> cytokines (IL-6, TNF-α) cause ↓ Epo responsiveness/production</p>
<p class="bl"><span class="sbl">•</span> Etiologies: autoimmune disorders, chronic infection, inflammation, HIV, malignancy</p>
<p class="bl"><span class="sbl">•</span> Dx: ↓ <b class="calibre4">Fe</b>, ↓ <b class="calibre4">TIBC (usually normal or low transferrin sat)</b>, ± ↑ <b class="calibre4">ferritin;</b> usually normochromic, normocytic (~70% of cases) but can be microcytic if prolonged</p>
<p class="bl"><span class="sbl">•</span> Coexisting iron deficiency common. Dx clues include ↓ serum ferritin levels, absence of iron staining on BM bx, ⊕ response to a trial of oral iron and/or ↑ soluble transferrin receptor/ferritin index <span class="s1r">(<i class="calibre3">Am J Clin Pathol</i> 2012;138:642)</span>.</p>
<p class="bl"><span class="sbl">•</span> Treatment: treat underlying disease ± iron and/or erythropoiesis-stimulating agent (ESA; eg, Epo). Iron if ferritin &lt;100 or Fe/TIBC &lt;20%. Consider ESA if Epo &lt;500. Avoid ESA in cancer if treatment goal is cure <span class="s1r">(<i class="calibre3">Lancet</i> 2009;373:1532)</span>. Transfuse PRBCs only if symptomatic &amp; insufficient time to wait for response to Epo or underlying disease Rx.</p>
<p class="h2a">Anemias of other chronic disorders</p>
<p class="bl"><span class="sbl">•</span> Anemia of chronic kidney disease: ↓ Epo; treat w/ Epo (see “Chronic Kidney Disease”)</p>
<p class="bl"><span class="sbl">•</span> Endocrine deficiencies: hypometabolism and ↓ O<sub class="calibre8">2</sub> demand with thyroid, pituitary, adrenal, or parathyroid disease → ↓ Epo; can be normocytic or macrocytic</p>
<p class="h2a">Sideroblastic anemia <span class="s">(see above)</span></p>
<p class="h2a">Pure red cell aplasia</p>
<p class="bl"><span class="sbl">•</span> Destructive antibodies or lymphocytes → ineffective erythropoiesis</p>
<p class="bl"><span class="sbl">•</span> Associated with thymoma, CLL and parvovirus infection, autoimmunity, drugs</p>
<p class="bl"><span class="sbl">•</span> Diagnostic studies: <b class="calibre4">lack of erythroid precursors on BM bx</b>, other lines normal</p>
<p class="bl"><span class="sbl">•</span> Treatment: thymectomy if thymus enlarged; IVIg if parvovirus and immunosuppressed <span class="s1r">(<i class="calibre3">Clin Infect Dis</i> 2013;56:968)</span>; immuno-suppression/chemoRx if CLL or idiopathic; supportive care w/ PRBC transfusions; ? erythropoietin receptor agonist if due to antierythropoietin Ab <span class="s1r">(<i class="calibre3">NEJM</i> 2009;361:1848)</span> consider hematopoietic cell transplantation.</p>
<p class="h"><a id="page_5-3" class="calibre7"></a>M<small class="calibre30">ACROCYTIC</small> A<small class="calibre30">NEMIAS</small></p>
<p class="cst"><i class="calibre3">includes megaloblastic and nonmegaloblastic causes</i></p>
<p class="h2a">Megaloblastic anemia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Impaired DNA synthesis</b> → cytoplasm matures faster than nucleus → ineffective erythropoiesis and macrocytosis; due to <b class="calibre4">folate</b> or <b class="calibre4">B<sub class="calibre8">1</sub></b><sub class="calibre8"><b class="calibre4">2</b></sub> <b class="calibre4">deficiency;</b> also in <b class="calibre4">MDS</b></p>
<p class="bl"><span class="sbl">•</span> ✔ <b class="calibre4">folate</b> and <b class="calibre4">vitamin B<sub class="calibre8">12</sub>;</b> ↑ LDH &amp; indirect bilirubin (due to ineffective erythropoiesis)</p>
<p class="bl"><span class="sbl">•</span> Smear: <b class="calibre4">neutrophil hypersegmentation</b>, <b class="calibre4">macro-ovalocytes</b>, anisocytosis, poikilocytosis</p>
<p class="h2a">Folate deficiency</p>
<p class="bl"><span class="sbl">•</span> Folate present in leafy green vegetables and fruit; total body stores sufficient for <b class="calibre4">2–3 mo</b></p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">malnutrition</b> (alcoholics, anorectics, elderly), ↓ absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim; <i class="calibre3">NEJM</i> 2015;373:1649), ↑ requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: ↓ folate; ↓ RBC folate, ↑ homocyst. but nl methylmalonic acid (unlike B<sub class="calibre8">12</sub> defic.)</p>
<p class="bl"><span class="sbl">•</span> Treatment: folate 1–5 mg PO qd for 1–4 mo or until complete hematologic recovery; <i class="calibre3">critical to r</i>/<i class="calibre3">o B</i><sub class="calibre8">12</sub> <i class="calibre3">deficiency first (see below)</i></p>
<p class="h2a">Vitamin B<sub class="calibre8">12</sub> deficiency <span class="s">(<i class="calibre3">NEJM</i> 2013;368:149)</span></p>
<p class="bl"><span class="sbl">•</span> B<sub class="calibre8">12</sub> present only in foods of animal origin; total body stores sufficient for <b class="calibre4">2–3 y</b></p>
<p class="bl"><span class="sbl">•</span> Binds to <b class="calibre4">intrinsic factor</b> (IF) secreted by gastric parietal cells; absorbed in terminal ileum</p>
<p class="bl"><span class="sbl">•</span> Etiologies: malnutrition (alcoholics, vegans), <b class="calibre4">pernicious anemia</b> (PA, autoimmune disease against gastric parietal cells, a/w polyglandular endocrine insufficiency and ↑ risk of gastric carcinoma), other causes of ↓ absorption (gastrectomy, sprue, Crohn’s disease), ↑ competition (intestinal bacterial overgrowth, fish tapeworm)</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: <b class="calibre4">neurologic</b> changes (<b class="calibre4">subacute combined degeneration</b>) affecting peripheral nerves, posterior and lateral columns of the spinal cord and cortex → numbness, paresthesias, ↓ vibratory and positional sense, ataxia, dementia</p>
<p class="bl"><span class="sbl">•</span> Dx: ↓ B<sub class="calibre8">12</sub>; ↑ homocysteine and methylmalonic acid; anti-IF Ab; Schilling test; ↑ gastrin in PA</p>
<p class="bl"><span class="sbl">•</span> Treatment: 1 mg B<sub class="calibre8">12</sub> IM qd × 7 d → q wk × 4–8 wk → q month for life</p>
<p class="bl1">neurologic abnormalities are reversible if treated w/in 6 mo</p>
<p class="bl1">folate can reverse <i class="calibre3">hematologic</i> abnormalities of B<sub class="calibre8">12</sub> deficiency but not <i class="calibre3">neurologic</i> changes (and can lead to “steal” of B<sub class="calibre8">12</sub> stores → worsening of neuro complications)</p>
<p class="bl1">oral supplementation (2 mg qd) appears feasible as well <span class="s1r">(<i class="calibre3">Cochrane Rev</i> CD004655)</span> even w/o IF</p>
<p class="h2a">Nonmegaloblastic macrocytic anemias</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Liver disease:</b> often macrocytic, may see target cells, or spur cell anemia w/ hemolysis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Alcoholism:</b> BM suppression &amp; macrocytosis independent of folate/B<sub class="calibre8">12</sub> defic. or cirrhosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Reticulocytosis</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Other causes:</b> hypothyroidism; MDS; meds that impair DNA synthesis (zidovudine, 5-FU, hydroxyurea, Ara-C); hereditary orotic aciduria; Lesch-Nyhan syndrome</p>
<p class="h">P<small class="calibre30">ANCYTOPENIA</small></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> Hypocellular bone marrow (nl cellularity ~100 – age): <b class="calibre4">aplastic anemia</b>, hypoplastic MDS</p>
<p class="bl"><span class="sbl">•</span> Cellular bone marrow: <b class="calibre4">MDS</b>, aleukemic leukemia, PNH, severe megaloblastic anemia</p>
<p class="bl"><span class="sbl">•</span> Marrow replacement (myelophthisis): <b class="calibre4">myelofibrosis</b>, metastatic solid tumors, granulomas</p>
<p class="bl"><span class="sbl">•</span> Systemic diseases: hypersplenism, sepsis, alcohol, toxins</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Anemia → fatigue</p>
<p class="bl"><span class="sbl">•</span> Neutropenia → recurrent infections</p>
<p class="bl"><span class="sbl">•</span> Thrombocytopenia → mucosal bleeding &amp; easy bruisability</p>
<p class="h2a">Aplastic anemia = stem cell failure <span class="s">(<i class="calibre3">NEJM</i> 2015;373:35)</span></p>
<p class="bl"><span class="sbl">•</span> Epidemiology: 2–5 cases/10<sup class="calibre15">6</sup>/y; biphasic (major peak in adolescents, 2<sup class="calibre15">nd</sup> peak in elderly)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: pancytopenia w/ ↓ retics, BM bx w/ cytogenetics showing hypocellularity</p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">idiopathic</b> (<sup class="calibre15">1</sup>/<sub class="calibre8">2</sub> – <sup class="calibre15">2</sup>/<sub class="calibre8">3</sub> of cases)</p>
<p class="bl1"><b class="calibre4">Stem cell destruction: radiation</b>, <b class="calibre4">chemotherapy</b>, <b class="calibre4">chemicals</b> (eg, benzene)</p>
<p class="bl1">Idiosyncratic <b class="calibre4">med rxn</b> (eg, chloramphenicol, NSAIDs, sulfa drugs, gold, carbamazepine, antithyroid)</p>
<p class="bl1"><b class="calibre4">Viruses</b> (HHV-6, HIV, EBV, parvovirus B19); <b class="calibre4">post-viral hepatic failure</b> (not Hep A/B/C)</p>
<p class="bl1"><b class="calibre4">Immune disorders</b> (SLE, GVHD post-HSCT, thymoma)</p>
<p class="bl1">PNH (see below); Fanconi’s anemia (congenital disorder w/ pancytopenia, macrocytic anemia, ↑ risk of MDS, AML, &amp; SCC of head &amp; neck, and multiple physical anomalies)</p>
<p class="bl1">Shortened telomeres: seen w/ telomerase (<i class="calibre3">TERT, TERC</i>) mut. (10% of aplastic anemia), dyskeratosis congenita/DKC1 mut; a/w IPF, cirrhosis <span class="s1r">(<i class="calibre3">NEJM</i> 2009;361:2353)</span></p>
<p class="bl1">Somatic mutations: PNH clones in ~50% of aplastic anemia <span class="s1r">(<i class="calibre3">Haematologica</i> 2010;95:1075)</span></p>
<p class="bl"><a id="page_5-4" class="calibre1"></a><span class="sbl">•</span> Treatment and prognosis</p>
<p class="bl1"><b class="calibre4">Allogeneic HSCT:</b> for <i class="calibre3">young</i> Pts → ~80% long-term survival and significantly ↓ risk of malignant evolution, but has risk of transplant-related morbidity &amp; mortality; if possible, avoid transfusions (and alloimmunization) pretransplant</p>
<p class="bl1"><b class="calibre4">Immunosuppression</b> (CsA/tacrolimus, ATG): 70–80% respond, with 80–90% 5-y survival in responders (96% vs. 76% w/ horse vs. rabbit ATG; <i class="calibre3">NEJM</i> 2011;365:430); 15–20% 10-y incidence of clonal disorders (mostly MDS, AML, PNH)</p>
<p class="bl1"><b class="calibre4">TPO mimetics</b> (eg, eltrombopag) use 1<sup class="calibre15">st</sup>-line w/ immunosuppression <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:1540)</span></p>
<p class="bl1"><b class="calibre4">Supportive care:</b> transfusions, abx, possible utility of G-CSF &amp; Epo (if Epo &lt;500)</p>
<p class="h2a">Myelodysplastic syndromes (MDS) <span class="s">(qv)</span></p>
<p class="h2a">Paroxysmal nocturnal hemoglobinuria (PNH) <span class="s">(<i class="calibre3">Blood</i> 2009;113:6522)</span></p>
<p class="bl"><span class="sbl">•</span> Acquired clonal stem cell disorder = inactivating somatic mutation of <i class="calibre3">PIG-A</i> gene → deficiency of GPI-anchor for CD55 &amp; CD59 (inhib of complement) → complement-mediated RBC lysis, plt aggreg., &amp; hypercoagulability</p>
<p class="bl"><span class="sbl">•</span> Clinical: intravascular <b class="calibre4">hemolytic anemia</b>, <b class="calibre4">hypercoagulability</b> (venous &gt; arterial; esp. intraabdominal, cerebral), smooth muscle dystonias, <b class="calibre4">deficient hematopoiesis</b> (cytopenias); a/w aplastic anemia, MDS and evolution to AML</p>
<p class="bl"><span class="sbl">•</span> Dx: <b class="calibre4">flow cytometry</b> (↓ CD55 &amp; CD59) on RBCs and granulocytes; urine hemosiderosis</p>
<p class="bl"><span class="sbl">•</span> Treatment: supportive care (iron, folate, transfusions); consider anticoagulation</p>
<p class="bl1">allogeneic HSCT for hypoplasia or severe thrombosis</p>
<p class="bl1">eculizumab (Ab inactivates terminal complement C5s): ↓ hemolysis, improves QoL &amp; stabilizes Hb levels <span class="s1r">(<i class="calibre3">NEJM</i> 2004;350:552 &amp; 2006;355:1233; <i class="calibre3">Lancet</i> 2009;373:759)</span>; effective in pregnancy <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:1032)</span>; must have meningococcal vaccination</p>
<p class="h2a">Myelophthisic anemia <span class="s">(see also “Primary Myelofibrosis”)</span></p>
<p class="bl"><span class="sbl">•</span> Infiltration of bone marrow by cancer, leukemia, infection, fibrosis (primary myelofi- brosis), granulomas, lysosomal storage disorders</p>
<p class="h">H<small class="calibre30">EMOLYTIC</small> A<small class="calibre30">NEMIAS</small></p>
<p class="image1"><img src="../images/00082.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> ↑ reticulocyte count (RI &gt;2%), ↑ LDH, ↓ haptoglobin (83% Se, 96% Sp), ↑ indirect bili</p>
<p class="bl"><span class="sbl">•</span> Autoimmune hemolysis: Coombs’ test = direct antiglobulin test (DAT) → ⊕ if agglutination occurs when antisera against Ig or C3 are applied to patient RBCs</p>
<p class="bl"><span class="sbl">•</span> Intravascular: ↑↑ LDH, ↓↓ haptoglobin; hemoglobinemia, hemoglobinuria, hemosiderinuria</p>
<p class="bl"><span class="sbl">•</span> Extravascular: splenomegaly</p>
<p class="bl"><span class="sbl">•</span> Family h/o anemia; personal or family h/o cholelithiasis</p>
<p class="h2a">Glucose-6-phosphate dehydrogenase (G6PD) deficiency <span class="s">(<i class="calibre3">Lancet</i> 2008;371:64)</span></p>
<p class="bl"><span class="sbl">•</span> X-linked defect of metabolism <span class="s1r">(<i class="calibre3">G6PD</i> mutations)</span> w/ ↑ susceptibility to oxidative damage</p>
<p class="bl"><span class="sbl">•</span> Most common in ♂ of African or Mediterranean descent (malaria-endemic areas)</p>
<p class="bl"><span class="sbl">•</span> Hemolysis precipitated by <b class="calibre4">drugs</b> (sulfonamides, dapsone, nitrofurantoin, rasburicase, primaquine, doxorubicin, methylene blue), <b class="calibre4">infxn</b>, <b class="calibre4">DKA</b>, <b class="calibre4">foods</b> (favism, <i class="calibre3">NEJM</i> 2018;378:60)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: smear may show RBC <b class="calibre4">Heinz bodies</b> (oxidized Hb) that result in <b class="calibre4">bite cells</b> once removed by spleen; ↓ G6PD levels <span class="s1r">(<i class="calibre3">may be normal after acute hemolysis</i> because older RBCs have already lysed and young RBCs may still have near-normal levels)</span></p>
<p class="h2a">Sickle cell anemia <span class="s">(<i class="calibre3">NEJM</i> 2017;376:1561 &amp; <i class="calibre3">Lancet</i> 2017;390:311)</span></p>
<p class="bl"><span class="sbl">•</span> Recessive β-globin mutation → structurally abnl hemoglobin (HbS). ~8% African Americans heterozygotes (“sickle trait”; usually w/o sx); ~1/400 homozygotes (sickle cell disease).</p>
<p class="bl"><span class="sbl">•</span> ↓ O<sub class="calibre8">2</sub> → HbS polymerizes → RBC sickles, ↓ RBC deformability → <b class="calibre4">hemolysis</b> &amp; <b class="calibre4">microvascular occlusion</b> due to endothelial activ. &amp; PMN adhesion <span class="s1r">(<i class="calibre3">Blood</i> 2013;122:3892)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anemia:</b> chronic hemolysis ± acute aplastic (parvo. B19) or splenic sequestration crises</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vaso-occlusion &amp; infarction:</b> acute chest syndrome &amp; stroke (high mortality), pulmonary HTN, painful crises, splenic sequestration, renal papillary necrosis, aseptic necrosis, dactylitis (hand-foot syndrome), priapism</p>
<p class="bl"><a id="page_5-5" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Infection:</b> splenic infarction → overwhelming infection by <b class="calibre4">encapsulated organisms;</b> infarcted bone → <b class="calibre4">osteomyelitis</b> (<i class="calibre3">Salmonella</i>, <i class="calibre3">Staph. aureus</i>), can be life threatening</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: sickle-shaped RBCs and Howell-Jolly bodies on smear; Hb electrophoresis</p>
<p class="bl"><span class="sbl">•</span> Treatment: hydroxyurea, folic acid; ? <small class="calibre40">L</small>-glutamine to prevent pain crises <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:226)</span></p>
<p class="bl"><span class="sbl">•</span> Vaccines: pneumo, meningo, H flu, HBV</p>
<p class="bl"><span class="sbl">•</span> Voxelotor (Hbs polymerization inhib) ↑ hemolysis to ↑ Hb <span class="s1r">(<i class="calibre3">NEJM</i> 2019;epub)</span></p>
<p class="bl"><span class="sbl">•</span> Pain &amp; vaso-occlusive crises: analgesia (consider PCA), IVF, transfusion if sx &amp; Hgb &lt; baseline; crizanlizumab (anti-P-selectin; <i class="calibre3">NEJM</i> 2017;376:429)</p>
<p class="bl"><span class="sbl">•</span> Acute chest: O<sub class="calibre8">2</sub>, abx, IVF, exchange transfusion</p>
<p class="bl"><span class="sbl">•</span> TIA/stroke: often exchange transfusion (goal Hgb 10) ± thrombolytics</p>
<p class="bl"><span class="sbl">•</span> Gene therapy in development <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:848)</span></p>
<p class="h2a">Hereditary spherocytosis (HS) <span class="s">(<i class="calibre3">Lancet</i> 2008;372:1411)</span></p>
<p class="bl"><span class="sbl">•</span> Defect in a cytoskeletal protein of RBC membrane → membrane loss mutations in ankyrin, α- and β-spectrin, band 3, and pallidin have been identified</p>
<p class="bl"><span class="sbl">•</span> Most common in N. European populations (1/5000 births); ⊕ FHx (75% of Pts)</p>
<p class="bl"><span class="sbl">•</span> Anemia, jaundice (mostly neonates), splenomegaly, pigmented gallstones</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: spherocytes on smear, ⊕ osmotic fragility test (~80% Se), ↓ eosin-5-maleimide (EMA) binding (93% Se; 99% Sp; <i class="calibre3">Haemat</i> 2012;97:516), acidified glycerol lysis test (Se 95%)</p>
<p class="bl"><span class="sbl">•</span> Treatment: folate, transfusions, splenectomy for moderate and severe HS (balance w/ ↑ risk of future thrombosis and infection; <i class="calibre3">J Thromb Haemost</i> 2008;6:1289)</p>
<p class="h2a">Paroxysmal nocturnal hemoglobinuria <span class="s">(see above)</span></p>
<p class="h2a">Autoimmune hemolytic anemia (AIHA)</p>
<p class="bl"><span class="sbl">•</span> Acquired, antibody-mediated RBC destruction</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Warm AIHA: IgG</b> Abs opsonize RBCs <i class="calibre3">at body temp</i> → removal by spleen</p>
<p class="bl1">Etiologies: idiopathic, lymphoproliferative (CLL, NHL), autoimmune (SLE), drugs, HIV, Babesiosis <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:939)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cold AIHA: IgM</b> Ab binds to RBCs <i class="calibre3">at temp</i> &lt;<i class="calibre3">37</i>°<i class="calibre3">C</i> → <b class="calibre4">complement fixation</b> → intravascular hemolysis and acrocyanosis on exposure to cold</p>
<p class="bl1">Etiologies: idiopathic, lymphoprolif. disorders (eg, Waldenström’s; monoclonal), <b class="calibre4"><i class="calibre3">Mycoplasma pneumoniae</i></b> infxn and infectious mononucleosis (polyclonal)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: spherocytes on smear, ⊕ <b class="calibre4">Coombs’;</b> ✔ cold agglutinin titer, splenomegaly</p>
<p class="bl"><span class="sbl">•</span> Treatment <span class="s1r">(<i class="calibre3">Blood</i> 2017;129:2971)</span>: treat underlying disease</p>
<p class="bl1"><b class="calibre4">Warm AIHA:</b> corticosteroids ± splenectomy, IVIg, cytotoxic agents, rituximab</p>
<p class="bl1"><b class="calibre4">Cold AIHA:</b> avoid cold; steroids ineffective; rituximab <span class="s1r">(<i class="calibre3">Blood</i> 2004;103:2925)</span></p>
<p class="h2a">Drug-induced hemolytic anemia</p>
<p class="bl"><span class="sbl">•</span> Acquired, Ab-mediated, RBC destruction precipitated by a med. Abx: ceph., sulfa drugs, rifampin, ribavirin. CV: methyldopa, procainamide, quinidine, thiazides. TCAs, phenothiazines, NSAIDs, sulfonylureas, MTX, 5-FU, rasburicase (G6PD defic.)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: Coombs’ usually negative, ↑ LDH; Treatment: discontinue offending agent</p>
<p class="h2a">Microangiopathic hemolytic anemia <span class="s">(<i class="calibre3">MAHA</i>; <i class="calibre3">NEJM</i> 2014;371:654)</span></p>
<p class="bl"><span class="sbl">•</span> Intra-arteriolar fibrin damages RBCs → acquired intravascular hemolysis</p>
<p class="bl"><span class="sbl">•</span> Etiologies: <b class="calibre4">hemolytic-uremic syndrome</b> (<b class="calibre4">HUS</b>), <b class="calibre4">thrombotic thrombocytopenic purpura</b> (<b class="calibre4">TTP</b>), <b class="calibre4">disseminated intravascular coagulation</b> (<b class="calibre4">DIC</b>), malignancy, malignant HTN, eclampsia/HELLP, mech. cardiac valves, infected vascular prostheses</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: <b class="calibre4">schistocytes</b> ± thrombocytopenia ± abnormalities a/w specific disorders (eg, ↑ PT in DIC, ↑ Cr in HUS, ↑ LFTs in HELLP)</p>
<p class="bl"><span class="sbl">•</span> Rx underlying dx; <b class="calibre4">urgent plasma exchange w/ TTP</b> (replace low ADAMTS13)</p>
<p class="h2a">Hypersplenism</p>
<p class="bl"><span class="sbl">•</span> Stasis/trapping in spleen → Mφ attack &amp; remodeling of RBC → spherocytosis → hemolysis</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Causes of Splenomegaly</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Etiology</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Comments<a id="st6" class="calibre1"></a><a href="part0010.html#sst6" class="calibre1">*</a></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">RES hyperplasia</p></td>
<td class="bg0-b"><p class="tab">Hemolytic anemia, sickle cell disease, <b class="calibre4">thalassemia major</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Immune hyperplasia</p></td>
<td class="bg0-b"><p class="tab">Infxn [HIV, EBV, CMV, TB, <b class="calibre4">malaria</b>, <b class="calibre4">kala azar</b> (“black water fever” from visceral leishmaniasis), <b class="calibre4"><i class="calibre3">Mycobacterium avium</i></b> complex], autoimmune disorders (SLE, RA w/ Felty’s syndrome), sarcoidosis, serum sickness</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Congestion</p></td>
<td class="bg0-b"><p class="tab">Cirrhosis, CHF, portal/splenic vein thrombosis, <b class="calibre4">schistosomiasis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Infiltration (nonmalignant)</p></td>
<td class="bg0-b"><p class="tab">Lysosomal storage disorders (<b class="calibre4">Gaucher’s</b>, Niemann-Pick), glycogen storage diseases, histiocytosis X, splenic cysts</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Neoplasm</p></td>
<td class="bg"><p class="tab"><b class="calibre4">MPN (CML</b>, <b class="calibre4">PMF</b>, <b class="calibre4">PV</b>, <b class="calibre4">ET)</b>, <b class="calibre4">CMML</b>, <b class="calibre4">leukemia</b>, <b class="calibre4">lymphoma (NHL</b>, <b class="calibre4">HL</b>, <b class="calibre4">hairy cell leukemia</b>, <b class="calibre4">CLL</b>, <b class="calibre4">PLL</b>, <b class="calibre4">WM)</b>, T-LGL, myeloma, amyloid</p></td>
</tr>
</table>
<p class="tsr">RES = reticuloendothelial system; <b class="calibre4"><a id="sst6" class="calibre1"></a><a href="part0010.html#st6" class="calibre1">*</a>boldface</b> = causes of massive splenomegaly.</p>
<h2 class="ct"><a id="h62" class="calibre7"></a><a id="page_5-6" class="calibre7"></a><a href="part0002.html#rh70" class="calibre7">DISORDERS OF HEMOSTASIS</a></h2>
<table class="t-topbot2">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre17"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Clinical Characteristics of Bleeding Disorders</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Feature</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Platelet/vascular Defect</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Coagulation Defect</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Site</p></td>
<td class="bg0-br"><p class="tab">Skin, mucous membranes</p></td>
<td class="bg0-b"><p class="tab">Deep in soft tissues (muscles, joints)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Lesions</p></td>
<td class="bg0-br"><p class="tab">Petechiae, ecchymoses</p></td>
<td class="bg0-b"><p class="tab">Hemarthroses, hematomas</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Bleeding</p></td>
<td class="bg0-r"><p class="tab">After minor cuts: yes</p>
<p class="tab">After surgery: immediate, mild</p></td>
<td class="bg"><p class="tab">After minor cuts: unusual</p>
<p class="tab">After surgery: delayed, severe</p></td>
</tr>
</table>
<p class="capf"><b class="calibre4">Figure 5-3</b> Approach to abnormal hemostasis <span class="tfont1">(<i class="calibre3">NEJM</i> 2014;370:847)</span></p>
<p class="image"><img src="../images/00083.jpeg" alt="" class="calibre2"/></p>
<p class="capf"><b class="calibre4">Figure 5-4</b> Coagulation cascade <span class="tfont1">(<i class="calibre3">NEJM</i> 2008;359:938)</span></p>
<p class="center"><img src="../images/00084.jpeg" alt="" class="calibre2"/></p>
<p class="fn">APC, activated protein C; AT, antithrombin; PrC, protein C; PrS, protein S; TF, tissue factor; TFPI, tissue factor pathway inhib.</p>
<p class="h2a">Purpura <span class="s">(</span><i class="calibre3">nonblanching</i> <span class="s">purple/red lesions due to extravasation of RBCs into dermis)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonpalpable</b> (macular; ≤3 mm in diameter = petechiae; &gt;3 mm = ecchymoses)</p>
<p class="bl1"><b class="calibre4">platelet disorder:</b> thrombocytopenia, defect in platelet fxn</p>
<p class="bl1"><b class="calibre4">thromboemboli:</b> DIC, TTP, cholesterol or fat emboli</p>
<p class="bl1">trauma or vascular fragility: amyloidosis, Ehlers-Danlos, scurvy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Palpable</b> (papular); <b class="calibre4">vasculitis:</b> leukocytoclastic, HSP, PAN, RMSF; <b class="calibre4">infectious emboli:</b> meningococcemia, bacterial endocarditis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">Purpura fulminans</i></b> (aka retiform purpura): <b class="calibre4">purpura</b> + <b class="calibre4">hypotension</b> + <b class="calibre4">DIC;</b> typically due to infxn/sepsis, protein C or S deficiency or APS (see section on DIC)</p>
<h2 class="ct"><a id="h63" class="calibre7"></a><a id="page_5-7" class="calibre7"></a><a href="part0002.html#rh71" class="calibre7">PLATELET DISORDERS</a></h2>
<p class="h">T<small class="calibre30">HROMBOCYTOPENIA</small> <span class="s1">(P<small class="calibre23">LT COUNT</small> &lt;150,000/µL)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Thrombocytopenia and Risk of Bleeding</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Platelet Count</b> (cells/µL)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Risk</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">50,000–100,000</p></td>
<td class="bg0-b"><p class="tab">Risk with major trauma; can proceed with general surgery</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">20,000–50,000</p></td>
<td class="bg0-b"><p class="tab">Risk with minor trauma or surgery</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">&lt;20,000</p></td>
<td class="bg0-b"><p class="tab">Risk of <i class="calibre3">spontaneous</i> bleeding (less so with ITP)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">&lt;10,000</p></td>
<td class="bg"><p class="tab">Risk of severe, life-threatening bleeding</p></td>
</tr>
</table>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> ↓ <b class="calibre4">production</b></p>
<p class="bl1"><b class="calibre4">Hypocellular bone marrow:</b> aplastic anemia (qv), rarely MDS, drugs (eg, thiazides, antibiotics, chemotherapy), alcohol, cirrhosis</p>
<p class="bl1"><b class="calibre4">Hypercellular bone marrow:</b> MDS, leukemia, severe megaloblastic anemia</p>
<p class="bl1"><b class="calibre4">Marrow replacement:</b> myelofibrosis, hematologic and solid malignancies, granulomas</p>
<p class="bl"><span class="sbl">•</span> ↑ <b class="calibre4">destruction</b></p>
<p class="bl1"><b class="calibre4">Immune-mediated</b> (distinguish primary from secondary; <i class="calibre3">Blood</i> 2009;113:2386) Primary (idiopathic): immune thrombocytopenic purpura (<b class="calibre4">ITP</b>, see below)</p>
<p class="bl2">Secondary: infxn (<b class="calibre4">HIV</b>, <b class="calibre4">HCV</b>, HSV), collagen vascular diseases (<b class="calibre4">SLE</b>), APS, lymphoproliferative (<b class="calibre4">CLL</b>, lymphoma), drugs (<i class="calibre3">many</i>, including <b class="calibre4">heparin</b>, abciximab, quinidine, sulfonamides, vancomycin), alloimmune (posttransfusion)</p>
<p class="bl1"><b class="calibre4">Non–immune-mediated: MAHA</b> (DIC, HUS, TTP), ticlopidine/clopidogrel, vasculitis, preeclampsia/HELLP, cardiopulm bypass, CVVH, IABP, cavernous hemangioma, viral</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abnormal distribution or pooling:</b> splenic sequestration, dilutional, hypothermia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Unknown:</b> ehrlichiosis/anaplasmosis, babesiosis, RMSF</p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> H&amp;P: meds, infxns, underlying conditions, splenomegaly, lymph nodes, <b class="calibre4">bleeding hx</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CBC with differential:</b> isolated thrombocytopenia <i class="calibre3">vs.</i> multilineage involvement</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peripheral smear</b> (r/o pseudothrombocytopenia due to platelet clumping)</p>
<p class="bl1">↑ destruction → look for large plts, <b class="calibre4">schistocytes</b> (see “Peripheral Smear” inserts)</p>
<p class="bl1">↓ production → rarely limited to platelets → look for <b class="calibre4">blasts</b>, hypersegmented PMNs, leukoerythroblastic Δs; can see inclusion bodies (anaplasma), parasites (<i class="calibre3">Babesia</i>)</p>
<p class="capf"><b class="calibre4">Figure 5-5</b> Approach to thrombocytopenia</p>
<p class="image"><img src="../images/00085.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><span class="sbl">•</span> Additional laboratory evaluations as indicated (eg, viral titers, flow cytometry, ANA, APLA)</p>
<p class="bl1">if anemia: ✔ reticulocyte count, LDH, haptoglobin, bilirubin to detect hemolysis</p>
<p class="bl1">if hemolytic anemia: ✔ PT, PTT, fibrinogen, D-dimer, Coombs, ANA</p>
<p class="bl1">BM bx for unexplained thrombocytopenia, esp. if associated with splenomegaly</p>
<p class="h2a">Primary immune thrombocytopenic purpura (ITP) <span class="s">(<i class="calibre3">Blood</i> 2010;115:168)</span></p>
<p class="bl"><span class="sbl">•</span> Isolated thrombocytopenia due to immune plt <i class="calibre3">destruction</i> (auto-Ab to plts) &amp; ↓ <i class="calibre3">production</i> (auto-Ab to megakaryocytes) without precipitant</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Diagnosis of exclusion (r/o 2</i><b class="calibre4">°</b> <i class="calibre3">ITP);</i> no robust clinical or lab parameters, but typically:</p>
<p class="bl1">CBC: isolated ↓ plt (&lt;100,000/µL); 10% have ITP + AIHA = Evans syndrome</p>
<p class="bl1">Peripheral smear: large platelets (not specific), r/o pseudothrombocytopenia</p>
<p class="bl1">BM bx: ↑ megakaryocytes, nl cellularity. Consider if other CBC or smear abnl or diagnostic uncertainty <span class="s1r">(<i class="calibre3">Blood</i> 2011;117:4910)</span>.</p>
<p class="bl1">✔ HBSAg &amp; anti-HBc prior to rituximab (and before IVIg, which could alter results)</p>
<p class="bl1">Clinical manifestations: insidious onset of mucocutaneous bleeding; ♀:♂ = 3:1</p>
<p class="bl"><span class="sbl">•</span> Treatment: rarely indicated if plt &gt;50,000/µL unless bleeding, trauma/surgery, anticoag.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre17"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><a id="page_5-8" class="calibre1"></a><p class="tabheadc"><b class="calibre4">Treatment of Primary ITP in Adults</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Approach</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Treatment</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Notes</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" rowspan="3"><p class="tab"><b class="calibre4">First-line or upfront therapy</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Steroids:</b> prednisone 0.5–2 mg/kg/d PO tapered ~4 wk, or dexamethasone 40 mg PO × 4 d</p></td>
<td class="bg0-b"><p class="tab">↓ Mφ FcR &amp; ↓ anti-plt Ab</p>
<p class="tab">70–90% have initial response</p>
<p class="tab">~20% sustained remission</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">IVIg</b> (1 g/kg/d IV × 2–3 d)</p>
<p class="tab"><i class="calibre3">Consider if need rapid</i> ↑ <i class="calibre3">in plt in 24</i>–<i class="calibre3">48 hrs; lasts 2</i>–<i class="calibre3">6 wks</i></p></td>
<td class="bg0-b"><p class="tab">Blocks Mφ FcR, ↓ anti-plt Ab</p>
<p class="tab">Interferes w/ Mφ uptake Ab-coated plts; 80% have initial response</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Anti-Rh(D) Ig: alternative to IVIg if RBC Rh(D) ⊕; 50–75 mcg/kg/d</p></td>
<td class="bg0-b"><p class="tab">Ab-coated RBCs overwhelm Mφ FcR</p>
<p class="tab">Avoid if h/o hemolysis; <i class="calibre3">not often used</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" rowspan="5"><p class="tab"><b class="calibre4">Second-line or maint. therapy</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Romiplostim</b> or <b class="calibre4">eltrombopag</b></p></td>
<td class="bg0-b"><p class="tab">TPO-R agonists → ↑ plt prod</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Rituximab</b> (anti-CD20) ± dex</p></td>
<td class="bg0-b"><p class="tab">anti–B-cell Ab</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Splenectomy</b> <i class="calibre3">(less common)</i></p></td>
<td class="bg0-b"><p class="tab">~65% long-term remission</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">AZA, CYC, MMF</p></td>
<td class="bg0-b"><p class="tab">Immunosuppressants</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Danazol: 600 mg/d</p></td>
<td class="bg0-b"><p class="tab">Androgen (hirsutism) ↓ plt clearance</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br" rowspan="2"><p class="tab"><b class="calibre4">Chronic/ refractory</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Romiplostim</b> or <b class="calibre4">eltrombopag</b></p></td>
<td class="bg0-b"><p class="tab">Allows splenectomy to be deferred</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Fostamatinib:</b> 75–150 mg BID</p></td>
<td class="bg0-b"><p class="tab">Spleen tyrosine kinase (SYK) inhibitor</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r" rowspan="4"><p class="tab"><b class="calibre4">Bleeding</b></p></td>
<td class="bg0-br"><p class="tab">Aminocaproic acid</p></td>
<td class="bg0-b"><p class="tab">Inhibits plasmin activation</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Methylprednisolone 1g/d IV × 3 d</p></td>
<td class="bg0-b"><p class="tab">See above</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">IVIg</p></td>
<td class="bg0-b"><p class="tab">See above</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Platelet transfusion</p></td>
<td class="bg"><p class="tab">Given w/ IVIg or anti-Rh(D)</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">Blood</i> 2017;129:2829 &amp; 130:3624; <i class="calibre3">Lancet Haem</i> 2016;3:e489; <i class="calibre3">Eur J Haem</i> 2018;100:304; <i class="calibre3">Immunother</i> 2018;10:9)</p>
<p class="h2a"><b class="calibre4">Secondary immune thrombocytopenic purpura (2° ITP)</b></p>
<p class="bl"><span class="sbl">•</span> Diagnosis: viral serologies (HIV, HCV, HBV, EBV), <i class="calibre3">H. pylori</i> Ab, ANA, pregnancy test, APLA, TSH, parvovirus, &amp; CMV PCR. <i class="calibre3">Anti-plt Ab tests not useful.</i></p>
<p class="bl"><span class="sbl">•</span> Treat underlying etiology</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre27"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Heparin-Induced Thrombocytopenias</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Chest</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">2;</span><span class="tfont">1</span><span class="tfont1">4</span><span class="tfont">1</span><span class="tfont1">:e495S;</span> <span class="tfont1"><i class="calibre3">NE</i></span><span class="tfont1"><i class="calibre3">JM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">5;373:252)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Feature</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Type I</b> (not clin. signif)</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Type II</b> (clinically significant HIT)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mechanism</b></p></td>
<td class="bg0-br"><p class="tab">Direct effect of heparin (non-immune)</p></td>
<td class="bg0-b"><p class="tab">Immune (Ab)-mediated</p>
<p class="tab">IgG against plt factor 4—heparin complex</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Incidence</b></p></td>
<td class="bg0-br"><p class="tab">10–20%</p></td>
<td class="bg0-b"><p class="tab">1–3% with UFH, 0–0.8% LMWH</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Onset</b></p></td>
<td class="bg0-br"><p class="tab">After 1–4 d of heparin therapy</p></td>
<td class="bg0-b"><p class="tab">After 4–10 d; but can occur in &lt;24 h if prior exposure w/in 100 d (persistent Ab). Postop highest risk. Can occur after heparin d/c.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Platelet nadir</b></p></td>
<td class="bg0-br"><p class="tab">&gt;100,000/µL</p></td>
<td class="bg0-b"><p class="tab">~60,000/µL, ↓ &gt;50%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Sequelae</b></p></td>
<td class="bg0-br"><p class="tab">None</p></td>
<td class="bg0-b"><p class="tab">Thrombotic events <b class="calibre4">(HITT)</b> in 30–50%</p>
<p class="tab">Rare hemorrhagic complications</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Management</b></p></td>
<td class="bg0-r"><p class="tab">Can continue heparin and observe</p></td>
<td class="bg"><p class="tab"><b class="calibre4">Discontinue heparin</b></p>
<p class="tab">Alternative anticoagulation</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> Pathophysiology (type II): Ab binds heparin-PF4 → immune complex binds to plt → <b class="calibre4">plt activation</b>, further PF4 release → plt aggregates removed from circulation → <b class="calibre4">thrombocytopenia;</b> procoagulants released by plts and tissue factor released by endothelial cells damaged by HIT Abs → <b class="calibre4">prothrombotic state</b></p>
<p class="bl"><span class="sbl">•</span> Diagnosis <i class="calibre3">(need clinical</i> + <i class="calibre3">pathologic)</i></p>
<p class="bl1"><b class="calibre4">Clinical:</b> plt &lt;100k <i class="calibre3">or</i> ↓ 50% from baseline; or <b class="calibre4">venous</b> (DVT/PE) or <b class="calibre4">arterial</b> (limb ischemia, CVA, MI) thrombosis (4:1 ratio); skin necrosis; ? ↑ heparin resistance</p>
<p class="bl1"><b class="calibre4">Pathologic:</b> ⊕ HIT Ab using PF4-heparin ELISA (≥90% Se, IgG-specific ELISA Sp 94%), may confirm w/ functional plt aggregation (serotonin-release) assay (&gt;95% Se/Sp)</p>
<p class="bl1">Clinical context important: HIT Ab (esp. IgM ELISA) may be ⊕ in 10–20% of Pts on UFH/LMWH <span class="s1r">(<i class="calibre3">Am J Hem</i> 1996;52:90)</span>, up to 50% of cardiac bypass Pts <span class="s1r">(<i class="calibre3">Circ</i> 1997;95:1242)</span></p>
<p class="bl1">Pretest prob w/ “4 T’s” criteria <span class="s1r">(<i class="calibre3">Blood</i> 2012;120:4160)</span>: ≤3 points → 99% NPV, investigate other causes; 4–5 points 22% PPV &amp; 6–8 points 64% PPV, ✔ lab test &amp; replace UFH</p>
<p class="image1"><img src="../images/00086.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><a id="page_5-9" class="calibre1"></a><span class="sbl">•</span> Treatment of HIT (type II) <span class="s1r">(<i class="calibre3">Chest</i> 2012;141:e495S; <i class="calibre3">Blood</i> 2012;119:2209; <i class="calibre3">NEJM</i> 2013;368:737)</span></p>
<p class="bl1"><b class="calibre4">Discontinue heparin</b> <i class="calibre3">(incl. flushes, LMWH Ppx, heparin lines).</i> Avoid plts (anecdotal link w/ thrombosis); if given warfarin, give vit K to reverse, prevent warfarin skin necrosis.</p>
<p class="bl1"><b class="calibre4">Nonheparin anticoag</b> (argatroban, bivalirudin; <i class="calibre3">NEJM</i> 2013;368:737) <i class="calibre3">regardless of thrombosis;</i> start warfarin when plt &gt;150k, overlap ≥5 d (✔ chromogenic Xa to titrate)</p>
<p class="bl1">⊕ thrombosis (HITT): anticoagulate for ≥3–6 mo</p>
<p class="bl1">⊖ thrombosis (HIT): screen for DVT; unclear duration of subsequent anticoag (until plt count recovers, often ~2–3 mo if no clot); <i class="calibre3">25–50% thrombosis rate w/in 30 d</i></p>
<p class="bl"><span class="sbl">•</span> H/o HIT: if PF4 Ab ⊖ or SRA ⊖ (typically &gt;100 d after dx) → may consider re-exposure to UFH (eg, for surgery); HIT recurrence low but can be seen <span class="s1r">(<i class="calibre3">Blood</i> 2014;123:2485)</span></p>
<p class="h2a">Thrombotic microangiopathies <span class="s">(<i class="calibre3">TMA; NEJM</i> 2014;371:654; <i class="calibre3">Lancet</i> 2017;390:681)</span></p>
<p class="bl"><span class="sbl">•</span> Endothelial injury → plt aggreg. &amp; microvasc. thrombosis → ↓ plt &amp; RBC hemolysis (MAHA)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thrombotic thrombocytopenic purpura (TTP)</b></p>
<p class="bl1">Pathophys: ↓↓ ADAMTS13 protease activity (hereditary or autoAb) → persistence of large vWF multimers on endothelial surface → adhesion &amp; aggregation of plts → thrombosis</p>
<p class="bl1">Clinical: <b class="calibre4">pentad</b> (all 5 in only ~5%) = ↓ plts + MAHA (100%) ± Δ MS (65%) ± renal failure (50%, late feature) ± fever (25%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hemolytic-uremic syndrome (HUS)</b></p>
<p class="bl1">Pathophys: (1) Shiga toxin damages renal endothelial cells → intrarenal thrombi; <i class="calibre3">or</i> (2) complement dysregulation (hereditary or acquired), so-called “atypical HUS”</p>
<p class="bl1">Clinical: <b class="calibre4">triad</b> = thrombocytopenia + MAHA + renal failure; (bloody diarrhea if Shiga)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Drug-induced TMA</b> <span class="s1r">(<i class="calibre3">Blood</i> 2017;129:2857)</span></p>
<p class="bl1">Immune-mediated (Ab reacts w/ plts &amp; endothelial cells): eg, quinine, gemcitabine?</p>
<p class="bl1">Direct toxicity mediated: eg, gemcitabine, mitomycin, tacrolimus, CsA, bevacizumab</p>
<p class="bl1">Clinically similar to TTP</p>
<p class="bl"><span class="sbl">•</span> Dx: unexplained <b class="calibre4">thrombocytopenia</b> (typically &lt;20k) + <b class="calibre4">MAHA</b> → <i class="calibre3">sufficient for dx</i> ⊕ <b class="calibre4">schistocytes</b> (&gt;2–3/hpf), ⊖ Coombs, normal PT/PTT &amp; fibrinogen ↑↑ LDH (tissue ischemia + hemolysis), ↑ indirect bili., ↓↓ haptoglobin, ↑ Cr (esp. in HUS)</p>
<p class="bl1">Biopsy: arterioles filled with platelet hyaline thrombi</p>
<p class="bl1">Ddx: DIC, vasculitis, malignant hypertension, preeclampsia/HELLP syndrome</p>
<p class="bl"><span class="sbl">•</span> Rx: <b class="calibre4">urgent plasma exchange</b> ± glucocorticoids if TTP; FFP if delay to plasma exchange? rituximab or caplacizumab (anti-vWF Ab) <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:335)</span> for TTP eculizumab for atypical HUS <span class="s1r">(<i class="calibre3">J Nephrol</i> 2017;30:127)</span> <i class="calibre3">plt transfusions contraindicated</i> → ↑ microvascular thromb <span class="s1r">(<i class="calibre3">NEJM</i> 2006;354:1927)</span></p>
<p class="h2a">Disseminated intravascular coagulation (DIC): <span class="s">see “Coagulopathies”</span></p>
<p class="h">D<small class="calibre30">ISORDERS</small> <small class="calibre30">OF</small> P<small class="calibre30">LATELET</small> F<small class="calibre30">UNCTION</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre27"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Mechanisms and Etiologies of Platelet Function Abnormalities</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Function</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Inherited</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Acquired</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Adhesion</b></p></td>
<td class="bg0-br"><p class="tab">Bernard-Soulier; vWD</p></td>
<td class="bg0-b"><p class="tab">Uremia; acquired vWD</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Aggregation</b></p></td>
<td class="bg0-br"><p class="tab">Afibrinogenemia</p>
<p class="tab">Glanzmann’s thrombasthenia</p></td>
<td class="bg0-b"><p class="tab">Ticlopidine, clopidogrel, GP IIb/IIIa</p>
<p class="tab">Dysproteinemias (myeloma)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Granule</b></p>
<p class="tab"><b class="calibre4">release</b></p></td>
<td class="bg0-r"><p class="tab">Chediak-Higashi syndrome</p>
<p class="tab">Hermansky-Pudlak syndrome</p></td>
<td class="bg"><p class="tab">Drugs (ASA, NSAIDs); liver disease; MPN; cardiopulmonary bypass</p></td>
</tr>
</table>
<p class="h2a">Tests of platelet function</p>
<p class="bl"><span class="sbl">•</span> Platelet aggregation tests: measure aggregation in response to agonists (eg, ADP)</p>
<p class="h2a">von Willebrand’s disease (vWD) <span class="s">(<i class="calibre3">NEJM</i> 2016;375:2067)</span></p>
<p class="bl"><span class="sbl">•</span> von Willebrand’s factor (vWF) function = platelet glue &amp; plasma carrier of factor VIII</p>
<p class="bl"><span class="sbl">•</span> vWD most common inherited (usually auto dom) bleeding disorder; ~85% (type 1) have partial quantitative defic of vWF, ~15% (type 2) have qualitative defic in vWF</p>
<p class="bl"><span class="sbl">•</span> Acquired vWD: a/w many disorders (malig, MPN w/ ↑ plt count; autoimmune; hypo-thyroidism; drugs) and caused by different mechanisms (anti-vWF Abs, ↑ clearance, ↓ synthesis); Heyde’s syndrome = vWF destruction by severe AS, a/w GI AVMs/bleed</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: ↓ <b class="calibre4">vWF:Ag</b>, ↓ <b class="calibre4">vWF activity</b> (measured by ristocetin cofactor assay), ↓ <b class="calibre4">factor VIII</b>, ± ↑ PTT, ± ↓ platelets; confirm with <b class="calibre4">vWF multimer analysis</b></p>
<p class="bl"><span class="sbl">•</span> Clinical condition, factor VIII levels and ristocetin cofactor assay useful to guide Rx decision</p>
<p class="bl"><span class="sbl">•</span> Rx: <b class="calibre4">desmopressin</b> (dDAVP, IV/IN) → ↑ endothelial cell release of vWF; efficacy depends on type (avoid in type 2), ∴ ✔ response before use w/ subseq. bleeding or procedures; <b class="calibre4">vWF replacement:</b> cryoprecipitate, factor VIII concentrates rich in vWF, recomb. vWF</p>
<p class="h2a">Uremic bleeding</p>
<p class="bl"><span class="sbl">•</span> Uremia → platelet dysfunction including ↓ aggregation, impaired adhesiveness</p>
<p class="bl"><span class="sbl">•</span> Treatment: <b class="calibre4">dDAVP</b>, cryoprecipitate, correct anemia (improves plt aggregation and</p>
<p class="bl1">adhesion by increasing plt interactions with endothelium), consider holding anti-plt agents</p>
<h2 class="ct"><a id="h64" class="calibre7"></a><a id="page_5-10" class="calibre7"></a><a href="part0002.html#rh72" class="calibre7">COAGULOPATHIES</a></h2>
<p class="image1"><img src="../images/00087.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Further coagulation tests <span class="s">(<i class="calibre3">JAMA</i> 2016;316:2146)</span></p>
<p class="bl"><span class="sbl">•</span> Mixing study: useful if ↑ PT or PTT; mix Pt’s plasma 1:1 w/ normal plasma and retest</p>
<p class="bl1">PT/PTT normalizes → factor <b class="calibre4">deficiency;</b> PT/PTT remains elevated → factor <b class="calibre4">inhibitor</b></p>
<p class="bl"><span class="sbl">•</span> Coagulation factor levels: useful if mixing study suggests factor deficiency</p>
<p class="bl1">DIC → all factors consumed; ∴ ↓ factors V and VIII</p>
<p class="bl1">Liver disease → ↓ all factors <i class="calibre3">except</i> VIII; ∴↓ factor V, normal factor VIII</p>
<p class="bl1">Vitamin K deficiency → ↓ factors II, VII, IX, X (and protein C, S); ∴ normal V and VIII</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">DIC screen:</b> fibrinogen (consumed), fibrin degradation products (FDPs, ⊕ due to intense fibrinolysis), D-dimer (more specific FDP test that detects degradation of X-linked fibrin)</p>
<p class="h2a">Hemophilias <span class="s">(<i class="calibre3">Lancet</i> 2016;388:187)</span></p>
<p class="bl"><span class="sbl">•</span> X-linked recessive <b class="calibre4">factor VIII</b> (hemophilia A) or <b class="calibre4">factor IX</b> (hemophilia B) <b class="calibre4">deficiency</b></p>
<p class="bl"><span class="sbl">•</span> Classification: mild (5–25% normal factor activity), moderate (1–5%) or severe (&lt;1%)</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: hematomas, hemarthroses, bruising, bleeding (mucosal, GI, GU)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: ↑ PTT (normalizes w/mixing study), normal PT &amp; vWF, ↓ factor VIII or IX</p>
<p class="bl"><span class="sbl">•</span> Prophylaxis indicated if &lt;1% activity of factor VIII or IX</p>
<p class="bl"><span class="sbl">•</span> Rx: purified/recomb. factor VIII <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:2054)</span> or IX; desmopressin (mild dis.); aminocaproic acid; cryo (FVIII); emicizumab (bridges factor IX and X), effective for hemophilia A w/ and w/o inhibitors <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:809 &amp; 2018;379:811)</span></p>
<p class="h2a">Coagulation factor inhibitors <span class="s">(most commonly anti–factor VIII)</span></p>
<p class="bl"><span class="sbl">•</span> Etiologies: hemophilia; postpartum; lymphoproliferative &amp; autoimmune disorders; cancers</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: ↑ PTT (does <i class="calibre3">not</i> normalize w/mixing study); Bethesda assay quantitates titer</p>
<p class="bl"><span class="sbl">•</span> Treatment: if high titer → <b class="calibre4">recomb. factor VIIa</b>, porcine factor concentrates, activated</p>
<p class="bl1">prothrombin complex; for others → high-purity human factor, plasmapheresis,</p>
<p class="bl1">immunosupp. w/ steroids, CYC and/or RTX <span class="s1r">(<i class="calibre3">Curr Opin Hematol</i> 2008;15:451)</span></p>
<p class="h2a">Disseminated intravascular coagulation (DIC) <span class="s">(<i class="calibre3">NEJM</i> 2014;370:847)</span></p>
<p class="bl"><span class="sbl">•</span> Etiologies: trauma, shock, infection, malignancy (esp. APL), obstetric complications</p>
<p class="bl"><span class="sbl">•</span> Pathogenesis: <i class="calibre3">massive</i> activation of coagulation that overwhelms control mechanisms</p>
<p class="bl1"><b class="calibre4">Thrombosis</b> in microvasculature → ischemia + microangiopathic hemolytic anemia</p>
<p class="bl1">Acute consumption of coagulation factors and platelets → <b class="calibre4">bleeding</b></p>
<p class="bl1">Chronic DIC → able to compensate by ↑ factors and platelets → <b class="calibre4">thrombosis</b></p>
<p class="bl"><span class="sbl">•</span> Diagnosis: ↑ PT, ↑ PTT, ↓ <b class="calibre4">fibrinogen</b> (may be <i class="calibre3">nl</i> b/c acute phase), ⊕ <b class="calibre4">FDP</b>/<b class="calibre4">D-dimer</b>, ↓ plts, ⊕ schistos, ↑ LDH, ↓ hapto; <i class="calibre3">chronic</i> DIC: ⊕ FDP/D-dimer, variable plts, other labs nl</p>
<p class="bl"><span class="sbl">•</span> Treatment: Rx underlying process; support w/ <b class="calibre4">FFP</b>, <b class="calibre4">cryo</b> (goal fbgn &gt;100 mg/dL) &amp; <b class="calibre4">plts</b></p>
<p class="h2a">Vitamin K deficiency</p>
<p class="bl"><span class="sbl">•</span> Etiologies: malnutrition, ↓ absorption (antibiotic suppression of vitamin K-producing intestinal flora or malabsorption), liver disease (↓ stores), warfarin</p>
<p class="imagef"><img src="../images/00088.jpeg" alt="" class="calibre2"/></p>
<p class="fn">*Routine monitoring not performed. Mode of excretion: K, kidney; L, liver; RES, reticuloendothelial system. 4F-PCC: prothrombin complex concentrate (FII, VII, IX, X; Protein C &amp; S). Anti-fibrinolytics: tranexamic, aminocaproic acid.</p>
<h2 class="ct"><a id="h65" class="calibre7"></a><a id="page_5-11" class="calibre7"></a><a href="part0002.html#rh73" class="calibre7">HYPERCOAGULABLE STATES</a></h2>
<p class="cst"><i class="calibre3">Suspect in Pts with venous or arterial thrombosis at young age or unusual locations, recurrent thromboses or pregnancy loss, or</i> ⊕ <i class="calibre3">FHx</i></p>
<p class="image1"><img src="../images/00089.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre16"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Vascular Beds Affected by Inherited and Acquired Hypercoagulable States</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"> </p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Venous</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Venous and Arterial</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabheadc"><b class="calibre4">Inher.</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Factor V Leiden</b></p>
<p class="tab">Prothrombin mutation ↓ protein C, S or AT III</p></td>
<td class="bg0-b"><p class="tab">Hyperhomocysteinemia (inherited or acquired)</p>
<p class="tab">Dysfibrinogenemia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tabheadc"><b class="calibre4">Acquired</b></p></td>
<td class="bg0-r"><p class="tabh">Stasis: immobilization, surgery, CHF</p>
<p class="tabh">Malignancy</p>
<p class="tabh">Hormonal: OCPs, HRT, tamoxifen, pregnancy</p>
<p class="tabh">Nephrotic syndrome</p></td>
<td class="bg"><p class="tabh">Platelet defects: myeloproliferative disorders, HIT, PNH (although venous &gt; arterial)</p>
<p class="tabh">Hyperviscosity: polycythemia vera, Waldenström’s macroglobulinemia, sickle cell, acute leukemia</p>
<p class="tabh">Vessel wall defects: vasculitis, trauma, foreign bodies</p>
<p class="tabh">Others: <b class="calibre4">antiphospholipid syndrome</b>, IBD</p></td>
</tr>
</table>
<p class="h2a">Diagnostic evaluation <span class="s">(not routinely required for initial VTE; <i class="calibre3">NEJM</i> 2017;377:1177)</span></p>
<p class="bl"><span class="sbl">•</span> APC resistance screen; prothrombin PCR test; functional assays for proteins C and S, ATIII; homocysteine level; factor VIII levels; anticardiolipin and lupus anticoagulant Ab. Also consider nephrotic syndrome, PNH (esp. if mesenteric thrombus).</p>
<p class="bl"><span class="sbl">•</span> Consider <i class="calibre3">JAK2</i> mutation testing if suspect MPN or splanchnic thrombosis</p>
<p class="bl"><span class="sbl">•</span> Proteins C &amp; S and ATIII levels are affected by acute thrombosis and anticoagulation ∴ levels best assessed ≥2 wk after completing anticoagulation course</p>
<p class="bl"><span class="sbl">•</span> Age-appropriate malignancy screening (occult cancer in ~4% of initial unprovoked VTE; no benefit of routine abd/pelvis CT; <span class="s"><i class="calibre3">NEJM</i> 2015;373:697</span>)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Asx w/ inherited risk factor: consider prophylactic anticoag. if develops acquired risk factor</p>
<p class="bl"><span class="sbl">•</span> Thrombosis w/ inherited risk factor: see “Venous Thromboembolism”</p>
<p class="h2a">Antiphospholipid syndrome (APS) <span class="s">(<i class="calibre3">NEJM</i> 2018;398:2010)</span></p>
<p class="bl"><span class="sbl">•</span> Definition: dx requires ≥1 clinical &amp; ≥1 laboratory criteria</p>
<p class="bl1">Clinical: thrombosis (any) or complication of pregnancy (≥3 spont. abortions before 10 wk or ≥1 fetal loss after 10 wk or premature birth before 34 wk)</p>
<p class="bl1">Laboratory: ⊕ moderate–high titer anticardiolipin (ACL), ⊕ lupus anticoagulant (LA), or ⊕ β<sub class="calibre8">2</sub>-glycoprotein-I (β<sub class="calibre8">2</sub>-GP-I) Ab, on ≥2 occasions, at least 12 wk apart</p>
<p class="bl"><span class="sbl">•</span> Clinical: <b class="calibre4">DVT/PE/CVA</b>, <b class="calibre4">recurrent fetal loss</b>, ↓ <b class="calibre4">plts</b>, hemolytic anemia, livedo reticularis; “<b class="calibre4">catastrophic APS</b>”: ≥3 organ systems in &lt;1 wk w/ ⊕ APLA &amp; tissue microthrombi; 44% mortality <span class="s1r">(<i class="calibre3">Arth Rheum</i> 2006;54:2568)</span>; Rx w/ plasmapheresis, rituximab</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antiphospholipid antibodies (APLA)</b></p>
<p class="bl1">✔ <i class="calibre3">if: SLE, age</i> &lt;<i class="calibre3">40 y &amp; arterial thromb, recurrent venous thromb, spontaneous abortion</i></p>
<p class="bl1">ACL: Ab against cardiolipin, a mitochondrial phospholipid; IgG more specific than IgM</p>
<p class="bl1">LA: Ab that prolongs phospholipid-dependent coagulation reactions; ∴ ↑ <b class="calibre4">PTT</b> that does <i class="calibre3">not</i> correct with mixing study but does correct with excess phospholipids or platelets; PT not affected b/c the reaction contains much more phospholipid</p>
<p class="bl1">β<sub class="calibre8">2</sub>-GP-I: Ab against β<sub class="calibre8">2</sub>-glycoprotein-I, IgG or IgM (uncertain role of Abs in pathogenesis)</p>
<p class="bl1">False ⊕ VDRL: nontreponemal test for syphilis in which cardiolipin is part of Ag complex</p>
<p class="bl1">Risk of thromboembolic phenomena may increase with titer of APLs</p>
<p class="bl"><span class="sbl">•</span> Etiologies: primary (idiopathic) or secondary due to <b class="calibre4">autoimmune syndromes</b> (eg, SLE), <b class="calibre4">malignancy</b>, <b class="calibre4">infections</b>, drug reactions</p>
<p class="bl"><span class="sbl">•</span> Treatment: UFH/LMWH → warfarin (lifelong for most Pts)</p>
<p class="bl1">Rivaroxaban inferior to warfarin in triple positive (⊕ ACL, LA, &amp; β<sub class="calibre8">2</sub>-GP) <span class="s1r">(<i class="calibre3">Blood</i> 2018;132:1365)</span></p>
<p class="bl1">Initial <i class="calibre3">venous thrombosis:</i> INR 2–3 <span class="s1r">(<i class="calibre3">NEJM</i> 2003;349:1133; <i class="calibre3">J Thromb Haemost</i> 2005;3:848)</span></p>
<p class="bl1">Initial <i class="calibre3">arterial thrombosis:</i> typically INR 2–3 + ASA 81 mg/d</p>
<p class="bl1"><i class="calibre3">Recurrent thrombosis</i> on warfarin: consider INR 3–4 vs. LMWH or fondaparinux <span class="s1r">(<i class="calibre3">Arth Rheum</i> 2007;57:1487)</span></p>
<h2 class="ct"><a id="h66" class="calibre7"></a><a id="page_5-12" class="calibre7"></a><a href="part0002.html#rh74" class="calibre7">DISORDERS OF LEUKOCYTES</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Neutrophilia (</b>&gt;<b class="calibre4">7500–10,000/µL)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Infection</p></td>
<td class="bg0-b"><p class="tab">Usually bacterial; ± toxic granulations, Döhle bodies</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Inflammation</p></td>
<td class="bg0-b"><p class="tab">Burn, tissue necrosis, MI, PE, collagen vascular disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Drugs and toxins</p></td>
<td class="bg0-b"><p class="tab">Corticosteroids, β-agonists, lithium, G-CSF; cigarette smoking</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Stress</p></td>
<td class="bg0-b"><p class="tab">Release of endogenous glucocorticoids and catecholamines</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Marrow stimulation</p></td>
<td class="bg0-b"><p class="tab">Hemolytic anemia, immune thrombocytopenia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Asplenia</p></td>
<td class="bg0-b"><p class="tab">Surgical, acquired (sickle cell), congenital (dextrocardia)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Neoplasm</p></td>
<td class="bg0-b"><p class="tab">Can be 1° (MPN) or paraneoplastic (eg, carcinomas of lung, GI)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Leukemoid reaction</p></td>
<td class="bg"><p class="tab">&gt;50,000/µL + left shift, not due to leukemia; unlike CML, ↑ LAP</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Neutropenia (ANC</b> &lt;<b class="calibre4">1000/µL)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Congenital</p></td>
<td class="bg0-b"><p class="tab">Myelokathexis, Shwachman-Diamond-Oski, Chédiak-Higashi, retic dysgen., WHIM syndrome, cyclic neutropenia, monoMAC syndrome (↓ monos, NKs)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Infection</p></td>
<td class="bg0-b"><p class="tab">Viral (CMV, EBV, HIV); bacterial (brucella, <i class="calibre3">Rickettsia</i>, TB); malaria</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Nutritional</p></td>
<td class="bg0-b"><p class="tab">Vit B<sub class="calibre13">1</sub><sub class="calibre13">2</sub> defic., copper defic.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Drugs and toxins</p></td>
<td class="bg0-b"><p class="tab">Chemotherapeutics, clozapine, methimazole, TMP-SMX, NSAIDs, sulfasalazine, phenytoin <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Am J Hem</i></span> <span class="tfont1">2009;84:428)</span>, alcohol</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Neoplasm</p></td>
<td class="bg"><p class="tab">MDS, leukemia (AML, ALL, hairy cell, LGL, others)</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Lymphocytosis (</b>&gt;<b class="calibre4">4000–5000/µL)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Infection</p></td>
<td class="bg0-b"><p class="tab">Usually viral; “atypical lymphocytes” with mononucleosis syndromes Other: pertussis, toxoplasmosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Hypersensitivity</p></td>
<td class="bg0-b"><p class="tab">Drug-induced, serum sickness</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Stress</p></td>
<td class="bg0-b"><p class="tab">Cardiac emergencies, trauma, status epilepticus, postsplenectomy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Autoimmune</p></td>
<td class="bg0-b"><p class="tab">Rheumatoid arthritis (large granular lymphocytes), malignant thymoma</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Neoplasm</p></td>
<td class="bg"><p class="tab">Leukemia (eg, CLL, hairy cell, LGL), lymphoma (eg, mantle cell, folic.)</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Monocytosis (</b>&gt;<b class="calibre4">500/µL)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Infection</p></td>
<td class="bg0-b"><p class="tab">Usually TB, SBE, <i class="calibre3">Listeria</i>, <i class="calibre3">Brucella</i>, <i class="calibre3">Rickettsia</i>, fungi, parasites</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Inflammation</p></td>
<td class="bg0-b"><p class="tab">IBD, sarcoidosis, collagen vascular diseases</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Neoplasm</p></td>
<td class="bg"><p class="tab">Hodgkin lymphoma, leukemias, MPD, carcinomas</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Eosinophilia (</b>&gt;<b class="calibre4">500/µL)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Infection</p></td>
<td class="bg0-b"><p class="tab">Usually parasitic (helminths)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Allergic</p></td>
<td class="bg0-b"><p class="tab">Drugs; asthma, hay fever, eczema; ABPA</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Collagen vasc dis.</p></td>
<td class="bg0-b"><p class="tab">RA, Churg-Strauss syndrome, eosinophilic fasciitis, PAN</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Endocrine</p></td>
<td class="bg0-b"><p class="tab">Adrenal insufficiency</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Neoplasm</p></td>
<td class="bg0-b"><p class="tab">HL, CML, mycosis fungoides, carcinomas, systemic mastocytosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Atheroembolic dis.</p></td>
<td class="bg0-b"><p class="tab">Cholesterol emboli syndrome</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Hypereosinophilic syndrome</p></td>
<td class="bg"><p class="tab">Multiorgan involvement incl. heart &amp; CNS, a/w FIP1L1-PDGFRA fusion <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">2003;348:</span><span class="tfont">1</span><span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">)</span></p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre24"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Basophilia (</b>&gt;<b class="calibre4">150/µL)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Neoplasm</p></td>
<td class="bg0-b"><p class="tab">MPN, Hodgkin lymphoma</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Alteration in BM or reticuloendothelial compartment</p></td>
<td class="bg0-b"><p class="tab">Hemolytic anemia, splenectomy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Inflammation or allergy</p></td>
<td class="bg"><p class="tab">IBD, chronic airway inflammation</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Lymphadenopathy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Viral</p></td>
<td class="bg0-b"><p class="tab">HIV, EBV, CMV, HSV, VZV, hepatitis, measles, rubella</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Bacterial</p></td>
<td class="bg0-b"><p class="tab">Generalized (brucellosis, leptospirosis, TB, atypical mycobacteria, syphilis)</p>
<p class="tab">Localized (streptococci, staphylococci, cat-scratch disease, tularemia)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Fungal and parasitic</p></td>
<td class="bg0-b"><p class="tab">Histoplasmosis, coccidioidomycosis, paracoccidioidomycosis</p>
<p class="tab">Toxoplasmosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Immunologic</p></td>
<td class="bg0-b"><p class="tab">Collagen vascular disease, drug hypersensitivity (eg, phenytoin), serum sickness, histiocytosis X, Castleman’s and Kawasaki disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Neoplasm</p></td>
<td class="bg0-b"><p class="tab">Lymphoma, leukemia, amyloidosis, metastatic carcinoma</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Other</p></td>
<td class="bg0-b"><p class="tab">Sarcoidosis; lipid storage diseases</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Factors that favor biopsy</p></td>
<td class="bg"><p class="tabh">Age (&gt;40 y), size (&gt;2 cm), location (supraclavicular is always abnormal), duration (&gt;1 mo)</p>
<p class="tab">Consistency (hard <i class="calibre3">vs.</i> rubbery <i class="calibre3">vs.</i> soft) &amp; tenderness are not reliable</p></td>
</tr>
</table>
<h2 class="ct"><a id="h67" class="calibre7"></a><a id="page_5-13" class="calibre7"></a><a href="part0002.html#rh75" class="calibre7">TRANSFUSION THERAPY</a></h2>
<p class="image1"><img src="../images/00090.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Transfusion reactions</p>
<p class="bl"><span class="sbl">•</span> For all reactions (except minor allergic): <b class="calibre4">stop transfusion;</b> send remaining blood product and fresh blood sample to blood bank</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acute hemolytic:</b> fever, HoTN, flank pain, AKI w/in 24 h. Due to ABO incompatibility → preformed Abs vs. donor RBCs. Rx: IVF, ↑ UOP w/ diuretics, mannitol, or dopamine.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Delayed hemolytic:</b> generally less severe than acute hemolytic; 5–7 d after transfusion</p>
<p class="bl1">Due to undetected allo-Abs against minor antigens → anamnestic response.</p>
<p class="bl1">Rx: usually no specific therapy required; dx is important for future transfusion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Febrile nonhemolytic:</b> fever, rigors 0–6 h post transfusion. Due to Abs vs donor WBCs and cytokines in blood product. Rx: acetaminophen ± meperidine; r/o infection, hemolysis.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Allergic:</b> urticaria; rarely, <b class="calibre4">anaphylaxis:</b> bronchospasm, laryngeal edema, hypotension</p>
<p class="bl1">Reaction to transfused proteins; anaphylaxis seen in IgA-deficient Pts w/ anti-IgA Abs.</p>
<p class="bl1">Rx: urticaria → diphenhydramine; anaphylaxis → epinephrine ± glucocorticoids</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transfusion-associated circulatory overload</b> (TACO): ↑ volume → pulm edema, ↑ BP. Rx: slow transfusion rate, diuretics, O<sub class="calibre8">2</sub>, ± nitrates, ± positive pressure ventilation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transfusion-related acute lung injury</b> (TRALI): noncardiogenic pulmonary edema Due to donor allo-Abs that bind recipient WBCs, which then aggregate in pulmonary vasculature and release mediators causing ↑ capillary permeability. Rx: see “ARDS.”</p>
<h2 class="ct"><a id="h68" class="calibre7"></a><a id="page_5-14" class="calibre7"></a><a href="part0002.html#rh76" class="calibre7">MYELODYSPLASTIC SYNDROMES (MDS)</a></h2>
<p class="h2a">Myeloid neoplasm overview <span class="s">(<i class="calibre3">Blood</i> 2016;127:2391)</span></p>
<p class="bl"><span class="sbl">•</span> Categories based on clinical features, morphology, immunophenotyping, and genetics</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">WHO 2016 Classification of Myeloid Neoplasms &amp; Acute Leukemia</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Acute myeloid leukemia</p></td>
<td class="bg0-b"><p class="tab">Clonal myeloid stem cell (SC) disorder w/ ≥20% blasts</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Myelodysplastic syndromes</p></td>
<td class="bg0-b"><p class="tab">Dysplastic clonal myeloid SC disorder → cytopenias; &lt;20% blasts, risk of leukemic transformation</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Myeloproliferative neoplasms</p></td>
<td class="bg0-b"><p class="tab">Nondysplastic multipotent myeloid SC clonal expansion</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">MDS/MPN neoplasms</p></td>
<td class="bg0-b"><p class="tab">Features of MDS &amp; MPN (eg, CMML, atypical CML)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Myeloid/lymphoid malig. w/ eos &amp; rearrangements of <i class="calibre3">PDGFR</i> or <i class="calibre3">FGFR1</i> or w/ <i class="calibre3">PCM1-JAK2</i></p></td>
<td class="bg0-b"><p class="tab">May be responsive to TKI therapy (eg, imatinib) for <i class="calibre3">PDGFR</i> rearrangement</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Mastocytosis</p></td>
<td class="bg0-b"><p class="tab">Systemic disease, assoc w/ <i class="calibre3">KIT</i> mutations</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Myeloid neoplasms w/ germ line predisposition</p></td>
<td class="bg"><p class="tab">MDS, MDS/MPN, acute leukemias in background of predisposing germline mutations</p></td>
</tr>
</table>
<p class="h2a">Myelodysplastic syndromes (MDS) overview <span class="s">(<i class="calibre3">Lancet</i> 2014;383:2239)</span></p>
<p class="bl"><span class="sbl">•</span> Acquired clonal stem cell disorder → ineffective hematopoiesis → <b class="calibre4">cytopenias</b>, <b class="calibre4">dysmorphic blood cells and precursors</b>, variable risk of <b class="calibre4">leukemic transformation</b></p>
<p class="bl"><span class="sbl">•</span> Epidemiology: 20–30,000 cases/y; median age ~70 y; male predominance (1.8×)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Idiopathic</b> or 2° to chemo w/ <b class="calibre4">alkylating agents;</b> ↑ risk w/ radiation, benzene</p>
<p class="bl"><span class="sbl">•</span> Clinical manifestations: <b class="calibre4">anemia</b> (85%), neutropenia (50%), thrombocytopenia (40–65%)</p>
<p class="bl"><span class="sbl">•</span> Diagnosis: dysplasia (usually multilineage) in peripheral smear (oval macrocytes, <b class="calibre4">pseudo-Pelger-Huët anomaly</b>) and bone marrow (≥10% dysplasia with blasts ± RS)</p>
<p class="bl"><span class="sbl">•</span> Both <b class="calibre4">cytogenetic</b> [eg, del(5q), mono 7, del(7q), trisomy 8, del(20q)] and <b class="calibre4">molecular</b> abnl (<b class="calibre4">TP53</b>, EZH2, ETV6, RUNX1, ASXL1, SF3B1, DNMT3A) may carry prognostic signif</p>
<p class="bl"><span class="sbl">•</span> Prior to dx MDS: exclude AML (≥20% blasts) and CMML (monos &gt;1 × 10<sup class="calibre15">9</sup>/L); r/o 2° BM Δs (defic. of B<sub class="calibre8">12</sub>, folate, copper); viral infx (eg, HIV); chemo; EtOH; lead, arsenic exposures</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre41"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">WHO 2016 Classification Systems for MDS</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Blood</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">6;</span><span class="tfont">1</span><span class="tfont1">27:239</span><span class="tfont">1</span><span class="tfont1">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Classification</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">WHO 2008</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Features</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">MDS w/ single lineage dysplasia (MDS-SLD)</p></td>
<td class="bg0-br"><p class="tab">RCUD</p>
<p class="tab">(RA/RN/RT)</p></td>
<td class="bg0-b"><p class="tab">1 dysplastic lineage, 1–2 cytopenias, &lt;15% RS<a id="st7" class="calibre1"></a><a href="part0010.html#sst7" class="calibre1">*</a>, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">MDS w/ multilineage dysplasia (MDS-MLD)</p></td>
<td class="bg0-br"><p class="tab">RCMD</p></td>
<td class="bg0-b"><p class="tab">2–3 dysplastic lineages, 1–3 cytopenias, &lt;15% RS<a href="part0010.html#sst7" class="calibre1">*</a>, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">MDS w/ ring sideroblast (MDS-RS)</p></td>
<td class="bg0-br"><p class="tab">RARS</p></td>
<td class="bg0-b"><p class="tab">≥15% RS or ≥5% RS if <i class="calibre3">SF3B1</i> mut. is present, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">MDS w/ isolated del(5q)</p></td>
<td class="bg0-br"><p class="tab">Del(5q)</p></td>
<td class="bg0-b"><p class="tab">Del(5q) alone or w/ 1 abnl except –7 or del(7q)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">MDS w/ excess blasts (MDS-EB)</p></td>
<td class="bg0-br"><p class="tab">RAEB-1</p>
<p class="tab">RAEB-2</p></td>
<td class="bg0-b"><p class="tab">EB-1: 5–9% BM/2–4% PB blasts, no Auer rods</p>
<p class="tab">EB-2: 10–19% BM/5–19% PB blasts or Auer rods</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">MDS, unclassifiable (MDS-U)</p></td>
<td class="bg0-r"><p class="tab">MDS-U</p></td>
<td class="bg"><p class="tab">w/ 1% PB blasts, single lineage dysplasia &amp; pancytopenia, or defining cytogenetic alteration</p></td>
</tr>
</table>
<p class="tsr">Certain cytogenetics [eg, t(15;17), t(8;21), inv16, t(16;16), or MLL rearrangement] classified as AML, regardless of BM blast count. RS, ring sideroblast; BM, bone marrow; PB, peripheral blood. <a id="sst7" class="calibre1"></a><a href="part0010.html#st7" class="calibre1">*</a> &lt;5% RS if <i class="calibre3">SF3B1</i> mutation.</p>
<p class="bl"><span class="sbl">•</span> Rx <span class="s1r">(<i class="calibre3">Am J Hematol</i> 2012;87:692)</span>: intensity based on IPSS-R (qv), age, performance status (PS)</p>
<p class="bl1">Poor PS, any risk → supportive care (transfusions, G-CSF, Epo, TPO-mimetic, abx prn)</p>
<p class="bl1">Low/intermediate risk → Epo (if Epo level &lt;500); lenalidomide (esp. for 5q syndrome; <i class="calibre3">Blood</i> 2011;118:3765); DNA hypomethylating agents (azacitidine or decitabine)</p>
<p class="bl1">Intermediate/high risk (&gt;4.5 on IPSS-4) → <b class="calibre4">allogeneic HSCT</b> if medically fit, otherwise <b class="calibre4">DNA hypomethylating agents</b> (decitabine or azacitidine; <i class="calibre3">Lancet Oncol</i> 2009;10:223)</p>
<p class="bl1">Hypoplastic MDS (rare) → consider <b class="calibre4">immunosuppression</b> (CsA, ATG, pred), HSCT</p>
<p class="bl"><span class="sbl">•</span> Prognosis: <i class="calibre3">TP53</i>, <i class="calibre3">RAS</i>, <i class="calibre3">JAK2</i> mutations <span class="s1r">(<i class="calibre3">NEJM</i> 2017; 376:536)</span> &amp; IPSS-R correlate w/ survival</p>
<p class="image1"><img src="../images/00091.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="h69" class="calibre7"></a><a id="page_5-15" class="calibre7"></a><a href="part0002.html#rh77" class="calibre7">MYELOPROLIFERATIVE NEOPLASMS (MPN)</a></h2>
<p class="h2a">General <span class="s">(<i class="calibre3">NEJM</i> 2017;376:2168)</span></p>
<p class="bl"><span class="sbl">•</span> Results from clonal expansion of multipotent hematopoietic stem cell</p>
<p class="bl"><span class="sbl">•</span> Different from MDS in that the cells are not dysplastic (ie, normally developed)</p>
<p class="bl"><span class="sbl">•</span> Categories of MPN: polycythemia vera (PV); essential thrombocythemia (ET); primary myelofibrosis (PMF); chronic myelogenous leukemia (CML), BCR-ABL1 ⊕; atypical CML (aCML); chronic neutrophilic leukemia (CNL); systemic mastocytosis; chronic eosinophilic leukemia, not otherwise specified; myeloproliferative neoplasms unclassifiable</p>
<p class="bl"><span class="sbl">•</span> Mutations useful as clonal markers &amp; dx tools:</p>
<p class="bl1">Gain of fxn mutations in <b class="calibre4"><i class="calibre3">JAK2</i></b> V617F (Janus kinase) frequently present (PV ~95%, ET ~50%, PMF ~50%; <i class="calibre3">NEJM</i> 2005;352:1779)</p>
<p class="bl1"><b class="calibre4"><i class="calibre3">BCR-ABL</i></b> fusion in <b class="calibre4">all</b> cases of CML; <b class="calibre4"><i class="calibre3">SETBP1</i></b> in aCML</p>
<p class="bl1"><b class="calibre4"><i class="calibre3">CALR</i></b> exon 9 mutation (most MPNs w/o <i class="calibre3">JAK2</i> or <i class="calibre3">MPL</i> mutation, including ~25% of ET, ~35% of myelofibrosis Pts; <i class="calibre3">NEJM</i> 2013;369:2379 &amp; 2391)</p>
<p class="bl1"><b class="calibre4"><i class="calibre3">MPL</i></b>, <b class="calibre4"><i class="calibre3">TET2, &amp; ASXL1</i></b> mutation w/ lower frequency</p>
<p class="bl1"><b class="calibre4"><i class="calibre3">CSF3R</i></b> mutation present in ~60% of CNL; <b class="calibre4"><i class="calibre3">KIT</i></b> in 90% of systemic mastocytosis</p>
<p class="h">P<small class="calibre30">OLYCYTHEMIA</small> V<small class="calibre30">ERA</small> (PV)</p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> ↑ in RBC mass ± ↑ granulocytes and platelets in the absence of physiologic stimulus</p>
<p class="h2a">Etiologies of erythrocytosis</p>
<p class="bl"><span class="sbl">•</span> Relative ↑ RBC (↓ plasma): dehydration; “stress” erythrocytosis (Gaisböck’s syndrome)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Absolute</i> ↑ RBC: 1° (PV, other MPD) or 2° due to <b class="calibre4">hypoxia; carboxyhemoglobinemia; inappropriate erythropoietin</b> (renal, hepatic, cerebellar tumors); Cushing’s syndrome</p>
<p class="h2a">Clinical manifestations <span class="s">(common between PV and ET)</span></p>
<p class="bl"><span class="sbl">•</span> Symptoms → often termed “vasomotor symptoms”</p>
<p class="bl1"><b class="calibre4">Hyperviscosity</b> (erythrocytosis): headache, dizziness, tinnitus, blurred vision</p>
<p class="bl1"><b class="calibre4">Thrombosis</b> (hyperviscosity, thrombocytosis): transient visual disturbances (amaurosis, ocular migraine); Budd-Chiari syndrome; erythromelalgia = intense burning, pain and erythema of extremities due to microvascular ischemia; ↑ risk of <b class="calibre4">DVT</b>, <b class="calibre4">MI</b>, <b class="calibre4">stroke.</b> Risk of thrombosis highly correlated with ↑ WBC in PV and ET (see below).</p>
<p class="bl1"><b class="calibre4">Bleeding</b> (abnormal platelet function): easy bruising, epistaxis, GI bleeding</p>
<p class="bl1">↑ histamine from basophils → <b class="calibre4">pruritus</b>, peptic ulcers; ↑ uric acid (cell turnover) → gout</p>
<p class="bl"><span class="sbl">•</span> Signs: <b class="calibre4">plethora</b>, <b class="calibre4">splenomegaly</b>, hypertension, engorged retinal veins</p>
<p class="bl"><span class="sbl">•</span> Expression profiling beyond <i class="calibre3">JAK2</i> may define different phenotypes <span class="s1r">(<i class="calibre3">NEJM</i> 2014;371:808)</span></p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> Men: Hb &gt;16.5 g/dL or HCT &gt;49%, women: Hb &gt;16 g/dL or HCT &gt;48%, or ↑ red cell mass</p>
<p class="bl"><span class="sbl">•</span> BM bx → hypercellularity for age, trilineage growth, pleomorphic mature megakaryocytes</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">JAK2</i> V617F</b> mutation in ~95% of PV; other Pts typically harbor <i class="calibre3">JAK2</i> exon 12 mutations</p>
<p class="bl"><span class="sbl">•</span> ✔ Epo to rule out secondary causes of erythrocytosis; <b class="calibre4">if Epo</b> ↓, <b class="calibre4">PV more likely</b></p>
<p class="bl1">If Epo ↑, then ✔ SaO<sub class="calibre8">2</sub> or PaO<sub class="calibre8">2</sub>, carboxyhemoglobin, BM exam</p>
<p class="bl"><span class="sbl">•</span> ± ↑ WBC, platelets, basophils; ↑ uric acid, leukocyte alkaline phosphatase, vit B<sub class="calibre8">12</sub></p>
<p class="bl"><span class="sbl">•</span> Peripheral smear → no morphologic abnormalities</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Phlebotomy</b> to goal Hct &lt;45% <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:22)</span>, consider &lt;42% in women</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Low-dose ASA</b> in all Pts <span class="s1r">(<i class="calibre3">NEJM</i> 2004;350:114)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hydroxyurea</b> if high risk of thrombosis (age ≥60, prior thrombosis) or symptomatic thrombocytosis (plt &gt;1.5 × 10<sup class="calibre15">6</sup>/µL), or if inadequate Hct by phlebotomy alone</p>
<p class="bl"><span class="sbl">•</span> PEG IFNα preferred in younger Pts and pregnancy <span class="s1r">(<i class="calibre3">Lancet Haematol</i> 2017;4:e165)</span></p>
<p class="bl"><span class="sbl">•</span> Ruxolitinib (JAK1/2 inhibitor) if refractory to or intolerant of hydroxyurea <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:426)</span></p>
<p class="bl"><span class="sbl">•</span> Supportive: allopurinol (gout), H<sub class="calibre8">2</sub>-blockers/antihistamines (pruritus)</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> Median survival w/ Rx ~13.5 y <span class="s1r">(<i class="calibre3">Blood</i> 2014;124:2507)</span>; ↑ age, WBC, additional acquired somatic mutations → worse prognosis <span class="s1r">(<i class="calibre3">Haematol</i> 2013;160:251)</span></p>
<p class="bl"><span class="sbl">•</span> Post-PV myelofibrosis (spent phase) occurs in 10–20% of cases, usually after 10 y</p>
<p class="bl"><span class="sbl">•</span> Risk of transformation into acute leukemia (&lt;2–5%)</p>
<p class="h"><a id="page_5-16" class="calibre7"></a>E<small class="calibre30">SSENTIAL</small> T<small class="calibre30">HROMBOCYTHEMIA</small> (ET)</p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Sustained ↑ in platelets (&gt;450,000/µL) ± ↑ RBC and granulocytes</p>
<p class="h2a">Etiologies of thrombocytosis</p>
<p class="bl"><span class="sbl">•</span> 1° = ET or other MPN; myelodysplastic syndromes (5q-syndrome); RARS-T</p>
<p class="bl"><span class="sbl">•</span> 2° = <b class="calibre4">reactive thrombocytosis:</b> inflammation (RA, IBD, vasculitis), infection, acute</p>
<p class="bl1">bleeding, iron deficiency, postsplenectomy, neoplasms (eg, Hodgkin lymphoma)</p>
<p class="bl"><span class="sbl">•</span> Of patients with plt &gt;10<sup class="calibre15">6</sup>/µL, &lt;1 in 6 will have ET</p>
<p class="h2a">Clinical manifestations <span class="s">(also see “Polycythemia Vera”)</span></p>
<p class="bl"><span class="sbl">•</span> Thrombosis with erythromelalgia (risk of thrombosis highest in Pts with leukocytosis), bleeding, pruritus; mild splenomegaly; migraine, TIA; early fetal loss</p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> Peripheral smear: large hypogranular platelets</p>
<p class="bl"><span class="sbl">•</span> BM bx: megakaryocytic hyperplasia; absence of Philadelphia chromosome; rarely minor reticulin fibrosis; normal iron stores; if atypical megakaryoctyes, consider pre-PMF</p>
<p class="bl"><span class="sbl">•</span> Mutations: <b class="calibre4"><i class="calibre3">JAK2</i> V617F</b> in 60-65%; <b class="calibre4"><i class="calibre3">CALR</i></b> in 20-25%; <b class="calibre4"><i class="calibre3">MPL</i></b> in 5%; triple negative 10-15%</p>
<p class="bl"><span class="sbl">•</span> Patients should not meet WHO criteria for diagnosis of CML, PV, PMF, or MDS</p>
<p class="image1"><img src="../images/00092.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> Low-risk Pts have overall survival ≈ control population</p>
<p class="bl"><span class="sbl">•</span> Risk of transformation into acute leukemia &lt;2%; risk of progression to MF similar</p>
<p class="h">P<small class="calibre30">RIMARY</small> M<small class="calibre30">YELOFIBROSIS</small> (PMF)</p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Clonal myeloproliferation with reactive marrow fibrosis &amp; extramedullary hematopoiesis</p>
<p class="bl"><span class="sbl">•</span> Prefibrotic stage (pre-PMF): megakaryocyte prolif, grade 1 reticulin fibrosis, ↑ BM cellularity. Important to distinguish from ET: ↑ thrombosis, ↑ progression, ↓ survival <span class="s1r">(<i class="calibre3">Blood</i> 2012;120:569)</span></p>
<p class="h2a">Etiologies of myelofibrosis</p>
<p class="bl"><span class="sbl">•</span> Myeloproliferative neoplasm = primary myelofibrosis; post-PV/ET myelofibrosis</p>
<p class="bl"><span class="sbl">•</span> Other hematologic (CML, AML, ALL, MDS) and solid cancers (breast, prostate)</p>
<p class="bl"><span class="sbl">•</span> Autoimmune (SLE and other collagen vascular disorders)</p>
<p class="bl"><span class="sbl">•</span> Toxins (benzene); radiation; granulomas (TB, fungal, sarcoid); deposition dis. (Gaucher’s)</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">BJH</i> 2012;158:453)</span></p>
<p class="bl"><span class="sbl">•</span> Ineffective erythropoiesis → anemia; extramedullary hematopoiesis → <b class="calibre4">massive splenomegaly</b> (abdominal pain, early satiety) ± hepatomegaly</p>
<p class="bl"><span class="sbl">•</span> Tumor bulk and ↑ cell turnover → fatigue, weight loss, fever, sweats</p>
<p class="h2a">Diagnostic evaluation <span class="s">(<i class="calibre3">JAMA</i> 2010;303:2513; <i class="calibre3">Blood</i> 2016;127:2391)</span></p>
<p class="bl"><span class="sbl">•</span> Anemia with variable WBC and platelet counts</p>
<p class="bl"><span class="sbl">•</span> Peripheral smear → “<b class="calibre4">leukoerythroblastic</b>” (<b class="calibre4">teardrop cells</b>, nucleated RBCs, immature WBCs); large abnormal platelets</p>
<p class="bl"><span class="sbl">•</span> BM aspirate → “dry” tap; BM bx → <b class="calibre4">severe fibrosis</b>, replacement by reticulin &amp; collagen</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">JAK2</i> V617F</b> in 45–50%; <b class="calibre4"><i class="calibre3">CALR</i></b> mut in 45–50%, <b class="calibre4"><i class="calibre3">MPL</i></b> mut in 7–10%, triple neg in 1–2%</p>
<p class="bl"><span class="sbl">•</span> No BCR-ABL translocation; also does not meet criteria for PV or MDS</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Blood</i> 2011;117:3494)</span></p>
<p class="bl"><span class="sbl">•</span> In absence of adverse prognostic factors (eg, anemia or sx) → no treatment</p>
<p class="bl"><span class="sbl">•</span> Allogeneic HSCT only potential cure → consider in young Pts with poor prognosis</p>
<p class="bl"><span class="sbl">•</span> Supportive care: <b class="calibre4">transfusions;</b> ESA if Epo &lt;500 but risk worsening splenomegaly; consider androgens vs immunomodulatory agents (eg, lenalidomide) + prednisone; ? splenectomy if refractory to transfusions, failed chemoRx, painful splenomegaly</p>
<p class="bl"><span class="sbl">•</span> Hydroxyurea for significant leukocytosis or thrombocytosis</p>
<p class="bl"><span class="sbl">•</span> Ruxolitinib (JAK1/JAK2 inhibitor) ↓ sx, ↓ splenomegaly, ↑ survival <span class="s1r">(<i class="calibre3">NEJM</i> 2012;366:787 &amp; 799)</span></p>
<p class="bl"><span class="sbl">•</span> JAK2 inh: pacritinib, momelotinib, &amp; fedratinib are in phase 3 trials <span class="s1r">(<i class="calibre3">JAMA Oncology</i> 2018;4:652)</span></p>
<p class="bl"><span class="sbl">•</span> Median survival ~6 y <span class="s1r">(<i class="calibre3">JCO</i> 2012;30:2981)</span>; transformation into AML occurs at a rate of ~8%/y</p>
<h2 class="ct"><a id="h70" class="calibre7"></a><a id="page_5-17" class="calibre7"></a><a href="part0002.html#rh78" class="calibre7">LEUKEMIA</a></h2>
<p class="h">A<small class="calibre30">CUTE</small> L<small class="calibre30">EUKEMIA</small></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Clonal proliferation of hematopoietic progenitor with failed differentiation into mature elements → ↑ blasts in bone marrow and periphery → ↓ RBCs, platelets, and neutrophils</p>
<p class="h2a">Epidemiology and risk factors</p>
<p class="bl"><span class="sbl">•</span> Acute myelogenous (AML): ~20k cases/y in U.S.; median age 68 y</p>
<p class="bl"><span class="sbl">•</span> Acute lymphocytic (ALL): ~6k cases/y in U.S.; median age 15 y but 2<sup class="calibre15">nd</sup> peak in older adults</p>
<p class="bl"><span class="sbl">•</span> Risk factors: <b class="calibre4">radiation</b>, <b class="calibre4">chemo</b> (alkylating agents, topo II inhib), benzene, smoking, ? rising from acquired somatic mutations and clonal hematopoiesis <span class="s">(<i class="calibre3">NEJM</i> 2014;371:2477)</span></p>
<p class="bl"><span class="sbl">•</span> Secondary to acquired hematopoietic dis.: MDS, MPN (esp. CML), aplastic anemia, PNH</p>
<p class="bl"><span class="sbl">•</span> Inherited: Down’s, Klinefelter’s, Fanconi’s anemia, Bloom syndrome, ataxia telangiectasia, Li-Fraumeni, germline mutations in <i class="calibre3">RUNX1</i>, <i class="calibre3">CEBPa</i>, &amp; <i class="calibre3">GATA2</i></p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Cytopenias → <b class="calibre4">fatigue</b> (anemia), <b class="calibre4">infection</b> (neutropenia), <b class="calibre4">bleeding</b> (thrombocytopenia)</p>
<p class="bl"><span class="sbl">•</span> More common in <b class="calibre4">AML</b></p>
<p class="bl1"><b class="calibre4">Leukostasis</b> (more often when blast count &gt;50,000/µL): dyspnea, hypoxemia, headache, blurred vision, confusion,TIA/CVA, interstitial infiltrates</p>
<p class="bl1"><b class="calibre4">DIC</b> (esp. with APL); leukemic infiltration of skin, gingiva (esp. with monocytic subtypes); chloroma: extramedullary tumor of leukemic cells, virtually any location</p>
<p class="bl"><span class="sbl">•</span> More common in <b class="calibre4">ALL</b></p>
<p class="bl1">bony/lumbar pain, LAN, hepatosplenomegaly (also in monocytic AML), SVC syndrome</p>
<p class="bl1">CNS involvement (up to 10%): cranial neuropathies, N/V, headache</p>
<p class="bl1">anterior mediastinal mass (esp. in T-cell); tumor lysis syndrome (qv)</p>
<p class="h2a">Diagnostic evaluation <span class="s">(<i class="calibre3">Blood</i> 2009;114:937)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peripheral smear:</b> anemia, thrombocytopenia, variable WBC + circulating <b class="calibre4">blasts</b> (seen in &gt;95%; ⊕ Auer Rods in AML), peripheral flow cytometry for blast origin (ALL vs. AML)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bone marrow:</b> &gt;20% blasts; mostly hypercellular; test for cytogenetics and flow cytometry</p>
<p class="bl"><span class="sbl">•</span> Presence of certain <b class="calibre4">cytogenetic anomalies</b>, eg, t(15;17), t(8;21), inv(16) or t(16;16), are sufficient for dx of AML <i class="calibre3">regardless of the blast count</i></p>
<p class="bl"><span class="sbl">•</span> ✔ for tumor lysis syndrome (rapid cell turnover): ↑ UA, ↑ LDH, ↑ K, ↑ PO<sub class="calibre8">4</sub>, ↓ Ca</p>
<p class="bl"><span class="sbl">•</span> Coagulation studies to r/o DIC: PT, PTT, fibrinogen, D-dimer, haptoglobin, bilirubin</p>
<p class="bl"><span class="sbl">•</span> LP (w/ <b class="calibre4">co-admin of intrathecal chemotherapy</b> to avoid seeding CSF w/ circulating blasts) for Pts w/ ALL (CNS is sanctuary site) and for Pts w/ AML w/ CNS sx</p>
<p class="bl"><span class="sbl">•</span> TTE if prior cardiac history or before use of anthracyclines</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HLA typing</b> of Pt, siblings &gt; parents/children for potential allogeneic HSCT candidates</p>
<p class="h">A<small class="calibre30">CUTE</small> M<small class="calibre30">YELOGENOUS</small> L<small class="calibre30">EUKEMIA</small> <span class="s1">(AML; <i class="calibre22">L<small class="calibre23">ANCET</small></i> 2018;392:593)</span></p>
<p class="h2a">Classification <span class="s">(WHO; <i class="calibre3">Blood</i> 20</span><sup class="calibre15">1</sup><span class="s">6;</span><sup class="calibre15">1</sup><span class="s">27:2391)</span></p>
<p class="bl"><span class="sbl">•</span> Features used to confirm myeloid lineage and subclassify AML to guide treatment: morphology: <b class="calibre4">blasts</b>, ⊕ <b class="calibre4">granules</b>, ± <b class="calibre4">Auer rods</b> (eosinophilic needle-like inclusions)</p>
<p class="bl"><span class="sbl">•</span> Immunophenotype: precursor: CD34, CD45, HLA-DR; myeloid: CD13, CD33, CD117; monocyte: CD11b, CD64, CD14, CD15</p>
<p class="bl"><span class="sbl">•</span> Prognosis: <i class="calibre3">age</i>, prior <i class="calibre3">antecedent MPN/MDS</i> and <i class="calibre3">genetics</i> (cytogenetics + molecular mutation status) are key independent risk factors</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">ENL 2017 Genetic Risk Classification</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Blood</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">7;</span><span class="tfont">1</span><span class="tfont1">29:424)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Risk Category</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Genetic Abnormality</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Favorable</p></td>
<td class="bg0-b"><p class="tab">APL: t(15;17);</p>
<p class="tab">t(8;21): RUNX1-RUNX1T1; inv(16): CBFB-MYH1;</p>
<p class="tab">mutated <i class="calibre3">NPM1 w/o FLT3-ITD or w/ FLT3-ITD<sup class="calibre35">low</sup></i>;</p>
<p class="tab">biallelic mutation in <i class="calibre3">CEBPA</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Intermediate</p></td>
<td class="bg0-b"><p class="tab">FLT3-ITD<sup class="calibre35">low</sup>; mutated NPM1 &amp; FLT3-ITD<sup class="calibre35">high</sup>;</p>
<p class="tab">t(9;11): MLL-MLLT3;</p>
<p class="tabh">cytogenetic abnl not classified as favorable or adverse, including normal karyotype w/o mutations in FLT3-ITD &amp; NPM1</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Adverse</p></td>
<td class="bg"><p class="tab">-5 or del(5q); -7; -17/abn(17p); complex or monosomal karyotype;</p>
<p class="tab">t(6;9): DEK-NUP214 ; t(9;22) BCR-ABL1; inv(3): GATA2-MECOM;</p>
<p class="tab">wildtype NPM1 &amp; FLT-ITD<sup class="calibre35">high</sup>;</p>
<p class="tab">mutated TP53, RUNX1, ASXL1</p></td>
</tr>
</table>
<p class="h2a"><a id="page_5-18" class="calibre1"></a>Upfront treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Induction chemo</b> “7+3”: 7 d cont. infusion cytarabine (Ara-C) + 3 d bolus anthracycline</p>
<p class="bl"><span class="sbl">•</span> Ability to tolerate 7+3 regimen key determinant in subsequent Rx received (see below)</p>
<p class="bl"><span class="sbl">•</span> Newer regimens if <b class="calibre4"><i class="calibre3">fit</i></b> (generally age &lt;75 y)</p>
<p class="bl1">FLT3-ITD/TKD mutation: 7+3+midostaurin (early generation FLT3 inhib; <i class="calibre3">NEJM</i> 2017;377:454)</p>
<p class="bl1">Cord-binding factor ⊕ → t(8;21) or inv(16): 7+3 ± gemtuzumab ozogamicin (mAb+cytotoxin)</p>
<p class="bl1">2° AML or w/ MDS-related changes: CPX-351 (liposomal Ara-C &amp; daunorubicin)</p>
<p class="bl1">Other: age &lt;60 y: 7+3 (high-dose daunorubicin 90 mg/m<sup class="calibre15">2</sup>); &gt;60 y: dauno 60 mg/m<sup class="calibre15">2</sup></p>
<p class="bl"><span class="sbl">•</span> Newer regimens if <b class="calibre4"><i class="calibre3">unfit</i></b> (generally age ≥75 y or comorbidities; <i class="calibre3">Leukemia</i> 2013;27:997)</p>
<p class="bl1">venetoclax (Bcl2 inhibitor) + <i class="calibre3">either</i> hypomethylating agents (azacytidine or decitabine) <i class="calibre3">or</i> low-dose cytarabine <span class="s1r">(<i class="calibre3">Blood</i> 2019;133:7)</span></p>
<p class="h2a">Consolidation therapy</p>
<p class="bl"><span class="sbl">•</span> If enters <i class="calibre3">complete remission</i> (CR) = ANC &gt;1000, plts &gt;100, off RBC Rx, &lt;5% BM blasts</p>
<p class="bl"><span class="sbl">•</span> CR does <i class="calibre3">not</i> equal cure</p>
<p class="bl"><span class="sbl">•</span> Favorable risk: high-dose cytarabine (HiDAC); Intermediate/Poor risk: Allo-HSCT</p>
<p class="h2a">Refractory/relapsed disease</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Repeating mutation analysis</i> key b/c clonal evolution common and may affect Rx</p>
<p class="bl"><span class="sbl">•</span> FLT3-ITD/TKD mutation: gilteritinib or quizartinib (both potent FLT3 inhibitors)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">IDH1</i> mutation: ivosidenib; <i class="calibre3">IDH2</i> mutation: enasidenib (small-molecule inhib of IDH1 or 2)</p>
<p class="bl"><span class="sbl">•</span> Chemo: MEC (mitoxantrone, etoposide, Ara-C); FLAG-Ida (fludarabine, Ara-C, G-CSF, &amp; idarubicin); CLAM (clofarabine, Ara-C, mitoxantrone)</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> CR achieved in 70–80% of Pts &lt;60 y and in 40–50% for Pts &gt;60 y</p>
<p class="bl"><span class="sbl">•</span> Overall survival variable, depends on prognostic factors: ranges from &lt;10% of older Pts w/ poor-risk tumor genetics to &gt;65% for younger Pts w/ favorable prognostic factors</p>
<p class="h2a">Acute promyelocytic leukemia (APL) <span class="s">(<i class="calibre3">Blood</i> 2009;113:1875)</span></p>
<p class="bl"><span class="sbl">•</span> Rare, ~8% of AML in U.S.; &gt;90% cure rates</p>
<p class="bl"><span class="sbl">•</span> Atypical promyelocytes (large, granular cells; bilobed nuclei) in blood and bone marrow</p>
<p class="bl"><span class="sbl">•</span> Defined by translocation of retinoic acid receptor: <b class="calibre4">t(15;17); <i class="calibre3">PML-RARA</i></b> (&gt;95% of cases)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Medical emergency</b> with <b class="calibre4">DIC</b> and <b class="calibre4">bleeding</b> common</p>
<p class="bl"><span class="sbl">•</span> Remarkable responses to <b class="calibre4">all-<i class="calibre3">trans</i>-retinoic acid (ATRA)</b> &amp; <b class="calibre4">arsenic trioxide (ATO)</b>, which induce differentiation of leukemic blasts. ∴ early initiation as soon as APL <i class="calibre3">suspected</i></p>
<p class="bl"><span class="sbl">•</span> Non-high-risk APL: ATRA + ATO (induction + 4 cycles consolidation) → CR ~100%; event-free survival 97% and overall survival 99% at 2 y <span class="s1r">(<i class="calibre3">NEJM</i> 2013;362:111)</span></p>
<p class="bl"><span class="sbl">•</span> High-risk APL: WBC &gt;10k at diagnosis. No clear consensus. In general, chemo (anthracycline or gemtuzumab ozogamicin) added to ATRA + ATO induction and consolidation.</p>
<p class="bl"><span class="sbl">•</span> Differentiation (ATRA) syndrome: ~25% of Pts; fever, pulm infiltrates, SOB, edema, HoTN, AKI; tx w/ dexamethasone 10 mg bid, supportive care (eg, diuresis) <span class="s1r">(<i class="calibre3">Blood</i> 2008;113:775)</span></p>
<p class="h">A<small class="calibre30">CUTE</small> L<small class="calibre30">YMPHOBLASTIC</small> L<small class="calibre30">EUKEMIA</small> (ALL)</p>
<p class="h2a">Classification</p>
<p class="bl"><span class="sbl">•</span> Lymphoblastic neoplasms may present as acute leukemia (ALL) with &gt;<b class="calibre4">20% BM blasts</b> or as lymphoblastic lymphoma (LBL) w/ mass lesion w/ &lt;20% BM blast</p>
<p class="bl"><span class="sbl">•</span> Morphology: <b class="calibre4">no granules</b> (granules seen in myeloid lineage)</p>
<p class="bl"><span class="sbl">•</span> Cytochemistry: ⊕ terminal deoxynucleotidyl transferase (TdT) in 95% of ALL</p>
<p class="bl"><span class="sbl">•</span> Immunophenotype</p>
<p class="bl1">Precursor: CD34, TdT</p>
<p class="bl1">B: CD19; variable CD10, CD22, CD79a</p>
<p class="bl1">T: CD1a, CD2, cytoplasmic CD3, CD5, CD7</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Induction chemo</b></p>
<p class="bl1">Ph ⊕ t(9;22) (seen in ~25% of B-ALL): tyrosine kinase inhibitor + chemo/steroids Adolescents &amp; young adults (&lt;40 y): pedi-like regimen typically w/ PEG-asparaginase Adults (40–75 y): multiagent chemo incl. anthracycline, vincristine, steroids, CYC Older (&gt;75 y): reduced-intensity chemo</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CNS prophylaxis:</b> intrathecal MTX/cytarabine ± cranial irradiation <i class="calibre3">or</i> systemic MTX</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Postremission therapy</b> (choice depends on risk of recurrence)</p>
<p class="bl1"><span class="sbl">1)</span> Average risk: consolidation/intensification chemo (~7 mo) → maintenance (~2–3 y)</p>
<p class="bl1"><span class="sbl">2)</span> High risk: high-dose chemo w/ allo HSCT considered for Pts in CR1. High-risk disease includes: Ph ⊕; Ph-like (based on gene expression); MLL translocation t(4;11); complex karyotype; hypodiploid (&lt;44 chromosomes); early T-cell phenotype (ETP; lacks CD1a, CD8, CD5<sup class="calibre15">weak</sup>, myeloid markers); minimal residual disease (MRD) = morphologic remission but flow cytometry or molec. markers of tumor still detectable.</p>
<p class="bl"><a id="page_5-19" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Relapse/refractory:</b> salvage therapy (<i class="calibre3">below</i>), then allogeneic HSCT if able</p>
<p class="bl1"><i class="calibre3">B cell:</i> blinatumomab (CD19 BiTE-bispecific T-cell engager; <i class="calibre3">NEJM</i> 2017;376:836), inotuzumab (CD22 Ab drug conjugate; <i class="calibre3">NEJM</i> 2016;375:740); tisagenlecleucel (CD19 CAR-T cell, <i class="calibre3">NEJM</i> 2018;378:449), TKI+chemo/steroids (Ph ⊕ t(9;22) only)</p>
<p class="bl1"><i class="calibre3">T cell:</i> nelarabine</p>
<p class="bl1"><i class="calibre3">Both B &amp; T cell:</i> chemo including high-dose cytarabine regimens; clofarabine</p>
<p class="h">C<small class="calibre30">HRONIC</small> M<small class="calibre30">YELOGENOUS</small> L<small class="calibre30">EUKEMIA</small> (CML)</p>
<p class="h2a">Definition <span class="s">(<i class="calibre3">Blood</i> 2009;114:937)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Myeloproliferative neoplasm</b> with clonal overproduction of hematopoietic myeloid stem cells that can differentiate</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Philadelphia chromosome</b> (Ph) = t(9;22) → <b class="calibre4">BCR-ABL</b> fusion → ↑ Abl kinase activity</p>
<p class="bl1"><i class="calibre3">BCR-ABL required for diagnosis</i> (make via karyotyping or FISH; PCR)</p>
<p class="h2a">Epidemiology and risk factors</p>
<p class="bl"><span class="sbl">•</span> ~6600 new cases/y in U.S.; median age ~64 at presentation; ~15% of adult leukemias</p>
<p class="bl"><span class="sbl">•</span> ↑ risk with irradiation; no clear relation to cytotoxic drugs</p>
<p class="h2a">Disease classification &amp; manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chronic phase (CP):</b> &lt;10% blasts (peripheral or bone marrow)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Accelerated phase (AP):</b> 10–19% blasts, ≥20% basos, plts &lt;100k, clonal evolution (karyotype changes) not seen at dx, megakaryocyte proliferation &amp; fibrosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Blastic phase (BP):</b> ≥20% blasts (2/3 w/ myeloid, 1/3 w/ lymphoid), may see extramedullary leukemia</p>
<p class="bl"><span class="sbl">•</span> 85% present in the chronic phase, classic triphasic clinical course rarely seen in TKI era</p>
<p class="bl"><span class="sbl">•</span> Most Pts asx or may have mild constitutional s/s related to splenomegaly.</p>
<p class="bl"><span class="sbl">•</span> Worsening constitutional sx, bone pain, rapid ↑ in spleen size herald disease progression</p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peripheral smear: leukocytosis</b>, left-shifted with <i class="calibre3">all stages of myeloid maturation;</i> anemia, thrombocytosis, <b class="calibre4">basophilia</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bone marrow with karyotype:</b> hypercellular, ↑ myeloid to erythroid ratio</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Lancet</i> 2015;385:1447; <i class="calibre3">Hematol Oncol Clin North Am</i> 2017;31:577)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Tyrosine kinase inhibitors (TKI)</b> inhibit abl kinase activity</p>
<p class="bl1">First line: imatinib, 1<sup class="calibre15">st</sup> TKI against BCR-ABL, remains gold standard <span class="s1r">(<i class="calibre3">NEJM</i> 2017;376:917)</span>. 2<sup class="calibre15">nd</sup> gen TKI: nilotinib, dasatinib, bosutinib; ↑ potency abl inhibitors, but ↑ toxicity.</p>
<p class="bl1">Resistance: due to ↑ in BCR-ABL transcript level on TKI, often result of <i class="calibre3">BCR-ABL</i> mutation or amplification. Nilotinib, dasatinib, bosutinib &amp; ponatinib approved for resistant disease, w/ only ponatinib effective on T315I resistance mutation <span class="s1r">(<i class="calibre3">NEJM</i> 2012;367:2075)</span>.</p>
<p class="bl1">Side effects: nausea, diarrhea, muscle cramps, cytopenias, ↓ PO<sub class="calibre8">4</sub>, ↑ QT, rarely CHF; dasatinib: pericardial &amp; pleural effusions and pulm HTN; nilotinib: ↑ bili &amp; lipase, CV toxicity; ponatinib: pancreatitis and arterial vascular events (cerebral, cardiac, &amp; PAD)</p>
<p class="bl"><span class="sbl">•</span> TKI discontinuation: consider if complete molecular response (&gt;4.5 log reduction in bcr-abl transcript) for &gt;2 y. Up to 50% of Pts remain off TKI at 2 y (ie, no molec. recurrence). Likelihood of success proportional to duration of CMR and risk score at presentation.</p>
<p class="bl"><span class="sbl">•</span> Consider upfront allogeneic HSCT for AP and BP.</p>
<p class="bl"><span class="sbl">•</span> CML in pregnancy: hydroxyurea &amp; all TKIs contraindicated. If Rx needed IFN an option.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre34"/>
<col class="calibre33"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Milestones of Therapy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Definition</b></p></td>
<td class="bg0-b"><p class="tabheadc"><b class="calibre4">Optimal Time</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">BCR-ABL ratio &lt;10% IS = 1-log reduction by quantitative PCR</p></td>
<td class="bg0-b"><p class="tabheadc">3 mo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">BCR-ABL ratio &lt;1% IS or &lt;35% Ph chr in metaphase cells</p></td>
<td class="bg0-b"><p class="tabheadc">6 mo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Absence of the Ph chromosome in metaphase cells</p></td>
<td class="bg0-b"><p class="tabheadc">12 mo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">BCR-ABL ratio &lt;0.1% IS = 3-log reduction by quantitative PCR</p></td>
<td class="bg0-b"><p class="tabheadc">12 mo</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab">BCR-ABL ratio determined using RT-PCR &amp; compares expression of BCR-ABL fusion in Pt to averaged expression in unRx’d Pts. Reported on International Scale (IS), which standardizes reporting across labs.</p></td>
</tr>
</table>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">NEJM</i> 2017;376:917)</span></p>
<p class="bl"><span class="sbl">•</span> Chronic phase CML Rx’d w/ imatinib: 89% 5-y overall survival, 95% survival free of CML-related deaths, 7% progression to blast phase at 5 y <span class="s1r">(<i class="calibre3">NEJM</i> 2006;355:2408)</span>. Pts with 4 log ↓ in bcr-abl transcript have normal life expectancy.</p>
<p class="h">C<small class="calibre30">HRONIC</small> L<small class="calibre30">YMPHOCYTIC</small> L<small class="calibre30">EUKEMIA</small> (CLL)</p>
<p class="cst"><i class="calibre3">see “Small Lymphocytic Lymphoma”</i></p>
<h2 class="ct"><a id="h71" class="calibre7"></a><a id="page_5-20" class="calibre7"></a><a href="part0002.html#rh79" class="calibre7">LYMPHOMA</a></h2>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Malignant disorder of lymphoid cells that reside predominantly in lymphoid tissues</p>
<p class="bl"><span class="sbl">•</span> Generally characterized as <b class="calibre4">Hodgkin lymphoma</b> (HL) or <b class="calibre4">non-Hodgkin lymphoma</b> (NHL)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Lymphadenopathy (nontender)</p>
<p class="bl1"><b class="calibre4">HL: Reed-Sternberg</b> (RS) <b class="calibre4">cells;</b> superficial (usually <b class="calibre4">cervical</b>/<b class="calibre4">supraclavicular</b>) ± mediastinal LAN; <b class="calibre4">nodal</b> disease with <b class="calibre4">orderly</b>, <b class="calibre4">anatomic spread</b> to adjacent nodes</p>
<p class="bl1"><b class="calibre4">NHL:</b> diffuse; <b class="calibre4">nodal and/or extranodal</b> disease with <b class="calibre4">noncontiguous spread;</b> symptoms reflect involved sites (abdominal fullness, bone pain)</p>
<p class="bl"><span class="sbl">•</span> Constitutional (“B”) symptoms: <b class="calibre4">fever</b> (&gt;38°), drenching <b class="calibre4">sweats</b>, ↓ <b class="calibre4">weight</b> (&gt;10% in 6 mo)</p>
<p class="bl1"><b class="calibre4">HL:</b> periodic, recurrent “Pel-Ebstein” fever; 10–15% have pruritus; ~35% “B” symptoms</p>
<p class="bl1"><b class="calibre4">NHL:</b> “B” symptoms vary between subtypes, ~15–50%</p>
<p class="h2a">Diagnostic and staging evaluation</p>
<p class="bl"><span class="sbl">•</span> Physical exam: lymph nodes, liver/spleen size, Waldeyer’s ring, testes (~1% of NHL), skin</p>
<p class="bl"><span class="sbl">•</span> Pathology: <b class="calibre4">excisional lymph node bx</b> (not FNA b/c need surrounding architecture) with immunophenotyping and cytogenetics; <b class="calibre4">BM</b> bx or <b class="calibre4">PET</b> (except in HL clinical stage IA/IIA w/ favorable features or CLL by flow); LP if CNS involvement clinically suspected</p>
<p class="bl"><span class="sbl">•</span> Lab tests: CBC, BUN/Cr, LFTs, ESR, LDH, UA, Ca, alb; ✔ HBV &amp; HCV (and must ✔ HBsAg &amp; anti-HBc if planning rituximab Rx, b/c can lead to HBV reactivation); consider HIV, HTLV, &amp; EBV serologies and connective tissue diseases autoAbs</p>
<p class="bl"><span class="sbl">•</span> Imaging: PET-CT scans b/c CT alone does <b class="calibre4">not</b> reliably detect spleen/liver involvement (espec. in HL, DLBCL). PET response to Rx can be prognostic &amp; possibly guide Rx <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:1598 &amp; 2016;374:2419)</span>. Head CT/MRI <i class="calibre3">only</i> if neurologic symptoms.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre42"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Ann Arbor Staging System with Cotswolds Modifications</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Stage</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Features</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">I</p></td>
<td class="bg0-b"><p class="tab">Single lymph node (LN) region</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">II</p></td>
<td class="bg0-b"><p class="tab">≥2 LN regions on the same side of the diaphragm</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">III</p></td>
<td class="bg0-b"><p class="tab">LN regions on both sides of the diaphragm</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">IV</p></td>
<td class="bg0-b"><p class="tab">Disseminated involvement of one or more extralymphatic organs</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab">Modifiers: A = no symptoms; B = fever, night sweats or weight loss; X = bulky disease = greatest transverse diam. of mediastinal mass/max diam. of chest wall &gt;1/3 on CXR or &gt;10 cm if in abd; E = involves single contiguous extranodal site; H = hepatic; S = splenic</p></td>
</tr>
</table>
<p class="h">H<small class="calibre30">ODGKIN</small> L<small class="calibre30">YMPHOMA</small> (HL) <span class="s1">(<i class="calibre22">Am J Hematol</i> 2018;93:704)</span></p>
<p class="h2a">Epidemiology and risk factors</p>
<p class="bl"><span class="sbl">•</span> ~9,000 cases/y; bimodal distribution (15–35 &amp; &gt;50 y); ↑ ♂; role of EBV in subsets of HL, esp. immunocompromised patients (eg, HIV)</p>
<p class="h2a">Pathology</p>
<p class="bl"><span class="sbl">•</span> Affected nodes show RS cells (&lt;1%) in background of non-neoplastic inflammatory cells</p>
<p class="bl"><span class="sbl">•</span> Classic RS cells: bilobed nucleus &amp; prominent nucleoli with surrounding clear space (“owl’s eyes”). RS cells are <b class="calibre4">clonal B-cells:</b> CD15+, CD30+, CD20– (rarely +).</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre41"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">WHO Histologic Classification of Classical HL</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Nodular sclerosis</b></p></td>
<td class="bg0-br"><p class="tabheadc">60–80%</p></td>
<td class="bg0-b"><p class="tab">Collagen bands; frequent mediastinal LAN; young adults; female predominance; usually stage I or II at dx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Mixed cellularity</b></p></td>
<td class="bg0-br"><p class="tabheadc">15–30%</p></td>
<td class="bg0-b"><p class="tab">Pleomorphic; older age; male predominance; ≥50% stage III or IV at presentation; intermediate prognosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Lymphocyte rich</b></p></td>
<td class="bg0-br"><p class="tabheadc">5%</p></td>
<td class="bg0-b"><p class="tab">Abundant normal-appearing lymphocytes; mediastinal LAN uncommon; male predominance; good prognosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Lymphocyte depleted</b></p></td>
<td class="bg0-r"><p class="tabheadc">&lt;1%</p></td>
<td class="bg"><p class="tab">Diffuse fibrosis and large numbers of RS cells; older, male patients; disseminated at dx; seen in HIV; worst prognosis</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonclassical</b> (5%): nodular lymphocyte predominant (NLP); involves peripheral LN</p>
<p class="bl1">80% present in stages I–II and Rx can be RT alone or combination chemo + RT w/ 4-yr progression-free survival 88% and overall survival 96% <span class="s">(<i class="calibre3">JCO</i> 2008;26:434)</span></p>
<p class="bl1">Consider rituximab because most NLP RS cells are CD20+</p>
<p class="bl1">Stages III–IV treated with combination chemo (see below)</p>
<p class="h2a"><a id="page_5-21" class="calibre1"></a>Treatment <span class="s">(<i class="calibre3">Lancet</i> 2012;380:836)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stages I–II: ABVD</b> (doxorubicin, bleomycin, vinblastine, dacarbazine) ± RT if favorable disease</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Stages III–IV: ABVD</b> × 6 cycles (can omit B if PET ⊖ after 2 cycles <i class="calibre3">NEJM</i> 2016;374:2419; brentuximab (anti-CD30) may replace bleo but more toxic <span class="s1r">(<i class="calibre3">NEJM</i> 2018;378:331)</span>; or <b class="calibre4">escalated BEACOPP</b> (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone); add RT for select Pts as consolidation</p>
<p class="bl"><span class="sbl">•</span> Refractory/relapsed disease: salvage chemo + auto HSCT ± RT</p>
<p class="bl1">brentuximab vedotin post-ASCT yields some long-term remissions <span class="s1r">(<i class="calibre3">Blood</i> 2016;128:1562)</span></p>
<p class="bl1">PD1/PDL1 blockade (eg, pembrolizumab or nivolumab) <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:311)</span></p>
<p class="bl"><span class="sbl">•</span> Late effects include ↑ risk for:</p>
<p class="bl1"><b class="calibre4">Second cancers:</b> ~4.6× risk for up to 40 y <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:2499)</span></p>
<p class="bl2"><i class="calibre3">breast</i> (if RT), ∴ annual screening at age 40 or 8–10 y post RT</p>
<p class="bl2"><i class="calibre3">lung</i>, efficacy of screening chest CT remains a topic of research</p>
<p class="bl2"><i class="calibre3">acute leukemia/MDS; NHL</i></p>
<p class="bl1"><b class="calibre4">Cardiac disease</b> (if RT or anthracycline), ? role of echo/stress at 10 y (controversial)</p>
<p class="bl1"><b class="calibre4">Pulmonary toxicity</b> (if bleomycin)</p>
<p class="bl1"><b class="calibre4">Hypothyroidism</b> (if RT), ∴ annual TSH (if neck RT)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre24"/>
<col class="calibre29"/>
<col class="calibre41"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">International Prognostic Score (IPS</b>) <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JCO</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">2;30:3383)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Negative Prognostic Indicators</b></p></td>
<td class="bg0-br"><p class="tabheadc"><b class="calibre4">Total # of Indicators</b></p></td>
<td class="bg0-b"><p class="tabheadc"><b class="calibre4">5-y PFS</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Albumin &lt;4 g/dL; Hb &lt;10.5 g/dL</p>
<p class="tab">Male; Age &gt;45 y</p>
<p class="tab">Stage IV</p>
<p class="tab">WBC ≥15k/µL</p>
<p class="tab">Lymphocytes &lt;600/µL or &lt;8% of differential</p></td>
<td class="bg0-r"><p class="tabc">0</p>
<p class="tabc">1</p>
<p class="tabc">2</p>
<p class="tabc">3</p>
<p class="tabc">4</p>
<p class="tabc">≥5</p></td>
<td class="bg"><p class="tabheadc">88%</p>
<p class="tabheadc">84%</p>
<p class="tabheadc">80%</p>
<p class="tabheadc">74%</p>
<p class="tabheadc">67%</p>
<p class="tabheadc">62%</p></td>
</tr>
</table>
<p class="h">N<small class="calibre30">ON</small>-H<small class="calibre30">ODGKIN</small> L<small class="calibre30">YMPHOMA</small> (NHL)</p>
<p class="h2a">Epidemiology and risk factors</p>
<p class="bl"><span class="sbl">•</span> ~70,000 new cases/y; median age at dx ~65 y; ♂ predominance; 85% B-cell origin</p>
<p class="bl"><span class="sbl">•</span> Associated conditions: immunodeficiency (eg, HIV, posttransplant); autoimmune</p>
<p class="bl1">disorders (eg, Sjögren’s, RA, SLE); infection (eg, EBV, HTLV-I, <i class="calibre3">H. pylori</i>)</p>
<p class="bl"><span class="sbl">•</span> Burkitt lymphoma: (1) endemic or African (jaw mass, 80–90% EBV-related); (2) sporadic or American (20% EBV-related); (3) HIV-related</p>
<p class="image1"><img src="../images/00093.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Lancet</i> 2017;390:298)</span></p>
<p class="bl"><span class="sbl">•</span> Treatment and prognosis determined by histopathologic classification rather than stage</p>
<p class="bl"><span class="sbl">•</span> Rituximab (anti-CD20; <i class="calibre3">NEJM</i> 2012;366:2008) if CD20+</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Indolent:</b> generally no cure (except allo HSCT), goal sx mgmt (bulky dis, cytopenia, “B” sx)</p>
<p class="bl1">Initial: RT if localized, rituximab + chemo (bendamustine, CVP, fludarabine), ibrutinib. Obinutuzumab (anti-CD20) + chemo w/ obinutuzumab maintenance ↑ PFS but ↑ toxicity <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:1331)</span></p>
<p class="bl1">Maintenance: rituximab in indolent, aggressive, and relapsed disease <span class="s1r">(<i class="calibre3">Lancet</i> 2011;377:42)</span></p>
<p class="bl1">Hairy cell: cladribine; oral BRAF inhibitor if relapsed/refractory <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:1733)</span></p>
<p class="bl1">Gastric MALT: can cure by treating <i class="calibre3">H. pylori</i> if ⊕, RT for relapsed/refractory</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aggressive:</b> goal is cure <span class="s1r">(<i class="calibre3">Am J Hematol</i> 2019;94:604)</span>, treatment depends on subtype</p>
<p class="bl1"><a id="page_5-22" class="calibre1"></a><b class="calibre4">R-CHOP</b> (<span class="underline">r</span>ituximab, <span class="underline">c</span>yclophosphamide, doxorubicin = <span class="underline">h</span>ydroxydaunorubicin, vincristine = <span class="underline">O</span>ncovin, <span class="underline">p</span>rednisone) <span class="s1r">(<i class="calibre3">NEJM</i> 2002;346:235 &amp; 2008;359:613)</span> DLBCL 10-y PFS = 45%; overall survival = 55% <span class="s1r">(<i class="calibre3">Blood</i> 2010;116:2040)</span></p>
<p class="bl1">+ <b class="calibre4">Radiation</b> for localized or bulky disease</p>
<p class="bl1">Consider <b class="calibre4">CNS prophylaxis</b> w/ intrathecal or systemic high-dose methotrexate if paranasal sinus, testicular, breast, periorbital, paravertebral, or bone marrow involved; ≥2 extranodal sites + ↑ LDH may also warrant</p>
<p class="bl1">Refractory/relapsed disease: salvage chemo; high-dose chemo + auto-HSCT <span class="s1r">(<i class="calibre3">JCO</i> 2001;19:406)</span>; allo-HSCT if beyond 2<sup class="calibre15">nd</sup> relapse <span class="s1r">(<i class="calibre3">JCO</i> 2011;29:1342)</span></p>
<p class="bl1"><b class="calibre4">CAR-T</b> (qv): axicabtagene or tisagenlecleucel <span class="s1r">(<i class="calibre3">NEJM</i> 2017;377:2531 &amp; 2545)</span></p>
<p class="bl1">Mantle cell: ibrutinib for relapsed/refractory disease <span class="s1r">(<i class="calibre3">Lancet</i> 2016;387:770)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Highly aggressive</b></p>
<p class="bl1"><b class="calibre4">Burkitt:</b> dose-adjusted EPOCH-R <span class="s1r">(<i class="calibre3">NEJM</i> 2013;369:1915)</span> or CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, ifosfamide, etoposide, high-dose cytarabine rituximab) <span class="s1r">(<i class="calibre3">Blood</i> 2008;112:2248)</span></p>
<p class="bl1">All Pts receive CNS prophylaxis &amp; tumor lysis syndrome prophylaxis</p>
<p class="bl1">Addition of rituximab improves EFS <span class="s1r">(<i class="calibre3">Lancet</i> 2016;387:2402)</span></p>
<p class="bl1"><b class="calibre4">Lymphoblastic lymphoma</b> (B or T cell): treated like ALL (see “Acute Leukemia”)</p>
<p class="bl1"><b class="calibre4">High-grade B-cell lymphoma w/ rearrangements of MYC and BCL2 and/or BCL6:</b> previously “double-/triple-hit” lymphoma, assoc. w/ poor prognosis</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> Indolent: typically incurable, but long median survival</p>
<p class="bl"><span class="sbl">•</span> Aggressive: ↑ chance of cure, but overall worse prognosis</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre49"/>
<col class="calibre49"/>
<col class="calibre50"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">Follicular Lymphoma International Prognostic Index (FLIPI)</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Blood</i></span> <span class="tfont1">2004;</span><span class="tfont">1</span><span class="tfont1">04:</span><span class="tfont">1</span><span class="tfont1">258)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="3"><p class="tabc">Factors: age &gt;60, stages III/IV, Hb &lt;12 g/dL, &gt;4 nodal areas, LDH &gt;nl</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4"># Factors</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">5-y Overall Survival</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">10-y Overall Survival</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">0–1</p></td>
<td class="bg0-br"><p class="tabc">90%</p></td>
<td class="bg0-b"><p class="tabc">71%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">2</p></td>
<td class="bg0-br"><p class="tabc">78%</p></td>
<td class="bg0-b"><p class="tabc">51%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">≥3</p></td>
<td class="bg0-r"><p class="tabc">52%</p></td>
<td class="bg"><p class="tabc">35%</p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre49"/>
<col class="calibre49"/>
<col class="calibre50"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">International Prognostic Index (IPI) for Aggressive NHL</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Blood</i></span> <span class="tfont1">2007;</span><span class="tfont">1</span><span class="tfont1">09:</span><span class="tfont">1</span><span class="tfont1">857)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="3"><p class="tabc">Factors: age &gt;60, stage III/IV, ≥2 extranodal sites, performance status ≥2, LDH &gt; nl</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4"># Factors</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">Complete Response</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">5-y Overall Survival</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">0–1</p></td>
<td class="bg0-br"><p class="tabc">87%</p></td>
<td class="bg0-b"><p class="tabc">73%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">2</p></td>
<td class="bg0-br"><p class="tabc">67%</p></td>
<td class="bg0-b"><p class="tabc">51%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">3</p></td>
<td class="bg0-br"><p class="tabc">55%</p></td>
<td class="bg0-b"><p class="tabc">43%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">4–5</p></td>
<td class="bg0-br"><p class="tabc">44%</p></td>
<td class="bg0-b"><p class="tabc">26%</p></td>
</tr>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">Revised IPI Prognosis in Patients Rx’d with CHOP-R</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Factors</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">% at Dx</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">4-y Overall Survival</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">0</p></td>
<td class="bg0-br"><p class="tabc">10%</p></td>
<td class="bg0-b"><p class="tabc">94%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">1–2</p></td>
<td class="bg0-br"><p class="tabc">45%</p></td>
<td class="bg0-b"><p class="tabc">79%</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">3–5</p></td>
<td class="bg0-r"><p class="tabc">45%</p></td>
<td class="bg"><p class="tabc">55%</p></td>
</tr>
</table>
<p class="h2a">HIV-associated NHL <span class="s">(<i class="calibre3">Blood</i> 2006;107:13)</span></p>
<p class="bl"><span class="sbl">•</span> HIV ⊕ imparts 60–100× relative risk</p>
<p class="bl"><span class="sbl">•</span> NHL is an AIDS-defining malignancy along with Kaposi’s, cervical CA, anal CA</p>
<p class="bl"><span class="sbl">•</span> Concurrent HAART &amp; chemotherapy likely provide survival benefit</p>
<p class="bl"><span class="sbl">•</span> DLBCL &amp; immunoblastic lymphoma (67%): CD4 &lt;100, EBV-associated Treat as immunocompetent (CHOP-R), but avoid rituximab if CD4 &lt;100 Alternative regimens include R-EPOCH (etop, pred, vincristine, cyclophos, doxorubicin)</p>
<p class="bl"><span class="sbl">•</span> Burkitt lymphoma (20%): can occur with CD4 &gt;200 Treat as immunocompetent; prognosis is not significantly worse</p>
<p class="bl"><span class="sbl">•</span> Primary CNS lymphoma (16%): CD4 &lt;50, EBV-associated (also seen in Pts w/o HIV). Rx w/ high-dose MTX-based regimen + steroids ± temozolomide ± RT, consider auto HSCT.</p>
<p class="bl"><span class="sbl">•</span> Primary effusion lymphoma (&lt;5%): HHV8 driven; also can be seen in other immuno- supp. Pts such as s/p solid organ transplant or w/ chronic HBV. Treat with standard CHOP (often CD20–) or consider EPOCH, overall poor prognosis.</p>
<p class="h"><a id="page_5-23" class="calibre7"></a>S<small class="calibre30">MALL</small> L<small class="calibre30">YMPHOCYTIC</small> L<small class="calibre30">YMPHOMA</small> (SLL) <small class="calibre30">OR</small> C<small class="calibre30">HRONIC</small> L<small class="calibre30">YMPHOCYTIC</small> L<small class="calibre30">EUKEMIA</small> (CLL)</p>
<p class="h2a">Definition <span class="s">(<i class="calibre3">NEJM</i> 2005;352:804; <i class="calibre3">Blood</i> 2008;111:5446)</span></p>
<p class="bl"><span class="sbl">•</span> Monoclonal accumulation of functionally incompetent mature B lymphocytes</p>
<p class="bl"><span class="sbl">•</span> CLL (&gt;5000/µL malignant cells) &amp; small lymphocytic lymphoma (SLL; &lt;5000/µL malignant cells, with + LAN ± splenomegaly) classified as same disease</p>
<p class="bl"><span class="sbl">•</span> Monoclonal B lymphocytosis: resembles but does not meet CLL criteria, observe</p>
<p class="h2a">Epidemiology and risk factors</p>
<p class="bl"><span class="sbl">•</span> ~15,000 new cases/y; median age at dx is 71 y; most common adult leukemia</p>
<p class="bl"><span class="sbl">•</span> ↑ incidence in 1<sup class="calibre15">st</sup>-degree relatives; no known association with radiation, chemicals, drugs</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Symptoms: <b class="calibre4">often asx</b> &amp; identified when CBC reveals lymphocytosis; 10–20% p/w fatigue, malaise, night sweats, weight loss (ie, lymphoma “B” sx)</p>
<p class="bl"><span class="sbl">•</span> Signs: <b class="calibre4">lymphadenopathy</b> (80%) and <b class="calibre4">hepatosplenomegaly</b> (50%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Autoimmune hemolytic anemia</b> (AIHA) (~10%) or <b class="calibre4">thrombocytopenia</b> (ITP) (~1–2%)</p>
<p class="bl"><span class="sbl">•</span> Hypogammaglobulinemia ± neutropenia → ↑ susceptibility to <b class="calibre4">infections</b></p>
<p class="bl"><span class="sbl">•</span> Bone marrow failure in ~13%; monoclonal gammopathy in ~5%</p>
<p class="bl"><span class="sbl">•</span> Aggressive transformation: ~5% develop <b class="calibre4">Richter’s syndrome</b> = transformation into high-grade lymphoma (usually DLBCL) and sudden clinical deterioration</p>
<p class="h2a">Diagnostic evaluation <span class="s">(see “Lymphoma” for general approach)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peripheral smear: lymphocytosis</b> (&gt;5000/µL, mature-appearing small cells) “<b class="calibre4">smudge</b>” cells from damage to abnl lymphs from shear stress of making blood smear</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Flow cytometry: clonality</b> with dim surface Ig (sIg); CD5+, CD19+, CD20(dim), CD23+. CD38+ or ZAP70+ a/w unmutated Ig variable heavy chain region &amp; worse prognosis.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bone marrow:</b> normo- or hypercellular; infiltrated w/ small B-cell lymphocytes (≥30%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lymph nodes:</b> infiltrated w/ small lymphocytic or diffuse small cleaved cells = SLL</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Genetics:</b> del 11q22-23 &amp; 17p13 unfavorable; trisomy 12 neutral; del 13q14 and mut <i class="calibre3">IgVH</i> favorable. Nine significantly mutated genes, including <i class="calibre3">TP53, NOTCH1</i>, <i class="calibre3">MYD88</i>, and <i class="calibre3">SF3B1.</i> Key role for spliceosome mutations <span class="s1r">(<i class="calibre3">NEJM</i> 2011;365:2497; <i class="calibre3">JCI</i> 2012;122:3432)</span>.</p>
<p class="image1"><img src="../images/00094.jpeg" alt="" class="calibre2"/></p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">Lancet</i> 2018;391:1524)</span></p>
<p class="bl"><span class="sbl">•</span> No treatment unless: Rai stage III/IV, Binet stage C, disease-related sx, progressive disease, AIHA or ITP refractory to steroids, recurrent infections</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">First-line:</b> ibrutinib (inhibits Bruton’s tyrosine kinase [BTK], which is found in B cells; <i class="calibre3">NEJM</i> 2015;375:25 &amp; 2018;379:2517), risk of AF, HTN &amp; bleeding (avoid if on warfarin), PNA, ILD</p>
<p class="bl"><span class="sbl">•</span> Other options: purine analogues: fludarabine (“F”), pentostatin (“P”);</p>
<p class="bl1">alkylating agents: cyclophosphamide (“C”), bendamustine (“B”);</p>
<p class="bl1">± anti CD20 (<b class="calibre4">rituximab</b>, “R”; ofatumumab; obinutuzumab) or CD52 (alemtuzumab)</p>
<p class="bl1">ibrutinib + obinutuzumab ↑ PFS vs. chlorambucil + obinutuzumab <span class="s1r">(<i class="calibre3">Lancet Oncol</i> 2019;20:43)</span></p>
<p class="bl1">venetoclax + obinutuzumab ↑ PFS vs. chlorambucil + obinutuzumab <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:2225)</span></p>
<p class="bl1">ibrutinib + venetoclax under study as 1<sup class="calibre15">st</sup>-line Rx: 88% with CR <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:2095)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Refractory:</b> venetoclax (α-BCL2; <i class="calibre3">NEJM</i> 2018;378:1107), acalabrutinib (BTK inhibitor; <i class="calibre3">NEJM</i> 2016;374:323), idelalisib (PI3K inhibitor; <i class="calibre3">NEJM</i> 2014;370:997)</p>
<p class="bl"><span class="sbl">•</span> 17p- or <i class="calibre3">TP53</i> mutation: venetoclax, idelalisib, or ibrutinib ± rituximab <span class="s1r">(<i class="calibre3">Lancet Oncol</i> 2014;10:1090)</span>, consider allo-HSCT with reduced intensity conditioning</p>
<p class="bl"><span class="sbl">•</span> Supportive care &amp; managing complications: PCP, HSV, VZV prophylaxis; CMV monitoring for Pts receiving anti-CD52; AIHA/ITP → steroids; recurrent infections → IVIg</p>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">NEJM</i> 2004;351:893; <i class="calibre3">JCO</i> 2006;24:4634)</span></p>
<p class="bl"><span class="sbl">•</span> Survival varies substantially. Median overall survival ~10 y <span class="s1r">(<i class="calibre3">Am J Hematol</i> 2011;12:985)</span></p>
<p class="bl"><span class="sbl">•</span> Favorable prognosis: 13q14 deletion (~50% of CLL cases)</p>
<p class="bl"><span class="sbl">•</span> Poor prognosis:</p>
<p class="bl1">unfavorable cytogenetics: eg, 17p- or <i class="calibre3">TP</i>53 mutation <span class="s1r">(<i class="calibre3">JCO</i> 2010;28:4473)</span>, IgH translocations</p>
<p class="bl1">unmutated (&lt;2% c/w germline) <i class="calibre3">IgVH</i> gene (&lt;8–10 y vs. &gt;20–25 y if mutated)</p>
<p class="bl1">high (&gt;20–30%) Zap-70 expression (part of T cell receptor; correlated w/ unmutated <i class="calibre3">IgVH</i>)</p>
<p class="bl1">CD38 &gt;30% or CD49d &lt;30%: correlated with unmutated <i class="calibre3">IgVH</i> <span class="s1r">(<i class="calibre3">Blood</i> 2008;111:865)</span></p>
<p class="bl1">higher β<sub class="calibre8">2</sub>-microglobulin levels (correlate with disease stage and tumor burden)</p>
<h2 class="ct"><a id="h72" class="calibre7"></a><a id="page_5-24" class="calibre7"></a><a href="part0002.html#rh80" class="calibre7">PLASMA CELL DYSCRASIAS</a></h2>
<p class="h">M<small class="calibre30">ULTIPLE</small> M<small class="calibre30">YELOMA</small> (MM)</p>
<p class="h2a">Definition and epidemiology <span class="s">(<i class="calibre3">NEJM</i> 2011;364:1046)</span></p>
<p class="bl"><span class="sbl">•</span> Malignant neoplasm of <b class="calibre4">plasma cells</b> producing a monoclonal Ig = “<b class="calibre4">M protein</b>”</p>
<p class="bl"><span class="sbl">•</span> ~27,000 new cases/y; median age at diagnosis 69 y; more common in African Americans</p>
<p class="h2a">Clinical manifestations <span class="s">(CRAB criteria and other less common features)</span></p>
<p class="bl"><span class="sbl">•</span> Hyper<b class="calibre4"><span class="underline">C</span></b>alcemia due to ↑ osteoclast activity</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><span class="underline">R</span></b>enal disease: multiple mechanisms include toxic effect of filtered light chains → <i class="calibre3">renal failure</i> (cast nephropathy) or <i class="calibre3">type II RTA;</i> amyloidosis or light chain deposition disease → <i class="calibre3">nephrotic syndrome;</i> hypercalcemia, urate nephropathy, type I cryoglobulinemia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><span class="underline">A</span></b>nemia (normocytic) due to bone marrow involvement; rarely, may see AIHA</p>
<p class="bl"><span class="sbl">•</span> Lytic <b class="calibre4"><span class="underline">B</span></b>one lesions due to ↑ osteoclast activity → pathologic fx</p>
<p class="bl"><span class="sbl">•</span> Recurrent infxns due to relative hypogammaglob. (clonal plasma cells suppress nl Ig)</p>
<p class="bl"><span class="sbl">•</span> Neurologic: cord compression; POEMS (<span class="underline">p</span>olyneuropathy, <span class="underline">o</span>rganomegaly, <span class="underline">e</span>ndocrinopathy, <span class="underline">M</span> protein, <span class="underline">s</span>kin changes) syndrome</p>
<p class="bl"><span class="sbl">•</span> Hyperviscosity: usually when IgM &gt;4 g/dL, IgG &gt;5 g/dL, or IgA &gt;7 g/dL</p>
<p class="bl"><span class="sbl">•</span> Coagulopathy: seen in amyloid due to binding &amp; depletion of Factor X</p>
<p class="bl"><span class="sbl">•</span> AL amyloidosis (see “Amyloidosis”)</p>
<p class="h2a">Diagnostic and staging evaluation <span class="s">(<i class="calibre3">Lancet Onc</i> 2014;15:e538)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MM criteria:</b> clonal BM plasma cells ≥10% or bx-proven plasmacytoma and ≥1 myeloma-defining event:</p>
<p class="bl1">(a) myeloma-related organ or tissue impairment (<b class="calibre4">ROTI</b>) = lytic bone lesions, Ca &gt;11 mg/dL, Cr &gt;2 mg/dL, or Hb &lt;10 g/dL</p>
<p class="bl1">(b) any of the following biomarkers: BM plasma cells ≥60%, serum free light chain (FLC) ratio ≥100:1, &gt;1 focal lesion on MRI studies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Variants</b></p>
<p class="bl1">Smoldering MM: M protein &gt;3 g/dL or plasmacytosis &gt;10%, but no myeloma-defining event or amyloidosis; see below under MGUS for approach</p>
<p class="bl1">Solitary bone plasmacytoma: 1 lytic lesion w/o plasmacytosis or other ROTI</p>
<p class="bl1">Extramedullary (nonosseous) plasmacytoma: usually upper respiratory tract</p>
<p class="bl1">Plasma cell leukemia: plasma cell count &gt;2000/µL in peripheral blood</p>
<p class="bl1">Nonsecretory MM (~2% of MM Pts): no M protein, but marrow plasmacytosis &amp; ROTI</p>
<p class="bl"><span class="sbl">•</span> Ddx of M component: MM, MGUS (see below), CLL, lymphoma, sarcoidosis, RA. Polyclonal hypergam can be seen in inflammatory states: HIV, rheumatic dis., cirrhosis.</p>
<p class="bl"><span class="sbl">•</span> Peripheral smear → rouleaux (see insert); ✔ Ca, alb, Cr; ↓ anion gap, ↑ globulin, ↑ ESR</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Protein electrophoresis and immunofixation</b></p>
<p class="bl1"><b class="calibre4">serum protein electrophoresis (SPEP):</b> quantitates M component; ⊕ in &gt;80% of Pts</p>
<p class="bl1">urine protein electrophoresis (UPEP): detects Pts who secrete only light chains (= Bence Jones proteins), which are filtered rapidly from the blood</p>
<p class="bl1">immunofixation: shows component is monoclonal and identifies Ig type → IgG (50%), IgA (20%), IgD (2%), IgM (0.5%), light chain only (20%), nonsecretors (&lt;5%)</p>
<p class="bl1"><b class="calibre4">serum FLC assay:</b> important for dx (esp. light chain–only Pts) and f/up response to Rx</p>
<p class="bl"><span class="sbl">•</span> β<sub class="calibre8">2</sub>-microglobulin and LDH levels reflect tumor burden</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">BM bx cytogenetics:</b> normal karyotype better than abnl. <b class="calibre4">Standard risk</b> = hyperdiploidy or t(11;14); <b class="calibre4">high risk</b> = hypodiploidy, del. 17p13 (~10% of Pts), t(4;14) &amp; t(4;16)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Skeletal survey</b> (plain radiographs) to identify lytic bone lesions and areas at risk for pathologic fracture; <i class="calibre3">bone scan is not useful for detecting lytic lesions.</i> Increasingly, whole-body PET-CT (scalp to toe) or MRI is being used to detect bone lesions.</p>
<p class="image1"><img src="../images/00095.jpeg" alt="" class="calibre2"/></p>
<p class="fn1">*Consider R-ISS incl chrom abnl &amp; LDH <span class="tfont1">(<i class="calibre3">JCO</i> 2005;23:3412 &amp; 2015;61:2267)</span>.</p>
<p class="h2a"><a id="page_5-25" class="calibre1"></a>Treatment <span class="s">(<i class="calibre3">NEJM</i> 2016;375:754 &amp; 1319; 2018;378:518 &amp; 379:1811)</span></p>
<p class="bl"><span class="sbl">•</span> Decisions generally dictated by <i class="calibre3">risk stratification</i> and <i class="calibre3">transplant eligibility</i></p>
<p class="bl"><span class="sbl">•</span> Rx incl. <b class="calibre4">proteasome inhibitors:</b> bortezomib (V), carfilzomib (K), ixazomib (I); <b class="calibre4">immunomodulators:</b> lenalidomide (R), thalidomide (T), pomalidomide (P); <b class="calibre4">immunotherapy:</b> daratumumab (anti-CD38, Dara), elotuzumab (Elo)</p>
<p class="bl1">Other active drugs incl. dexamethasone (D), melphalan (M), panobinostat, cyclophosphamide (CYC);</p>
<p class="bl1">CAR-T cells (anti-BCMA) promising <span class="s">(<i class="calibre3">NEJM</i> 2015;373:621 &amp; 1207; 380:1726; <i class="calibre3">Lancet</i> 2016;387:1551)</span></p>
<p class="bl"><span class="sbl">•</span> Induction Rx w/ best response rate: proteasome inhib (V or K) + immunomod (eg, R). Triplet Rx ↑ OS vs. double <span class="s">(<i class="calibre3">Lancet</i> 2017;389:519)</span>. RVD most common regimen in US; KRD if high-risk <span class="s">(<i class="calibre3">NEJM</i> 2014;371:906 &amp; 2016;374:1621)</span>. Dara-RD an option <span class="s">(<i class="calibre3">NEJM</i> 2019;380:2104)</span>.</p>
<p class="bl"><span class="sbl">•</span> If <i class="calibre3">not</i> transplant eligible: <b class="calibre4">induction chemo</b> ↑ survival, not curative; consider maint chemo</p>
<p class="bl"><span class="sbl">•</span> If transplant <i class="calibre3">eligible:</i> after induction chemo then <b class="calibre4">high-dose melphalan</b> + <b class="calibre4">auto-HSCT.</b> Not curative, but ↑ progression-free survival (PFS) vs. chemo alone <span class="s">(<i class="calibre3">NEJM</i> 2014;371:895, <i class="calibre3">Lancet Onc</i> 2015;16:1617)</span>. Offer if good perf. status &amp; no prohibitive comorbid. Maint Rx w/ R improves PFS/OS <span class="s">(<i class="calibre3">NEJM</i> 2014;371:10)</span>. Timing of HSCT (upfront vs. relapse) debatable.</p>
<p class="bl"><span class="sbl">•</span> Relapsed/refractory: based on prior response &amp; HSCT eligibility: HSCT (if good prior response, no prior HSCT), Elo-PD, Dara-PD; rarely use Allo-SCT.</p>
<p class="bl"><span class="sbl">•</span> Local radiation for solitary or extramedullary plasmacytoma</p>
<p class="bl"><span class="sbl">•</span> Adjunctive Rx: <i class="calibre3">bone:</i> <b class="calibre4">bisphosphonates</b> <span class="s">(<i class="calibre3">JCO</i> 2007;25:2464)</span>, XRT for sx bony lesions</p>
<p class="bl1"><i class="calibre3">renal:</i> avoid NSAIDs &amp; IV contrast; consider plasmapheresis for acute renal failure</p>
<p class="bl1"><i class="calibre3">hyperviscosity syndrome:</i> plasmapheresis; <i class="calibre3">infxns:</i> consider IVIg for recurrent infections</p>
<p class="bl"><span class="sbl">•</span> Common <b class="calibre4">toxicities</b> of Rx: melphalan → myelosuppression; lenalidomide → low plts &amp; thromboembolism; bortezomib → periph. neuropathy; steroids → hyperglycemia, infxn</p>
<p class="h">M<small class="calibre30">ONOCLONAL</small> G<small class="calibre30">AMMOPATHY</small> <small class="calibre30">OF</small> U<small class="calibre30">NCERTAIN</small> S<small class="calibre30">IGNIFICANCE</small> (MGUS)</p>
<p class="h2a">Definition and epidemiology <span class="s">(<i class="calibre3">NEJM</i> 2006;354:1362 &amp; 355:2765)</span></p>
<p class="bl"><span class="sbl">•</span> M prot. &lt;3 g/dL, marrow plasmacytosis &lt;10%, neither myeloma ROTI nor amyloidosis</p>
<p class="bl"><span class="sbl">•</span> Prevalence ~3% in population &gt;50 y of age, ~5% in &gt;70 y of age, 7.5% in &gt;85 y of age</p>
<p class="h2a">Management</p>
<p class="bl"><span class="sbl">•</span> ✔ CBC, Ca, Cr, SPEP, serum free light chains, UPEP w/ immunofixation (to exclude MM)</p>
<p class="bl"><span class="sbl">•</span> Close observation: repeat SPEP in 6 mo, then yearly thereafter if stable</p>
<p class="h2a">Prognosis <span class="s">(<i class="calibre3">NEJM</i> 2018;378:241)</span></p>
<p class="bl"><span class="sbl">•</span> ~1%/y or ~25% lifetime risk → MM, WM, amyloidosis, or malign. lymphoproliferative dis.</p>
<p class="bl"><span class="sbl">•</span> Abnormal serum free light chain ratio &amp; M protein ≥1.5 g/dL: ↑ risk of progression to MM</p>
<p class="h2a">Smoldering MM <span class="s">(not MGUS, but variant of MM that req no Rx)</span></p>
<p class="bl"><span class="sbl">•</span> Need whole-body MRI or PET-CT to rule out occult bone lesions</p>
<p class="bl"><span class="sbl">•</span> Risk of prog. 10%/y, depends on [M protein], subtype, FLC ratio. No defined role for Rx yet.</p>
<p class="h">W<small class="calibre30">ALDENSTRÖM</small>’<small class="calibre30">S</small> M<small class="calibre30">ACROGLOBULINEMIA</small> (WM)</p>
<p class="h2a">Definition <span class="s">(<i class="calibre3">Blood</i> 2009;114:2375; <i class="calibre3">NEJM</i> 2012;367:826)</span></p>
<p class="bl"><span class="sbl">•</span> B-cell neoplasm (lymphoplasmacytic lymphoma) that secretes monoclonal IgM</p>
<p class="bl"><span class="sbl">•</span> 91% w/ <i class="calibre3">MYD88</i> (NF-κB pathway) L265P mut., may distinguish from MM</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">No evidence of bone lesions</i> (IgM M component + lytic bone lesions = “IgM myeloma”)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fatigue</b> from anemia is most common sx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Tumor infiltration:</b> BM (cytopenias), hepatomegaly, splenomegaly, lymphadenopathy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Circulating monoclonal IgM</b></p>
<p class="bl1"><b class="calibre4">Hyperviscosity syndrome</b> (~15%): <i class="calibre3">Neurologic:</i> blurred vision (“sausage” retinal veins), HA, dizziness, Δ MS. <i class="calibre3">Cardiopulmonary:</i> congestive heart failure, pulm. infiltrates.</p>
<p class="bl1">Type I <b class="calibre4">cryoglobulinemia</b> → <b class="calibre4">Raynaud’s phenomenon</b></p>
<p class="bl1">Platelet dysfxn → mucosal bleeding</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">IgM deposition</b> (skin, intestine, kidney); amyloidosis and glomerulopathy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Autoantibody activity of IgM:</b> <i class="calibre3">Chronic AIHA</i> (prominent <b class="calibre4">rouleaux;</b> 10% Coombs’ ⊕ = AIHA). <i class="calibre3">Peripheral neuropathy:</i> may be due to IgM against myelin-associated glycoprotein.</p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> SPEP + immunofixation with IgM &gt;3 g/dL; 24-h urine for UPEP (only 20% have ⊕ UPEP)</p>
<p class="bl"><span class="sbl">•</span> Bone marrow biopsy: ↑ plasmacytoid lymphocytes; β<sub class="calibre8">2</sub>-microglobulin for prognostic eval</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Relative serum viscosity:</b> ratio serum viscosity to H<sub class="calibre8">2</sub>O (nl 1.8); hyperviscosity when &gt;5–6</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Hyperviscosity: <b class="calibre4">plasmapheresis</b></p>
<p class="bl"><span class="sbl">•</span> Sx (eg, prog. anemia): rituximab ± chemo (eg, bendamustine, Cy, etc.); data for rituximab + ibrutinib <span class="s">(<i class="calibre3">NEJM</i> 2018;378:2399)</span>. Everolimus or HSCT in salvage.</p>
<h2 class="ct"><a id="h73" class="calibre7"></a><a id="page_5-26" class="calibre7"></a><a href="part0002.html#rh81" class="calibre7">HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)</a></h2>
<p class="cst"><i class="calibre3">Transplantation of donor pluripotent cells that can reconstitute all recipient blood lineages</i></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre39"/>
<col class="calibre60"/>
<col class="calibre60"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">Categories of Stem Cell Transplantation</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Feature</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">Allogeneic (Allo)</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">Autologous (Auto)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Donor-recipient relationship</p></td>
<td class="bg0-br"><p class="tabc">Immunologically distinct</p></td>
<td class="bg0-b"><p class="tabc">Donor is also recipient</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">Graft-vs.-host disease</i></b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4"><i class="calibre3">Yes</i></b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4"><i class="calibre3">No</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">Graft-vs.-tumor effect</i></b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4"><i class="calibre3">Yes</i></b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4"><i class="calibre3">No</i></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Risk of graft contam. w/ tumor</p></td>
<td class="bg0-br"><p class="tabc">No</p></td>
<td class="bg0-b"><p class="tabc">Yes</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Relapse risk (leukemia)</p></td>
<td class="bg0-br"><p class="tabc">Lower</p></td>
<td class="bg0-b"><p class="tabc">Higher</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4"><i class="calibre3">Transplant-related mortality</i></b></p></td>
<td class="bg0-r"><p class="tabc"><b class="calibre4"><i class="calibre3">Higher</i></b></p></td>
<td class="bg"><p class="tabc"><b class="calibre4"><i class="calibre3">Lower</i></b></p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Types of Allo HSCT:</b> <i class="calibre3">based on donor/recipient matching of major HLA antigens on Chr. 6</i> (4 principal genes for serotyping: <i class="calibre3">HLA-A</i>, <i class="calibre3">-B</i>, -<i class="calibre3">C</i>, &amp; <i class="calibre3">-DR;</i> each w/ 2 alleles ∴ 8 major Ag)</p>
<p class="bl1"><i class="calibre3">Matched related</i> (MRD, sibling 8/8 major Ag match): lowest GVHD; <b class="calibre4">preferred donor</b></p>
<p class="bl1"><i class="calibre3">Matched unrelated (MUD):</i> ↑ risk of GVHD; ∴ matching of 10 HLA alleles <span class="s">(<i class="calibre3">DQ</i> also)</span> to ↓ risk; chance of match correlates w/ ethnicity <span class="s">(<i class="calibre3">NEJM</i> 2014;371:339)</span></p>
<p class="bl1"><i class="calibre3">Mismatched related</i> (eg, 1/8 Ag mismatch): ↑ available donor pool, but ↑ GVHD, rejection; ∴ need additional immunosuppression</p>
<p class="bl1"><i class="calibre3">Haploidentical</i>: typically, between parents and children (“half” match); early post-tx cyclophosphamide reduces GVH by destroying proliferating alloreactive T-cells</p>
<p class="bl1"><i class="calibre3">Umbilical cord blood:</i> HSC processed at birth &amp; stored. Low cell number, need 2 cords in adults. Neonatal immune cells: HLA-mismatch tolerated better, ↓ GVHD, slow immune reconstitution → ↑ late viral infections <span class="s">(<i class="calibre3">Blood</i> 2010;116:4693)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Graft-vs.-host disease (GVHD):</b> <i class="calibre3">undesirable</i> side effect of allo HSCT allogeneic T cells view host cells as foreign; ↑ incid. w/ mismatch or unrelated donors</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Graft-vs.-tumor (GVT):</b> <i class="calibre3">desired</i> effect in allo-SCT; graft T cells attack host tumor cells</p>
<p class="h2a">Indications <span class="s">(<i class="calibre3">BBMT</i> 2015;21:1863; <i class="calibre3">BMT</i> 2015;50:1037)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Malignant disease:</b></p>
<p class="bl1"><b class="calibre4">Auto HSCT</b> allows <i class="calibre3">high-dose myeloablative chemo</i> and then rescue what would be otherwise lethal cytopenias with autologous stem cells. Used in chemosensitive diseases such as relapsed/refractory DLBCL, MM, testicular germ cell tumor.</p>
<p class="bl1"><b class="calibre4">Allo HSCT</b> produces <b class="calibre4">graft-vs.-tumor</b> (GVT) effect, in addition to hematopoietic rescue (used for AML, ALL, MDS, CML-blast crisis, CLL, lymphoma)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nonmalignant disease:</b> allo HSCT replaces abnl lymphohematopoietic system w/ one from nl donor (eg, immunodeficiencies, aplastic anemia, hemoglobinopathies)</p>
<p class="h2a">Transplantation procedure <span class="s">(for Allo HSCT)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pre-tx preparative regimen goal:</b> immunosuppression to allow donor cell engraftment &amp; anti-tumor efficacy to ↓ relapse risk. Type and dose of agents determine this balance.</p>
<p class="bl1"><i class="calibre3">Myeloablative conditioning</i>: high-dose chemo and/or total body irradiation. Low relapse rates, high immunosuppression, high transplant–related morbidity.</p>
<p class="bl1"><i class="calibre3">Reduced-intensity conditioning (“RIC”)</i>: lower dose of chemo → ↓ transplant-related morbidity/mortality, but ↑ relapse b/c it relies more on GVT effect <span class="s">(<i class="calibre3">Blood</i> 2015;126:23)</span>. Allows allo HSCT for older adults (&gt;60) or Pts w/ comorbidities.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Sources of stem cells</b> <span class="s">(<i class="calibre3">NEJM</i> 2012;367:1487)</span></p>
<p class="bl1"><b class="calibre4">Bone marrow (BM):</b> original source of HSCT, now less commonly used than PBSC</p>
<p class="bl1"><b class="calibre4">Peripheral blood stem cells (PBSC):</b> easier to collect, more commonly used. BM vs. PBSC ≈ survival; BM ↓ chronic GVHD, PBSC ↓ graft failure, faster engraftment.</p>
<p class="bl1"><b class="calibre4">Umbilical cord blood stem cells (UCB):</b> see above in Types of Allo HSCT</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Engraftment:</b> absolute neutrophil count (ANC) recovers to 500/µL w/in ~2 wk w/ PBSC, ~2.5 wk w/ BM, ~4 wk w/ UCB. G-CSF accelerates recovery by 3–5 d in all scenarios.</p>
<p class="bl1"><i class="calibre3">Engraftment syndrome:</i> fever, rash, noncardiogenic pulm edema, abnl LFTs, AKI, wt gain. Dx of exclusion: r/o infection, GVHD; Rx w/ 1 mg/kg steroids, rapid taper over 3–4 d.</p>
<p class="h2a">Complications</p>
<p class="bl"><span class="sbl">•</span> Either <b class="calibre4">direct chemoradiotoxicities</b> associated with preparative regimen or consequences of <b class="calibre4">interaction between donor and recipient immune systems</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Sinusoidal obstruction syndrome (SOS):</b> incidence ~10%, mortality ~30%</p>
<p class="bl1">Previously known as <b class="calibre4">veno-occlusive disease (VOD)</b> <span class="s">(<i class="calibre3">BBMT</i> 2016;22:400)</span>. Mechanism: direct cytotoxic injury to hepatic venules → <i class="calibre3">in situ</i> thrombosis.</p>
<p class="bl1">Symptoms: tender hepatomegaly, ascites, jaundice, fluid retention with severe disease → liver failure, encephalopathy, hepatorenal syndrome</p>
<p class="bl1">Diagnosis: ↑ ALT/AST, ↑ bilirubin; ↑ PT with severe disease; Doppler U/S <i class="calibre3">may</i> show reversal of portal vein flow; ↑ hepatic wedge pressure; abnl liver bx</p>
<p class="bl1">Treatment: supportive; prophylaxis with <b class="calibre4">ursodiol;</b> treat w/ defibrotide <span class="s">(<i class="calibre3">Blood</i> 2016;127:1656)</span></p>
<p class="bl"><a id="page_5-27" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Idiopathic pneumonia syndrome (IPS):</b> 5–25% of Pts, &gt;50% mortality <span class="s">(<i class="calibre3">Blood</i> 2003;102:2777)</span></p>
<p class="bl1">Alveolar injury 2/2 direct toxicity → fever, hypoxia, diffuse infiltrates; occult infxn frequent</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Diffuse alveolar hemorrhage (DAH):</b> Diagnosis: bronchoscopy to exclude infection; ↑ bloody lavage fluid seen with DAH. Treatment: pulse 500–1000 mg Solu-Medrol × 3 d ± etanercept <span class="s">(<i class="calibre3">BBMT</i> 2015;1:67)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Acute GVHD</b> (usually within 6 mo of transplant; <i class="calibre3">NEJM</i> 2017;377:2167)</p>
<p class="bl1">Clinical grades I–IV based on scores for <b class="calibre4">skin</b> (severity of maculopapular rash), <b class="calibre4">liver</b> (bilirubin level) and <b class="calibre4">GI</b> (volume of diarrhea); bx supports diagnosis</p>
<p class="bl1">Prevention: <b class="calibre4">immunosuppression</b> (MTX + CsA or tacrolimus) or T-cell depletion of graft</p>
<p class="bl1">Treatment: grade I → topical Rx; grades II–IV → associated with ↓ survival and ∴ treated with immunosuppressants (corticosteroids, CsA, tacrolimus, rapamycin, MMF)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chronic GVHD</b> (developing or persisting &gt;3 mo posttransplant; <i class="calibre3">NEJM</i> 2017;377:2565)</p>
<p class="bl1">Clinical: malar rash, sicca syndrome, arthritis, obliterative bronchiolitis, bile duct degeneration, cholestasis and many others. More common w/ PBSC than BM.</p>
<p class="bl1">Treatment: immunosuppression; rituximab; photopheresis; ibrutinib <span class="s">(<i class="calibre3">Blood</i> 2017;130:21)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Graft failure</b></p>
<p class="bl1">Primary = persistent neutropenia without evidence of engraftment</p>
<p class="bl1">Secondary = delayed pancytopenia after initial engraftment; either immune mediated via immunocompetent host cells (<b class="calibre4">graft rejection</b>) or non–immune mediated (eg, CMV)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infectious complications</b></p>
<p class="bl1">due to regimen-induced pancytopenia and immunosuppression</p>
<p class="bl1">auto HSCT recipients: no immunosuppression ∴ at ↑ risk only pre-/postengraftment</p>
<p class="bl1">both primary infections and reactivation events occur (eg, CMV, HSV, VZV)</p>
<p class="imagef"><img src="../images/00096.jpeg" alt="" class="calibre2"/></p>
<p class="fn">*Primarily among persons who are seropositive before transplant.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre46"/>
<col class="calibre45"/>
<col class="calibre46"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">Prophylaxis/Supportive Medications During HSCT</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Medication</b></p></td>
<td class="bg0-br"><p class="tabc"><b class="calibre4">Prophylaxis Against</b></p></td>
<td class="bg0-b"><p class="tabc"><b class="calibre4">Duration</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Fluconazole or posaconazole</p></td>
<td class="bg0-br"><p class="tabc"><i class="calibre3">Candida</i></p></td>
<td class="bg0-b"><p class="tabc">75 d</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Acyclovir</p></td>
<td class="bg0-br"><p class="tabc">HSV/VZV</p></td>
<td class="bg0-b"><p class="tabc">365 d</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Valganciclovir or ganciclovir if CMV ⊕</p></td>
<td class="bg0-br"><p class="tabc">CMV</p></td>
<td class="bg0-b"><p class="tabc">100 d or when no longer immunosuppressed</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Antibiotics (eg, fluoroquinolone)</p></td>
<td class="bg0-br"><p class="tabc">Bacterial infxn</p></td>
<td class="bg0-b"><p class="tabc">While neutropenic</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">TMP-SMX</p></td>
<td class="bg0-br"><p class="tabc">PCP</p></td>
<td class="bg0-b"><p class="tabc">365 d or when off immunosupp.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Allopurinol</p></td>
<td class="bg0-br"><p class="tabc">Hyperuricemia</p></td>
<td class="bg0-b"><p class="tabc">Until d –1</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Ursodiol</p></td>
<td class="bg0-r"><p class="tabc">SOS/VOD</p></td>
<td class="bg"><p class="tabc">60 d</p></td>
</tr>
</table>
<h2 class="ct"><a id="h74" class="calibre7"></a><a id="page_5-28" class="calibre7"></a><a href="part0002.html#rh82" class="calibre7">LUNG CANCER</a></h2>
<p class="imagef"><img src="../images/00097.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(<i class="calibre3">NEJM</i> 2008;359:1367; <i class="calibre3">JCO</i> 2012;30:863; <i class="calibre3">J Thorac Oncol</i> 2012;7:924; <i class="calibre3">Nature</i> 2011;489:519; <i class="calibre3">Cell</i> 2012;150:1107)</p>
<p class="h2a">Epidemiology and risk factors</p>
<p class="bl"><span class="sbl">•</span> Most common cause of cancer-related death for both men and women in the U.S.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cigarette smoking:</b> 85% of lung cancers occur in smokers; risk ∝ total pack-yrs, ↓ risk after quitting/reducing but not to baseline <span class="s">(<i class="calibre3">Int J Cancer</i> 2012;131:1210)</span></p>
<p class="bl1">squamous &amp; small cell almost exclusively in smokers</p>
<p class="bl1">adenocarcinoma most common type in nonsmokers</p>
<p class="bl"><span class="sbl">•</span> Asbestos: when combined with smoking, synergistic ↑ in risk of lung cancer</p>
<p class="bl"><span class="sbl">•</span> Other: RT (for other cancer); HIV; environ. toxins (radon, 2<sup class="calibre15">nd</sup>-hand smoke); pulm. fibrosis</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> ~10% asymptomatic at dx, detected incidentally (only 16% w/ localized dis. at presentation)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Endobronchial growth</b> of 1° tumor: <b class="calibre4">cough</b>, <b class="calibre4">hemoptysis</b>, <b class="calibre4">dyspnea</b>, pain, wheezing, post-obstructive pneumonia; more common with squamous or small cell (central location)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Regional spread</b></p>
<p class="bl1"><b class="calibre4">Pleural effusion</b>, pericardial effusion, hoarseness (recurrent laryngeal nerve palsy), dysphagia (esophageal compression), stridor (tracheal obstruction)</p>
<p class="bl1"><b class="calibre4">Pancoast’s syndrome:</b> apical tumor → brachial plexus involvement (C8, T1, T2) → Horner’s syndrome, shoulder pain, rib destruction, atrophy of hand muscles</p>
<p class="bl1"><b class="calibre4">SVC syndrome</b> <span class="s">(<i class="calibre3">NEJM</i> 2007;356:1862)</span>: central tumor → SVC compression → face/arm swelling (&gt;80%), neck/chest vein distention (~60%), SOB/cough (~50%), HA (~10%); Rx = steroids, diuretics, RT ± chemo, SVC stent if severe sx, anticoag if clot</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Extrathoracic metastases:</b> brain, bone, liver, adrenal, weight loss</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Paraneoplastic syndromes</b></p>
<p class="bl1"><i class="calibre3">Endocrine:</i></p>
<p class="bl2">ACTH (SCLC) → <b class="calibre4">Cushing’s syndrome;</b> ADH (SCLC) → <b class="calibre4">SIADH</b></p>
<p class="bl2">PTH-rP (squamous cell) → <b class="calibre4">hypercalcemia</b></p>
<p class="bl1"><i class="calibre3">Skeletal:</i> digital clubbing (non-small cell), <b class="calibre4">hypertrophic pulm. osteoarthropathy</b> (adenocarcinoma) = symmetric polyarthritis and proliferative periostitis of long bones</p>
<p class="bl1"><i class="calibre3">Neurologic</i> (SCLC): <b class="calibre4">Eaton-Lambert</b> (anti-P/Q-type voltage-gated Ca<sup class="calibre15">2</sup><sup class="calibre15">+</sup> channel Abs), peripheral neuropathy (anti-Hu, anti-PCA-2, anti-CRMP5), cerebellar degeneration (anti-Hu, anti-Yo, anti-Ri, anti-Tr), encephalomyelitis (anti-Hu, anti-Ma1/2, anti-CRMP5)</p>
<p class="bl1"><i class="calibre3">Cutaneous:</i> acanthosis nigricans, dermatomyositis</p>
<p class="bl1"><i class="calibre3">Hematologic:</i> hypercoagulable state (adenocarcinoma), DIC, marantic endocarditis</p>
<p class="h2a">Screening <span class="s">(<i class="calibre3">Lancet</i> 2014;382:732)</span></p>
<p class="bl"><span class="sbl">•</span> No benefit to CXR or sputum cytology, even in high-risk Pts</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Annual low-dose chest CT</b> in ≥30 pack-y current or former (quit w/in 15 y) smokers, age 55–74 y → 20% ↓ lung cancer-related mortality <span class="s">(<i class="calibre3">NEJM</i> 2011;365:395; 2013;368:1980; USPSTF)</span></p>
<p class="bl1">number needed to screen = 320; high false ⊕ rate</p>
<p class="bl1">consider risk scores to target screening <span class="s">(<i class="calibre3">NEJM</i> 2013;369:245 &amp; 910; <i class="calibre3">JAMA</i> 2016;315:2300)</span></p>
<p class="h2a">Diagnostic and staging evaluation <span class="s">(<i class="calibre3">NCCN Guidelines</i> v.1.2019)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Initial imaging:</b> contrast chest CT including liver and adrenals</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pathology:</b> via <b class="calibre4">bronchoscopy</b> (central lesions) or <b class="calibre4">CT-guided needle bx</b> (peripheral lesions or accessible sites of suspected metastasis); mediastinoscopy (LN bx), VATS (eval. of pleura peripheral lesions), thoracentesis (cell block for cytology)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TNM staging:</b> based on tumor size and extent of invasion (T), regional LN involvement [N: N0 (none), N1 (ipsilat. hilar), N2 (ipsilat. mediast.), N3 (contralat., supraclav.)] and presence of metastases (M) (<i class="calibre3">Chest 2017</i>;151:193). 5-y survival: ~70-90% for stage I, 50-60% stage II, 15–35% stage III, 0–10% stage IV <span class="s">(<i class="calibre3">J Thorac Oncol</i> 2016;11:39)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pretreatment evaluation</b></p>
<p class="bl1"><i class="calibre3">Intrathoracic:</i> <b class="calibre4">mediastinoscopy</b> (± preceded by U/S-guided transesoph. or transbronch. needle aspiration; <i class="calibre3">JAMA</i> 2010;304:2245) or <b class="calibre4">VATS;</b> thoracentesis if pleural effusion</p>
<p class="bl1"><a id="page_5-29" class="calibre1"></a><i class="calibre3">Extrathoracic:</i> <b class="calibre4">PET-CT</b> more Se than CT alone for detecting mediastinal and distant mets as well as bone mets <span class="s">(<i class="calibre3">NEJM</i> 2009;361:32)</span>; <b class="calibre4">brain MRI</b> for all Pts (except stage IA)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Genetics:</b> ✔ <i class="calibre3">EGFR</i> mut., <i class="calibre3">ALK, ROS1, RET, BRAF, NTRK</i> fusion for adv/metastatic non-squamous dis. (note incidence lower in squamous; only test if nonsmoker, mixed histo)</p>
<p class="bl"><span class="sbl">•</span> PFTs w/ quantitative V/Q if planned treatment includes surgical resection; need to have 30% of normal, predicted lung fxn <i class="calibre3">after</i> resection</p>
<p class="h2a">NSCLC treatment <span class="s">(<i class="calibre3">Lancet</i> 2017;389:299; <i class="calibre3">NEJM</i> 2017;377:849; <i class="calibre3">NCCN Guidelines</i> v.1.2019)</span></p>
<p class="capf"><b class="calibre4">Figure 5-6</b> NSCLC treatment algorithm</p>
<p class="center"><img src="../images/00098.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><i class="calibre3">NEJM</i> 2018;379:2342. Encouraging data on PD-1 blockade as <i class="calibre3">neoadjuvant</i> therapy <span class="tfont1">(<i class="calibre3">NEJM</i> 2018;378:1976)</span>.</p>
<p class="imagef"><img src="../images/00099.jpeg" alt="" class="calibre2"/></p>
<p class="fn">TKI toxicities: rash &amp; diarrhea (common); lung &amp; liver injury (rare but potentially serious)</p>
<p class="h2a">SCLC staging and treatment <span class="s">(NCCN Guidelines v.1.2019)</span></p>
<p class="bl"><span class="sbl">•</span> SCLC usually disseminated at presentation but can be very responsive to chemoradiation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chemotherapy</b> (platinum + etoposide) is primary treatment modality</p>
<p class="bl"><span class="sbl">•</span> Addition of anti-PD-L1 Ab (eg, atezolizumab) ↑ survival <span class="s">(<i class="calibre3">NEJM</i> 2018;379:2220)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Thoracic radiation</b> added to chemotherapy improves survival in limited-stage disease</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prophylactic cranial irradiation</b> (PCI) ↑ survival for limited disease in complete remission <span class="s">(<i class="calibre3">NEJM</i> 1999;341:476)</span> &amp; ↓ symptomatic brain mets in extensive disease <span class="s">(<i class="calibre3">NEJM</i> 2007;357:664)</span></p>
<p class="image1"><img src="../images/00100.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="h75" class="calibre7"></a><a id="page_5-30" class="calibre7"></a><a href="part0002.html#rh83" class="calibre7">BREAST CANCER</a></h2>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> In U.S., most common cancer in women; 2<sup class="calibre15">nd</sup> leading cause of cancer death in women</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Genetic risk:</b> 15–20% ⊕ FHx → 2× ↑ risk; ~45% familial cases a/w germline mutation</p>
<p class="bl1"><b class="calibre4">BRCA1/2:</b> 35–85% lifetime risk of breast ca &amp; ↑ risk of <b class="calibre4">ovarian</b> &amp; prostate ca; ? ↑ colon ca; BRCA2: ↑ <i class="calibre3">male</i> breast, prostate &amp; pancreatic ca. Germline loss-of-function mutations in <i class="calibre3">PALB2</i> a/w 35% ↑ risk breast cancer by age 70 <span class="s">(<i class="calibre3">NEJM</i> 2014;371:497)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Estrogen:</b> ↑ risk with early menarche, late menopause, late parity or nulliparity <span class="s">(<i class="calibre3">NEJM</i> 2006;354:270)</span>; ↑ risk with prolonged HRT (RR = 1.24 after 5.6 y; <i class="calibre3">JAMA</i> 2003;289:3243); OCP use a/w extremely low to no ↑ risk <span class="s">(<i class="calibre3">NEJM</i> 2017:317:2228; <i class="calibre3">JAMA Oncol</i> 2018;4:516)</span></p>
<p class="bl"><span class="sbl">•</span> Benign breast conditions: ↑ risk if atypia (atypical ductal or lobular hyperplasia; <i class="calibre3">NEJM</i> 2015;372:78) or proliferative (ductal hyperplasia, papilloma, radial scar, or sclerosing adenosis) features; <i class="calibre3">no</i> ↑ risk w/ cysts, simple fibroadenoma, or columnar changes</p>
<p class="bl"><span class="sbl">•</span> ↑ risk with h/o ionizing radiation to chest for treatment of Hodgkin lymphoma</p>
<p class="h2a">Prevention <span class="s">(if high-risk: eg, FHx, LCIS, atypical hyperplasia)</span></p>
<p class="bl"><span class="sbl">•</span> Tamoxifen (contraindic. in preg): ↓ risk contralat. breast ca as adjuvant Rx. Approved for 1° prevent. if ↑ risk: ↓ invasive breast cancer, but ↑ DVT &amp; uterine ca.</p>
<p class="bl"><span class="sbl">•</span> Raloxifene (only if post-menopausal): ↓ risk of invasive breast ca &amp; vertebral fx, ↑ risk of stroke &amp; DVT/PE <span class="s">(<i class="calibre3">NEJM</i> 2006;355:125)</span>; less effective than tamoxifen in prevention of breast ca but lower risk of VTE, cataracts, &amp; uterine ca <span class="s">(<i class="calibre3">Ann Int Med</i> 2013;158:604)</span></p>
<p class="bl"><span class="sbl">•</span> Aromatase inhib. (post-menopausal): ↓ risk &gt;50% <span class="s">(<i class="calibre3">Lancet</i> 2014;383:1041)</span>, ↑ osteoporosis</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">BRCA1/2</i> ⊕: intensified surveillance vs. prophylactic bilat. mastectomy which ↓ risk ~90%; bilat. salpingo-oophorectomy ↓ risk of ovarian <i class="calibre3">and</i> breast cancer <span class="s">(<i class="calibre3">NEJM</i> 2016;374:454)</span></p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Breast mass (hard, irregular, fixed, nontender), nipple discharge (higher risk if unilateral, limited to 1 duct, bloody, associated with mass)</p>
<p class="bl"><span class="sbl">•</span> Special types: <b class="calibre4">Paget</b> disease → unilateral nipple eczema + nipple discharge; <b class="calibre4">inflammatory</b> breast cancer → skin erythema and edema <i class="calibre3">(peau d’orange)</i></p>
<p class="bl"><span class="sbl">•</span> Metastases: lymph nodes, bone, liver, lung, brain</p>
<p class="h2a">Screening <span class="s">(<i class="calibre3">JAMA</i> 2015;314:1599; <i class="calibre3">Annals</i> 2019;170:547)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mammography:</b> ~20–30% ↓ <b class="calibre4">in breast cancer mortality</b>, smaller abs. benefit in women &lt;50 y <span class="s">(<i class="calibre3">JAMA</i> 2018;319:1814)</span>; digital breast tomosynthesis (3-D) ↑ specificity <span class="s">(<i class="calibre3">JAMA Oncol</i> 2019;5:635)</span>; suspicious findings: clustered <b class="calibre4">microcalcifications</b>, <b class="calibre4">spiculated</b>, <b class="calibre4">enlarging</b></p>
<p class="bl"><span class="sbl">•</span> ACS recommends annual mammo beginning at age 45 (consider biennial after age 54)</p>
<p class="bl"><span class="sbl">•</span> USPSTF recommends beginning at 50 and biennially (some may want to begin at age 40)</p>
<p class="bl"><span class="sbl">•</span> ↑ risk: screen earlier w/ exam and mammo (age 25 in <i class="calibre3">BRCA1/2</i> carrier, 5–10 y before earliest FHx case, 8–10 y after thoracic RT, upon dx of ↑ risk benign disease)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRI:</b> superior to mammo in high-risk and young Pts; consider annually if &gt;20% lifetime risk (eg, ⊕ FHx, <i class="calibre3">BRCA1/2</i>, prior chest RT) <span class="s">(<i class="calibre3">Lancet</i> 2011;378:1804)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Genetic testing:</b> recommended in women with strong FHx <span class="s">(<i class="calibre3">NCCN</i> v2.2019)</span></p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Palpable breast mass:</b> age &lt;30 y → observe for resolution over 1–2 menstrual cycles; age &lt;30 y, unchanging mass → <b class="calibre4">U</b>/<b class="calibre4">S</b> → aspiration if mass not simple cyst;</p>
<p class="bl1">age &gt;30 y <i class="calibre3">or</i> solid mass on U/S <i class="calibre3">or</i> bloody aspirate <i class="calibre3">or</i> recurrence after aspiration → <b class="calibre4">mammo</b> (detect other lesions) <i class="calibre3">and</i> either <b class="calibre4">fine-needle asp.</b> or <b class="calibre4">core-needle bx</b></p>
<p class="bl1">clearly cancerous on exam or indeterminate read or atypia on bx → <b class="calibre4">excisional bx</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Suspicious mammogram</b> with normal exam: stereotactically guided bx</p>
<p class="bl"><span class="sbl">•</span> MRI: detects contralateral cancer in 3% of Pts w/ recently dx breast cancer &amp; contra-lateral mammo (but PPV only 21%) <span class="s">(<i class="calibre3">NEJM</i> 2007;356:1295)</span>; utility remains unclear</p>
<p class="h2a">Staging</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anatomic:</b> tumor size, chest wall invasion, axillary LN mets (<i class="calibre3">strongest prognostic factor</i>)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Histopathologic:</b> type (little prognostic relevance) &amp; grade; lymphatic/vascular invasion</p>
<p class="bl1"><b class="calibre4"><i class="calibre3">In situ</i></b> carcinoma: no invasion of surrounding stroma</p>
<p class="bl2"><b class="calibre4">Ductal</b> (DCIS): ↑ risk of invasive cancer in <i class="calibre3">ipsilateral</i> breast (~30%/10 y)</p>
<p class="bl2"><b class="calibre4">Lobular</b> (LCIS): marker of ↑ risk of invasive cancer in <i class="calibre3">either</i> breast (~1%/y)</p>
<p class="bl1"><b class="calibre4">Invasive</b> carcinoma: infiltrating ductal (70–80%); invasive lobular (5–10%); tubular, medullary and mucinous (10%, better prognosis); papillary (1–2%); other (1–2%)</p>
<p class="bl1"><b class="calibre4">Inflammatory breast cancer</b> (see above): not a histologic type but a clinical reflection of tumor invasion of dermal lymphatics; very poor prognosis</p>
<p class="bl1"><b class="calibre4">Paget disease</b> (see above)<b class="calibre4">:</b> ductal cancer invading nipple epidermis ± associated mass</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biomarkers:</b> estrogen, progesterone receptor (ER/PR) and HER2/<i class="calibre3">neu</i> amplification</p>
<p class="bl"><span class="sbl">•</span> Oncotype DX 21-gene expression recurrence score is predictive &amp; prognostic in ER ⊕, HER2 ⊖, node ⊖ cancers <span class="s">(<i class="calibre3">NEJM</i> 2018;379:111)</span>; also 70-gene profile <span class="s">(<i class="calibre3">NEJM</i> 2016;375:717)</span></p>
<p class="image1"><a id="page_5-31" class="calibre1"></a><img src="../images/00101.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre37"/>
<col class="calibre59"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">General Approach to Treatment</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JAMA</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">9;32</span><span class="tfont">1</span><span class="tfont1">:288 &amp;</span> <span class="tfont">1</span><span class="tfont1">7</span><span class="tfont">1</span><span class="tfont1">6)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">LCIS</b></p></td>
<td class="bg0-b"><p class="tab">Close surveillance ± chemoprevention (often tamoxifen) <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JCO</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">5;33:3945)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">DCIS</b></p></td>
<td class="bg0-b"><p class="tab">Mastectomy or lumpectomy ± RT ± chemoprevention <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">6;387:849 &amp; 866)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">I</b></p></td>
<td class="bg0-b"><p class="tab">Surgery + RT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">II</b></p></td>
<td class="bg0-b"><p class="tab">+ adjuvant chemo if ↑ risk: tumor &gt;2 cm <i class="calibre3">or</i> ⊕ LN <i class="calibre3">or</i> ER/PR ⊖ <i class="calibre3">or</i> Oncotype DX ≥31</p>
<p class="tab">+ hormonal Rx for ER/PR ⊕: add ovarian suppression if ↑ risk <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">8; 379:</span><span class="tfont">1</span><span class="tfont1">22)</span></p>
<p class="tab">+ anti-<i class="calibre3">HER2</i> Rx and chemo if <i class="calibre3">HER2</i> ⊕ and tumor ≥1 cm or ⊕ LN</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">III</b></p></td>
<td class="bg0-b"><p class="tab">Neoadjuvant chemo → surgery + RT ± adjuvant chemotherapy</p>
<p class="tab">+ hormonal Rx for ER/PR ⊕: add ovarian suppression if premenopausal</p>
<p class="tab">+ anti-<i class="calibre3">HER2</i> Rx for <i class="calibre3">HER2</i> ⊕: usually trastuzumab + pertuzumab</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tabc"><b class="calibre4">IV</b></p></td>
<td class="bg"><p class="tab">ER/PR ⊕: combined aromatase &amp; CDK4/6 inhibitors <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">6; 375:</span><span class="tfont">1</span><span class="tfont1">925)</span></p>
<p class="tab">ER/PR ⊖: <i class="calibre3">HER2</i> ⊕ → chemo + anti-<i class="calibre3">HER2</i> therapy; <i class="calibre3">HER2</i> ⊖ → chemotherapy</p>
<p class="tab">Bony mets: bisphosphonates &amp; denosumab ↓ fractures <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Cochrane</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">7;CD003474)</span></p></td>
</tr>
</table>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre51"/>
<col class="calibre52"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Surgery and Radiation for Local Control</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Intervention</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Indication</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Breast conserving</p></td>
<td class="bg0-b"><p class="tab">Stage I-II, lumpectomy + sentinel lymph node biopsy<a id="st8" class="calibre1"></a><a href="part0010.html#sst8" class="calibre1">*</a> + RT</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Modified radical mastectomy</p></td>
<td class="bg0-b"><p class="tab">Large tumor relative to breast, multicentric dis., prior chest RT, diffuse microcalcifications, ⊕ margins after lumpectomy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Post mastectomy radiation</p></td>
<td class="bg"><p class="tab">≥4 ⊕ LN, tumor &gt;5 cm, ⊕ surgical margins, chest wall or skin involvement <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">4;384:</span><span class="tfont">1</span><span class="tfont1">848)</span></p></td>
</tr>
</table>
<p class="tsr"><a id="sst8" class="calibre1"></a><a href="part0010.html#st8" class="calibre1">*</a>Axillary lymph node dissection indicated for palpable axillary LNs</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre61"/>
<col class="calibre61"/>
<col class="calibre62"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">Systemic Therapy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Indic.</b></p></td>
<td class="bg0-br2"><p class="tab"><b class="calibre4">Class</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Examples</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="3"><p class="tab">ER/PR ⊕</p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">7;389: 2403)</span></p></td>
<td class="bg0-br2"><p class="tab">Endo <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">9;380:</span> <span class="tfont">1</span><span class="tfont1">226)</span></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Tamoxifen:</b> adjuvant Rx for low risk pre-meno; ↓ recurrence &amp; ↓ mortality; 10 y superior to 5 y <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont">11</span><span class="tfont1">;378:77</span><span class="tfont">1</span> <span class="tfont1">&amp; 20</span><span class="tfont">1</span><span class="tfont1">3;38</span><span class="tfont">1</span><span class="tfont1">:805)</span></p>
<p class="tabh"><b class="calibre4">Aromatase inhibitor</b> (AI; anastrozole, letrozole, exemestane): adjuvant Rx for post-meno; ↑ OS vs. tam. <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">5;386:</span><span class="tfont">1</span><span class="tfont1">34</span><span class="tfont">1</span><span class="tfont1">)</span>; 10 y of Rx ↑ DFS vs. 5 y of Rx <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">6;375:209)</span></p>
<p class="tabh">Adding selective ER degrader (fulvestrant) to AI ↑ OS if mets</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Ovarian suppress.</p></td>
<td class="bg0-b2"><p class="tab"><b class="calibre4">LHRH agonists</b> (eg, leuprolide) or oophorectomy: adjuvant Rx for high risk pre-meno combined with tam. or AI <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">8;379:</span><span class="tfont">1</span><span class="tfont">22)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Cell prolif.</p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">2;366: 520)</span></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">CDK 4/6 inhib</b> (eg, palbociclib, abemaciclib, ribociclib): + AI (preferred 1<sup class="calibre35">st</sup>-line Rx for metastatic dis.) or fulvestrant ↑ PFS in stage IV vs. AI alone <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">8;379:</span><span class="tfont">1</span><span class="tfont1">926;</span> <span class="tfont1"><i class="calibre3">JCO</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">7;35:3638)</span></p>
<p class="tabh"><b class="calibre4">mTOR inhib</b> (everolimus): + AI (exemestane) ↑ OS in stage IV</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">PIK3CA ⊕</p></td>
<td class="bg0-br2"><p class="tab">PI3K inhib</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Alpelisib</b> added to fulvestrant ↑ PFS in metastatic ER/PR ⊕ <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">9;380:</span><span class="tfont">1</span><span class="tfont1">929)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">HER2 ⊕</p>
<p class="tab"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Lancet</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">7;389: 24</span><span class="tfont">1</span><span class="tfont1">5)</span></p></td>
<td class="bg0-br2"><p class="tab">HER2-targeted</p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Trastuzumab</b> (anti-HER2): 1<sup class="calibre35">st</sup>-line Rx combined w/ chemo</p>
<p class="tabh"><b class="calibre4">Pertuzumab</b> (prevents HER2 dimerization): + trastuzumab ↑ PFS in adjuvant &amp; metastatic settings <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">7;377:</span><span class="tfont">1</span><span class="tfont1">22)</span></p>
<p class="tabh"><b class="calibre4">Trastuzumab emtansine</b> (mAb linked to chemo): ↓ risk of recurrence/death if residual disease post neoadjuvant Rx <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">9;380:6</span><span class="tfont">1</span><span class="tfont1">7)</span>; preferred 2<sup class="calibre35">nd</sup> line Rx for metastatic disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Stage I–IV (above)</p></td>
<td class="bg0-br2"><p class="tab">Chemo</p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Neoadjuvant:</b> conserve breast &amp; evaluate Rx efficacy, equivalent OS as adjuvant <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">JCO</i></span> <span class="tfont1">2008;26:778)</span></p>
<p class="tabh"><b class="calibre4">Adjuvant:</b> calc Oncotype DX score for benefit after surgery in ER/PR⊕ <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">8;379:</span><span class="tfont">111</span><span class="tfont1">)</span>; use anthracycline ± taxane</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">PDL-1 ⊕ triple ⊖</p></td>
<td class="bg0-br2"><p class="tab">Immune</p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">PDL-1 Ab</b> (atezolizumab) added to nab-paclitaxel (microtubule inhibitor): ↑ PFS &amp; OS in stage IV <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">8;379:2</span><span class="tfont">1</span><span class="tfont1">08)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">BRCA ⊕</p></td>
<td class="bg0-br2"><p class="tab">PARP inh</p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Olaparib &amp; talazoparib</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">7;377:523 &amp; 20</span><span class="tfont">1</span><span class="tfont1">8;379:753)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tab">Triple ⊖</p></td>
<td class="bg0-r1"><p class="tab">Ab-drug conjugate</p></td>
<td class="bg"><p class="tab">Sacituzumab govitecan: anti-trop-2 linked to chemo ↑ PFS &amp; OS in heavily pre-Rx’d metastatic disease <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">9;380:74</span><span class="tfont">1</span><span class="tfont1">)</span></p></td>
</tr>
</table>
<p class="tsr">DFS, disease-free survival; OS, overall survival; PFS, progression-free survival</p>
<h2 class="ct"><a id="h76" class="calibre7"></a><a id="page_5-32" class="calibre7"></a><a href="part0002.html#rh84" class="calibre7">PROSTATE CANCER</a></h2>
<p class="h2a">Epidemiology and risk factors <span class="s">(<i class="calibre3">NEJM</i> 2003;349:366)</span></p>
<p class="bl"><span class="sbl">•</span> Most common cancer in U.S. men; 2<sup class="calibre15">nd</sup> most common cause of cancer death in men</p>
<p class="bl"><span class="sbl">•</span> Lifetime risk of prostate cancer dx ~16%; lifetime risk of dying of prostate cancer ~3%</p>
<p class="bl"><span class="sbl">•</span> ↑ risk with ↑ age (rare if &lt;45 y), in African Americans, ⊕ FHx, BRCA mutations</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Most prostate cancers (78%) are asymptomatic and localized at diagnosis</p>
<p class="bl"><span class="sbl">•</span> Metastatic dis. sx primarily from bone mets: bone pain, spinal cord compression, cytopenias</p>
<p class="h2a">Screening <span class="s">(<i class="calibre3">JAMA</i> 2014;311:1143; <i class="calibre3">Lancet</i> 2014;384:2027)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">PSA:</b> 4 ng/mL cut point neither Se nor Sp; can ↑ with BPH, prostatitis, acute retention, after bx or TURP, and ejaculation <span class="s">(<i class="calibre3">no significant</i> ↑ <i class="calibre3">after DRE, cystoscopy</i>)</span>; 15% of men &gt;62 y w/ PSA &lt;4 &amp; nl DRE have bx-proven T1 cancer <span class="s">(<i class="calibre3">NEJM</i> 2004;350:2239)</span></p>
<p class="bl"><span class="sbl">•</span> Digital rectal exam no longer recommended due to limitations, no mortality benefit</p>
<p class="bl"><span class="sbl">•</span> ACS rec: ≥50 y (or ≥45 y AA or ⊕ FHx) discuss PSA screening, informed decision making</p>
<p class="bl"><span class="sbl">•</span> USPSTF <span class="s">(<i class="calibre3">JAMA</i> 2018;319:1901)</span> rec <i class="calibre3">against</i> screening if asx (no ↓ in prostate ca-related mort.)</p>
<p class="h2a">Diagnostic evaluation, staging, and treatment <span class="s">(<i class="calibre3">NCCN Guidelines</i> v4.2018)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Transrectal ultrasound</b> (TRUS) <b class="calibre4">guided biopsy</b> (6–12 cores)</p>
<p class="bl"><span class="sbl">•</span> Multiparametric MRI (± endorectal coil): improves detection <span class="s">(<i class="calibre3">NEJM</i> 2018;378:1767)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Gleason grade and grouping (histology</b><i class="calibre3">): Gleason score</i> = sum of Gleason grades (1 = best, 5 = worst) of 2 most prevalent patterns in bx; correlates w/ prognosis</p>
<p class="imagef"><img src="../images/00102.jpeg" alt="" class="calibre2"/></p>
<p class="fn">*In asx Pts w/ life expectancy ≤5 y &amp; very low-to-intermediate risk disease, no workup or Rx indicated until sx. <i class="calibre3">NEJM</i> 2016;375:1415 &amp; 2017;376:417 &amp; 2018;378:2465 &amp; 2018;379:2319; <i class="calibre3">JCO</i> 2016;34:2182.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Treatment of Metastatic Prostate Cancer</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">8;378:645)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Androgen deprivation therapy (ADT)</b></p></td>
<td class="bg0-b"><p class="tab">Prostate ca requires androgen signaling for growth. ADT backbone of Rx.</p>
<p class="tabh">Med: 1. Luteinizing hormone-releasing hormone (LHRH) agonist<br class="calibre6"/>        (eg, goserelin) ± 1<sup class="calibre35">st</sup>-gen anti-androgen (nilutamide, bicalutamide), <i class="calibre3">or</i></p>
<p class="tabh1">    2. LHRH antagonist (degarelix)</p>
<p class="tab">Surg: Bilateral orchiectomy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc"><b class="calibre4">Hormone- sensitive prostate cancer (HSPC)</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Def:</b> ADT sensitive (ie, PSA ↓ w/ Rx): all prostate ca initially sensitive</p>
<p class="tab"><b class="calibre4">Workup/testing:</b> PEx &amp; PSA q 3-6 mos; sx-guided imaging</p>
<p class="tab"><b class="calibre4">Rx:</b> 1. ADT; <i class="calibre3">or</i><br class="calibre6"/>2. Docetaxel + ADT (↑ OS vs. ADT alone, espec. in high-volume dis.); <i class="calibre3">or</i> 3. ADT + abiraterone/pred (↑ OS vs. ADT alone)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc"><b class="calibre4">Castration-resistant prostate cancer (CRPC)</b></p>
<p class="tabc"><i class="calibre3">Always continue ADT</i></p></td>
<td class="bg"><p class="tabh"><b class="calibre4">Def:</b> All met. HSPC eventually becomes CRPC (ie, progression despite castration level of androgens on ADT), due to re-estab. of androgen signaling via other mech. ∴ more potent anti-androgens are active Rx.</p>
<p class="tabh"><b class="calibre4">Rx: New-gen. anti-androgens:</b> abiraterone (biosynth inhib.), enzalutamide (receptor blocker), &amp; apalutamide (receptor blocker) ↑ PFS &amp; OS</p>
<p class="tabh"><b class="calibre4">Chemo:</b> docetaxel &amp; cabazitaxel +pred/dex</p>
<p class="tabh"><b class="calibre4">Bone-active agents:</b> 1. denosumab or zoledronic acid ↓ skeletal-related events (SREs); 2. radium-223 used in bone-only dis, ↓ SREs &amp; ↑ OS</p>
<p class="tabh"><b class="calibre4">Misc:</b> <i class="calibre3">Homologous recombination-defic. tumors (BRCA1/2, ATM)</i>: olaparib; <i class="calibre3">MSI-H/Lynch synd.</i>: pembrolizumab; <i class="calibre3">Cancer vaccine</i>: Sipuleucel-T</p></td>
</tr>
</table>
<p class="tsr"><i class="calibre3">NEJM</i> 2010;363:411 &amp; 2013;368:138 &amp; 2013;369:213 &amp; 2014;371:424 &amp; 2015;373:737 &amp; 2015;373:1697 &amp; 2017;377:338 &amp; 352; 2018;378:1408; 2019;381:13; <i class="calibre3">Lancet</i> 2016;387:1163; <i class="calibre3">JCO</i> 2017; 35:2189.</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> PSA level, Gleason grade and age are predictors of metastatic disease</p>
<p class="bl"><span class="sbl">•</span> In surgically treated Pts, 5-y relapse-free survival &gt;90% if disease confined to organ, ~75% if extension through capsule, and ~40% if seminal vesicle invasion</p>
<p class="bl"><span class="sbl">•</span> Metastatic disease: median survival ~44–57 mo <span class="s">(<i class="calibre3">NEJM</i> 2015;373:737)</span></p>
<h2 class="ct"><a id="h77" class="calibre7"></a><a id="page_5-33" class="calibre7"></a><a href="part0002.html#rh85" class="calibre7">COLORECTAL CANCER (CRC)</a></h2>
<p class="h2a">Epidemiology and risk factors <span class="s">(<i class="calibre3">CA Cancer J Clin</i> 2018;68:7)</span></p>
<p class="bl"><span class="sbl">•</span> 4<sup class="calibre15">th</sup> most common cancer in U.S. men &amp; women; 2<sup class="calibre15">nd</sup> leading cause of all cancer death</p>
<p class="bl"><span class="sbl">•</span> 90% of cases occur after age 50. ~75% are sporadic.</p>
<p class="image1"><img src="../images/00103.jpeg" alt="" class="calibre2"/></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">COX-2</b> plays a role. ASA rec for 1° prevention if 50–59 y &amp; ≥10% 10-y CRC risk</p>
<p class="h2a">Screening <span class="s">(<i class="calibre3">NEJM</i> 2017;376:149)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Colonoscopy:</b> preferred; 90% Se for lesions &gt;1 cm. If polyp, re ✔ in 3–5 y. Removal of adenomatous polyps a/w lower CRC mortality <span class="s">(<i class="calibre3">NEJM</i> 2012;366:687)</span></p>
<p class="bl1"><i class="calibre3">Average-risk Pts</i>: start at age 50 &amp; repeat q10y preferred</p>
<p class="bl1">↑ <i class="calibre3">risk Pts</i>: ⊕ FHx: screen age 40 or 10 y before index dx, then q5y. IBD: 8–10 y after dx, then q1–2y. Suspect familial syndrome: gene counsel, screen 20–25 yo yearly.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Sigmoidoscopy:</b> benefit w/ 1-time flex-sig <span class="s">(<i class="calibre3">Lancet</i> 2017;389:1299)</span>; less Se than colo or CTC</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CT colonography (CTC):</b> ~90% Se for lesions ≥1 cm but less if smaller <span class="s">(<i class="calibre3">NEJM</i> 2008;359:1207)</span>. If high-risk, Se only 85% for neoplasia ≥6 mm <span class="s">(<i class="calibre3">JAMA</i> 2009;301:2453)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Occult blood</b> (FOBT): use 3-card home testing (Se 24%) yearly</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">DNA:</b> ↑ Se, ≈ Sp c/w FOBT but less Se than colonoscopy <span class="s">(<i class="calibre3">NEJM</i> 2004;351:2704)</span></p>
<p class="bl"><span class="sbl">•</span> Combo DNA + Hb immunoassay w/ ~90% Se &amp; Sp <span class="s">(<i class="calibre3">NEJM</i> 2014;370:1287)</span></p>
<p class="h2a">Pathology and genetics <span class="s">(<i class="calibre3">Cell</i> 1990;61:759; <i class="calibre3">Nature</i> 2014;513:382)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Adenoma:</b> ↑ risk of malig. if polyps &gt;2.5 cm, villous, or sessile. Adenomas typically observed ~10 y prior to onset of cancer (both sporadic &amp; familial).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Microsatellite stable (MSS) vs. high instability (MSI-H):</b> latter sign of mismatch repair gene failure, accounts for 15% CRC, presents more often as early stage, ~5% of met dis.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mutations:</b> <i class="calibre3">APC</i> (~80%); <i class="calibre3">KRAS</i> (~40%); <i class="calibre3">TP53</i> (50–70%); <i class="calibre3">DCC</i>, <i class="calibre3">SMAD4</i>, <i class="calibre3">BRAF</i> (~15%)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Distal colon: Δ <b class="calibre4">bowel habits</b>, <b class="calibre4">obstruction</b>, colicky abdominal pain, <b class="calibre4">hematochezia</b></p>
<p class="bl"><span class="sbl">•</span> Proximal colon: <b class="calibre4">iron defic. anemia</b>, dull vague abd pain, liquid stool</p>
<p class="bl"><span class="sbl">•</span> Associated with <i class="calibre3">Streptococcus bovis</i> bacteremia and <i class="calibre3">Clostridium septicum</i> sepsis</p>
<p class="h2a">Staging and treatment <span class="s">(<i class="calibre3">NCCN Clin Pract Guidelines</i>; version 1.2019)</span></p>
<p class="bl"><span class="sbl">•</span> TNM staging: <b class="calibre4">colonoscopy</b> + <b class="calibre4">biopsy/polypectomy</b> + <b class="calibre4">intraoperative</b> + <b class="calibre4">pathologic</b></p>
<p class="bl"><span class="sbl">•</span> CT scans of chest and abdomen/pelvis for mets</p>
<p class="bl"><span class="sbl">•</span> Baseline <b class="calibre4">CEA</b>: monitor post resection or follow response; <i class="calibre3">not</i> for screening</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chemo options</b> <span class="s">(<i class="calibre3">Lancet</i> 2014;383:1490)</span>: 5FU/ &amp; leucovorin (LV) foundation. 5FU/LV + oxaliplatin &amp;/or irinotecan (FOLFOX, FOLFIRI, FOLFOXIRI, resp). Capecitabine oral 5FU prodrug. TAS102 (trifluridine + tipiracil) in progressive disease <span class="s">(<i class="calibre3">NEJM</i> 2015;372:1909)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biologics:</b> <i class="calibre3">anti-VEGF</i> (bevacizumab) added to chemo ↑ OS in all subsets of mCRC; <i class="calibre3">anti-EGFR mAb</i> (cetuximab or panitumumab) only in unmutated KRAS/NRAS/BRAF <span class="s">(<i class="calibre3">NEJM</i> 2013;369:1023)</span>; <i class="calibre3">multikinase inhibitor</i> (regorafenib) generally in chemo (&amp; biologic) refractory setting <span class="s">(<i class="calibre3">Lancet</i> 2013;381:303)</span>; anti PD-1 &amp; PD-1 + CTLA-4 in MSI-H met CRC.</p>
<p class="image1"><img src="../images/00104.jpeg" alt="" class="calibre2"/></p>
<h2 class="ct"><a id="h78" class="calibre7"></a><a id="page_5-34" class="calibre7"></a><a href="part0002.html#rh86" class="calibre7">PANCREATIC TUMORS</a></h2>
<p class="h2a">Genetics and path <span class="s">(<i class="calibre3">Nat Rev Dis Primers</i> 2016;2:16022)</span></p>
<p class="bl"><span class="sbl">•</span> Histologic types: <b class="calibre4">adenocarcinoma</b> (~85%), acinar cell carcinoma, endocrine tumors, cystic neoplasms (&lt;10%); rarely, mets to pancreas (eg, lung, breast, renal cell)</p>
<p class="bl"><span class="sbl">•</span> Location: ~60% in head, 15% in body, 5% in tail; in 20% diffuse infiltration of pancreas</p>
<p class="bl"><span class="sbl">•</span> Mutations in adenoca.: <i class="calibre3">KRAS</i> (&gt;90%), <i class="calibre3">p16</i> (80–95%), <i class="calibre3">p53</i> (50–75%), <i class="calibre3">SMAD4</i> (~55%)</p>
<p class="h2a">Epidemiology and risk factors <span class="s">(<i class="calibre3">Lancet</i> 2016;388:73)</span></p>
<p class="bl"><span class="sbl">•</span> 4<sup class="calibre15">th</sup> leading cause of cancer death in U.S.; 80% panc adeno in ages 60–80 y; M&gt;F (1.3:1)</p>
<p class="bl"><span class="sbl">•</span> Acquired risk factors: <b class="calibre4">smoking</b> (RR ~1.5; 25% cases), obesity, chronic pancreatitis, T2DM</p>
<p class="bl"><span class="sbl">•</span> Hereditary (5–10%): familial breast/ovarian CA (<i class="calibre3">BRCA2</i>); <i class="calibre3">hereditary chronic pancreatitis</i> (mutation in cationic trypsinogen gene (<i class="calibre3">PRSS1</i>, <i class="calibre3">SPINK1</i>); <i class="calibre3">familial cancer syndromes:</i> atypical multiple mole melanoma (<i class="calibre3">CDKN2A/p16</i>), Peutz-Jeghers (<i class="calibre3">LKB1</i>), ataxia-telang.</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Painless jaundice</b> (w/ pancreatic head mass), <b class="calibre4">pain</b> radiating to back, ↓ <b class="calibre4">weight</b> &amp; appetite</p>
<p class="bl"><span class="sbl">•</span> New-onset atypical DM (25%); migratory thrombophlebitis (Trousseau’s syndrome)</p>
<p class="bl"><span class="sbl">•</span> Exam: RUQ/epigastric nontender mass, palpable gallbladder (Courvoisier’s sign); hepatomegaly; ascites; L supraclav. node (Virchow’s) &amp; palpable rectal shelf (non-spec.)</p>
<p class="bl"><span class="sbl">•</span> Laboratory tests may show ↑ bilirubin, ↑ alk phos, anemia</p>
<p class="h2a">Diagnostic and staging evaluation <span class="s">(<i class="calibre3">NCCN Guidelines</i> v.1.2019)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pancreatic protocol CT scan</b> (I<sup class="calibre15">+</sup> w/ arterial &amp; venous phase imaging) or <b class="calibre4">MRI w/ contrast</b></p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">If no lesion seen</i> → EUS, ERCP, or MRCP</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biopsy pancreatic lesion</b> via EUS-guided FNA (preferred in potential surgical candidates) or CT-guided (potential risk of seeding) or biopsy of possible metastasis</p>
<p class="bl"><span class="sbl">•</span> ✔ <b class="calibre4">CA19-9</b> preop (nb, can be ↑ in benign liver/biliary dis.); may be useful to trend postop</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre10"/>
<col class="calibre11"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Clinical (Radiologic) Staging Non-Metastatic Panc Adenoca (~40% of cases)</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Resectable</b></p></td>
<td class="bg0-b"><p class="tab">No extrapanc dis. or bulky LAN; no <b class="calibre4">arterial</b> tumor contact [celiac axis (CA), SMA, common hepatic (CHA)]; and no <b class="calibre4">venous</b> contact [SMV, portal vein (PV)] or ≤180<b class="calibre4">°</b> + patent veins (ie, no tumor thrombus)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Borderline resectable</b></p></td>
<td class="bg0-b"><p class="tab">No extrapanc dis. or bulky LAN. <b class="calibre4">Head/uncinate:</b> contact w/ CHA (no extension to CA or HA bifurcation), SMA contact ≤180<b class="calibre4">°</b>, variant anatomy.</p>
<p class="tab"><b class="calibre4">Body/tail:</b> contact CA ≤180<b class="calibre4">°</b> or &gt;180<b class="calibre4">°</b> but w/o gastro-duodenal art. or aortic. <b class="calibre4">Venous:</b> SMV &amp; PV contact ≤180<b class="calibre4">°</b> w/ contour irreg; contact w/ IVC.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Unresect.</b></p></td>
<td class="bg"><p class="tab"><b class="calibre4">Distant mets</b>; or <b class="calibre4">head/uncinate:</b> contact &gt;180<b class="calibre4">°</b> SMA, CA; or <b class="calibre4">Body/tail:</b> contact &gt;180<b class="calibre4">°</b> SMA or CA; CA &amp; aortic involvement; or</p>
<p class="tab"><b class="calibre4">Venous:</b> SMV/PV involvement/not reconstructible</p></td>
</tr>
</table>
<p class="h2a">Treatment of pancreatic adenocarcinoma <span class="s">(<i class="calibre3">Lancet</i> 2016;388:73)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Resectable:</b> pancreaticoduodenectomy (<b class="calibre4">Whipple procedure</b>) + adjuvant chemo:</p>
<p class="bl1">modified FOLFIRINOX (5-FU + leucovorin, irinotecan, oxaliplatin) if ECOG 0-1 <span class="s">(<i class="calibre3">NEJM</i> 2018;379:2395)</span>, o/w gemcitabine + capecitabine <span class="s">(<i class="calibre3">Lancet</i> 2017;389:1011)</span>. Gemcitabine monoRx used to be recent standard, but now w/ ↓ role. Role of RT is controversial.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Borderline:</b> goal to ↓ tumor to allow complete resection (R0 – neg margin at histology) using neoadjuvant Rx (various approaches tested). General schema: <b class="calibre4">chemo</b> ± <b class="calibre4">RT</b> → <b class="calibre4">restage &amp; potential resection</b> depending on response<b class="calibre4">.</b> May need vasc. reconstruction during resection. Regimens include: FOLFIRINOX; gemcitabine + nab-paclitaxel.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Locally advanced</b> (ie, unresectable): Rx is typically palliative. However, in highly select Pts recent trend toward Rx w/ FOLFIRINOX plus XRT followed by laparotomy for response assessment (imaging can be unreliable) and potential resection.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Metastatic:</b> <i class="calibre3">clinical trials preferred;</i> Rx based on performance status (PS)</p>
<p class="bl1"><i class="calibre3">Good PS:</i> <b class="calibre4">FOLFIRINOX</b> (± olaparib); <b class="calibre4">gemcita.</b> + nab-paclitaxel <span class="s">(<i class="calibre3">NEJM</i> 2013;369:1691)</span></p>
<p class="bl1"><i class="calibre3">Poor PS:</i> gemcitabine; capecitabine; continuous infusion 5-FU</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Palliative and supportive care</b></p>
<p class="bl1">obstructive jaundice or gastric outlet obstruction: endoscopic stenting or surgical bypass</p>
<p class="bl1">pain: opiates, celiac plexus neurolysis, XRT; wt loss: enzyme replacement, nutrition c/s</p>
<p class="h2a"><b class="calibre4">Prognosis</b></p>
<p class="bl"><span class="sbl">•</span> Resectable: if Rx’d w/ adjuvant FOLFIRINOX, 50+ mos, o/w ~30 mos</p>
<p class="bl"><span class="sbl">•</span> Unresectable: if locally advanced ~1–2 y; if metastatic, ~1 y</p>
<p class="h2a">Cystic lesions of the pancreas <span class="s">(<i class="calibre3">NEJM</i> 2004;351:1218; <i class="calibre3">Oncologist</i> 2009;14:125)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Serous cystadenoma:</b> usually benign; central scar or honeycomb appearance on imaging</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mucinous cystic neoplasm</b> (MCN): predominantly young females; multiloculated tumors in body or tail w/ ovarian-type stroma and mucin-rich fluid w/ ↑ CEA levels; precancerous</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Intraductal papillary mucinous neoplasm</b> (IPMN): arises in main panc duct or branch → ductal dilation; ? prog to CA (5–20 y); surgery based on age, size, location, dysplasia</p>
<h2 class="ct"><a id="h79" class="calibre7"></a><a id="page_5-35" class="calibre7"></a><a href="part0002.html#rh87" class="calibre7">HEPATOCELLULAR CARCINOMA (HCC)</a></h2>
<p class="h2a">Risk factors <span class="s">(globally, 3<sup class="calibre35">rd</sup> leading cause of cancer death, espec. in Africa &amp; Asia)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cirrhosis:</b> present in 70–90% HCC cases</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Infectious:</b> HCV &amp; HBV (~75%), HBV/HDV coinfection; HBV can cause HCC w/o cirrhosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Toxic:</b> EtOH (⅓ cases in U.S.), tobacco, aflatoxin from Aspergillus</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Metabolic disorders:</b> NASH, DM, autoimmune hepatitis, hemochromatosis</p>
<p class="h2a">Screening <span class="s">(screen Pts w/ cirrhosis, chronic HBV or HCV infection)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ultrasonography</b> (U/S) + AFP q 6 mos; if high-risk may alternate U/S w/ <b class="calibre4">MRI</b></p>
<p class="bl"><span class="sbl">•</span> If lesion found or increasing AFP, perform <b class="calibre4">3-phase contrast CT or MRI</b></p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> At least <b class="calibre4">3-phase contrast-enhanced CT</b> or <b class="calibre4">MRI</b>; no biopsy or PET required for HCC dx</p>
<p class="bl"><span class="sbl">•</span> Of note, only 15% of liver masses are HCC; metastatic dis. from other 1° more common</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Exam: nonspecific, c/w liver dysfxn (eg, hepatomegaly, ascites, jaundice, encephalopathy)</p>
<p class="bl"><span class="sbl">•</span> Labs: as above, c/w liver dysfunction (eg, coagulopathy, low albumin, elevated LFTs)</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2019;380:1450)</span></p>
<p class="bl"><span class="sbl">•</span> If localized disease, goal is cure</p>
<p class="bl1"><b class="calibre4">Resection:</b> typically ablation of HCC; surgery generally only considered for solitary lesions in Pts w/ preserved liver fxn &amp; adequate postop liver volume</p>
<p class="bl1"><b class="calibre4">Liver transplant:</b> 1 lesion ≤5 cm or 3 lesions ≤3 cm, no vasc invasion or mets</p>
<p class="bl"><span class="sbl">•</span> Palliative</p>
<p class="bl1"><b class="calibre4">Transarterial embolization</b> (TAE), ± chemo (TACE) or radioembolization</p>
<p class="bl1"><b class="calibre4">Systemic therapy:</b> kinase inhibitors (lenvatinib, sorafenib), PD-1 inhib (nivolumab) ä OS in advanced HCC <span class="s">(<i class="calibre3">Lancet</i> 2017;389:2492 &amp; 2018;391:1163)</span></p>
<h2 class="ct"><a id="h80" class="calibre7"></a><a href="part0002.html#rh88" class="calibre7">ONCOLOGIC EMERGENCIES</a></h2>
<p class="h">F<small class="calibre30">EVER AND</small> N<small class="calibre30">EUTROPENIA</small> (FN) <span class="s1">(<i class="calibre22">NCCN Guidelines</i> v.1.2019)</span></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Fever: single oral temp ≥38.3°C (101°F) or ≥38°C (100.4°F) for ≥1 h</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neutropenia:</b> ANC &lt;500 cells/µL or &lt;1000 cells/µL with predicted nadir &lt;500 cells/µL</p>
<p class="h2a">Pathophysiology and microbiology</p>
<p class="bl"><span class="sbl">•</span> Predisposing factors: catheters, skin breakdown, GI mucositis, obstruction (lymphatics, biliary tract, GI, urinary tract), immune defect associated with malignancy</p>
<p class="bl"><span class="sbl">•</span> Most episodes thought to result from seeding of bloodstream by GI flora</p>
<p class="bl"><span class="sbl">•</span> Neutropenic enterocolitis (typhlitis): RLQ pain, watery/bloody diarrhea, cecal wall thickening</p>
<p class="bl"><span class="sbl">•</span> GNRs (esp. <i class="calibre3">P. aeruginosa</i>) were historically most common</p>
<p class="bl"><span class="sbl">•</span> Gram ⊕ infections have recently become more common (60–70% of identified organisms)</p>
<p class="bl"><span class="sbl">•</span> Fungal superinfection often results from prolonged neutropenia &amp; antibiotic use</p>
<p class="h2a">Prevention <span class="s">(only if intermediate or high-risk)</span></p>
<p class="bl"><span class="sbl">•</span> Bacterial: consider fluoroquinolone if neutropenic; no mortality Δ <span class="s1r">(<i class="calibre3">NEJM</i> 2005;353:977 &amp; 988)</span></p>
<p class="bl"><span class="sbl">•</span> Fungal: consider during neutropenia in blood cancers (posa/fluconazole, micafungin)</p>
<p class="bl"><span class="sbl">•</span> Viral: consider during active Rx in blood cancers (acyclovir, famciclovir, valacyclovir)</p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> Exam: skin, oropharynx, lung, perirectal area, surgical &amp; catheter sites; avoid DRE</p>
<p class="bl"><span class="sbl">•</span> Labs: CBC with differential, electrolytes, BUN/Cr, LFTs, U/A</p>
<p class="bl"><span class="sbl">•</span> Micro: blood (peripheral &amp; through each indwelling catheter port), urine, &amp; sputum cx; for localizing s/s → ✔ stool (<i class="calibre3">C. difficile</i>, cx), peritoneal fluid, CSF (rare source)</p>
<p class="bl"><span class="sbl">•</span> Imaging: CXR; for localizing s/s → CNS, sinus, chest or abdomen/pelvis imaging</p>
<p class="bl"><span class="sbl">•</span> Caveats: neutropenia → impaired inflammatory response → <i class="calibre3">exam and radiographic findings may be subtle;</i> absence of neutrophils by Gram stain does <i class="calibre3">not</i> r/o infection</p>
<p class="h2a">Risk stratification <span class="s">(factors that predict lower risk)</span></p>
<p class="bl"><span class="sbl">•</span> History: outPt, ECOG 0-1, age &lt;60 y, solid tumor, no sx, no major comorbidities, no h/o fungal infection, MASCC Risk Index ≥21 <span class="s1r">(<i class="calibre3">Support Care Cancer</i> 2013;21:1487)</span></p>
<p class="bl"><span class="sbl">•</span> Exam: temp &lt;39 °C, no tachypnea, no HoTN, no Δ MS, no dehydration</p>
<p class="bl"><span class="sbl">•</span> Labs: ANC &gt;100 cells/µL, anticipated duration of neutropenia ≤100 cells/µL &lt;7 d</p>
<p class="h2a">Initial antibiotic therapy <span class="s">(<i class="calibre3">NCCN Guidelines</i> v.1.2019)</span></p>
<p class="bl"><span class="sbl">•</span> Empiric regimens should include <b class="calibre4">antipseudomonal activity;</b> consider VRE coverage if ⊕</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Low risk:</b> PO abx or home IV abx may be considered in select Pts;</p>
<p class="bl1">PO options: cipro+amoxicillin-clavulanate; levofloxacin; moxifloxacin (avoid if FQ ppx)</p>
<p class="bl"><a id="page_5-36" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">High risk: hospital admission &amp; IV abx;</b> monotherapy preferred</p>
<p class="bl1">options: cefepime, imipenem, meropenem, piperacillin/tazobactam, ceftazidime</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Vancomycin</b> if HoTN, PNA, clinically apparent catheter-related or soft-tissue infxn, gram ⊕ BCx, mucositis on quinolone ppx &amp; ceftazidime for viridans strep; d/c when BCx ⊖ × 48 h</p>
<p class="h2a">Modification to initial antibiotic regimen based on site-specific evaluation</p>
<p class="bl"><span class="sbl">•</span> Mouth/esophageal (ulcer, thrush): consider anaerobic, anti-HSV and/or antifungal Rx</p>
<p class="bl"><span class="sbl">•</span> Sinus/nasal: add vanc if periorbital cellulitis, ampho if concern for Aspergillus/Mucor</p>
<p class="bl"><span class="sbl">•</span> Abd pain/diarrhea: PO vanc if concern for <i class="calibre3">C. diff</i>; ensure adequate anaerobic coverage</p>
<p class="bl"><span class="sbl">•</span> Lung infiltrates: consider atypical coverage; vanc/linezolid if c/f MRSA; TMP/SMX if c/f PCP</p>
<p class="bl"><span class="sbl">•</span> CNS: ID consult; empiric meningitis Rx (incl. <i class="calibre3">Listeria</i>), high-dose acyclovir for encephalitis</p>
<p class="bl"><span class="sbl">•</span> Antifungal Rx added for neutropenic fever ≥5 d despite abx. Liposomal amphotericin B, caspofungin, micafungin, anidulafungin, voriconazole, &amp; posaconazole are options.</p>
<p class="h2a">Duration of therapy</p>
<p class="bl"><span class="sbl">•</span> Known source: complete standard course (eg, 14 d for bacteremia)</p>
<p class="bl"><span class="sbl">•</span> Unknown source: continue antibiotics until afebrile <i class="calibre3">and</i> ANC &gt;500 cells/µL</p>
<p class="bl"><span class="sbl">•</span> Less clear when to d/c abx when Pt is afebrile but prolonged neutropenia</p>
<p class="h2a">Role of hematopoietic growth factors <span class="s">(<i class="calibre3">NCCN Guidelines</i> 2.2018)</span></p>
<p class="bl"><span class="sbl">•</span> Granulocyte (G-CSF) and granulocyte-macrophage (GM-CSF) colony-stimulating factors can be used as 1° prophylaxis when expected FN incidence &gt;20% or as 2° prophylaxis after FN has occurred in a previous cycle (to maintain dose-intensity for curable tumors). CSFs ↓ rate of FN but have not been shown to affect mortality <span class="s1r">(<i class="calibre3">Cochrane</i> 2014 CD003039)</span>.</p>
<p class="bl"><span class="sbl">•</span> Colony-stimulating factors can be considered as adjuvant therapy in high-risk FN Pts</p>
<p class="h">S<small class="calibre30">PINAL</small> C<small class="calibre30">ORD</small> C<small class="calibre30">OMPRESSION</small></p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet Neuro</i> 2008;7:459)</span></p>
<p class="bl"><span class="sbl">•</span> Metastases located in vertebral body extend and cause epidural spinal cord compression</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prostate</b>, <b class="calibre4">breast</b>, and <b class="calibre4">lung</b> cancers are most common, followed by RCC, NHL, myeloma</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Site of involvement: thoracic</b> (60%), lumbar (25%), cervical (15%)</p>
<p class="bl"><span class="sbl">•</span> Signs and symptoms: <b class="calibre4">pain</b> (&gt;95%, <i class="calibre3">precedes neuro</i> Δ<i class="calibre3">s</i>), <b class="calibre4">weakness</b>, <b class="calibre4">autonomic dysfunction</b> (urinary retention, ↓ anal sphincter tone), <b class="calibre4">sensory loss</b></p>
<p class="h2a">Diagnostic evaluation</p>
<p class="bl"><span class="sbl">•</span> Always take back pain in Pts with solid tumors very seriously</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Do <i class="calibre3">not</i> wait for neurologic signs to develop</b> before initiating evaluation b/c duration &amp; severity of neuro dysfunction before treatment are best predictors of neurologic outcome</p>
<p class="bl"><span class="sbl">•</span> Urgent <b class="calibre4">whole-spine MRI</b> (Se 93%, Sp 97%); CT if unable to get MRI</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2017;376:1358)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dexamethasone</b> (10 mg IV × 1 stat, then 4 mg IV or PO q6h)</p>
<p class="bl1"><i class="calibre3">initiate immediately</i> while awaiting imaging if back pain + neurologic deficits</p>
<p class="bl"><span class="sbl">•</span> Emergent RT or surgical decompression if confirmed compression/neuro deficits</p>
<p class="bl"><span class="sbl">•</span> Surgery + RT superior to RT alone for neuro recovery in solid tumors <span class="s1r">(<i class="calibre3">Lancet</i> 2005;366:643)</span></p>
<p class="bl"><span class="sbl">•</span> If pathologic fracture causing compression → surgery; if not surgical candidate → RT</p>
<p class="h">T<small class="calibre30">UMOR</small> L<small class="calibre30">YSIS</small> S<small class="calibre30">YNDROME</small></p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">NEJM</i> 2011;364:1844)</span></p>
<p class="bl"><span class="sbl">•</span> Large tumor burden or a rapidly proliferating tumor → spontaneous or chemotherapy-induced release of intracellular electrolytes and nucleic acids</p>
<p class="bl"><span class="sbl">•</span> Most common w/ treatment of high-grade lymphomas (<b class="calibre4">Burkitt’s</b>) and leukemias (<b class="calibre4">ALL</b>, <b class="calibre4">AML</b>, <b class="calibre4">CML in blast crisis</b>); rare with solid tumors; rarely due to spontaneous necrosis</p>
<p class="bl"><span class="sbl">•</span> Electrolyte abnormalities: ↑ K, ↑ uric acid, ↑ PO<sub class="calibre8">4</sub> → ↓ Ca; <b class="calibre4">renal failure</b> (urate nephropathy)</p>
<p class="h2a">Prophylaxis</p>
<p class="bl"><span class="sbl">•</span> Allopurinol 300 mg qd to bid PO or 200–400 mg/m<sup class="calibre15">2</sup> IV (adjusted for renal fxn) &amp; aggressive hydration prior to beginning chemotherapy or RT</p>
<p class="bl"><span class="sbl">•</span> Rasburicase (recombinant urate oxidase) 0.15 mg/kg or 6-mg fixed dose (except in obese Pts) &amp; aggressive hydration prior to beginning chemotherapy or RT (see below)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Avoid</i> IV contrast and NSAIDs; treat hyperK, hyperphos, and symptomatic hypocalcemia</p>
<p class="bl"><span class="sbl">•</span> Allopurinol + aggressive IV hydration ± diuretics to ↑ UOP for goal 80–100 cc/h</p>
<p class="bl"><span class="sbl">•</span> Consider alkalinization of urine w/ isotonic NaHCO<sub class="calibre8">3</sub> to ↑ UA solubility, ↓ urate nephropathy risk (controversial: avoid w/ rasburicase; may cause met. alkalosis or Ca<sub class="calibre8">3</sub>(PO4)<sub class="calibre8">2</sub> precip.)</p>
<p class="bl"><span class="sbl">•</span> Rasburicase (0.1–0.2 mg/kg) for ↑↑ uric acid esp. in aggressive malig <span class="s1r">(<i class="calibre3">JCO</i> 2003;21:4402; <i class="calibre3">Acta Haematol</i> 2006;115:35)</span>. <b class="calibre4"><i class="calibre3">Avoid in G6PD deficiency</i></b> b/c causes hemolytic anemia. Consider G6PD testing in Jehovah’s witnesses espec. if African American (12% prevalence).</p>
<p class="bl"><span class="sbl">•</span> Hemodialysis may be necessary; early renal consultation for renal insufficiency or ARF</p>
<h2 class="ct"><a id="h81" class="calibre7"></a><a id="page_5-37" class="calibre7"></a><a href="part0002.html#rh89" class="calibre7">CHEMO AND IMMUNORX SIDE EFFECTS</a></h2>
<p class="cst"><i class="calibre3">Nausea &amp; vomiting common</i> <span class="s1r">(<i class="calibre3">NEJM</i> 2016;374:1356; 375:134 &amp; 177)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre16"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">Select Adverse Effects from Chemotherapy</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">Toxicity</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Common Agents</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Comments</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="6"><p class="tabc"><b class="calibre4">Cardiotoxicity</b></p>
<p class="tabc"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">NEJM</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">6;375;</span><span class="tfont">1</span><span class="tfont1">457)</span></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Anthracyclines</b></p></td>
<td class="bg0-b"><p class="tab">Dose-dependent CMP; ✔ EF pre-Rx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">5-FU</p></td>
<td class="bg0-b"><p class="tab">Spasm → ischemia; CCB may prevent</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Trastuzumab</b></p></td>
<td class="bg0-b"><p class="tab">CMP, esp w/ anthracycline, ✔ EF pre-Rx</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Tyrosine kinase inhib (TKI)</p></td>
<td class="bg0-b"><p class="tab">QTc prolongation, CMP, angina</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Cyclophosphamide</p></td>
<td class="bg0-b"><p class="tab">Myopericarditis (esp. in BMT)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Cisplatin</p></td>
<td class="bg0-b"><p class="tab">HypoMg → arrhythmia, ischemia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="5"><p class="tabc"><b class="calibre4">Pulmonary</b></p>
<p class="tabc"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Sem Oncol</i></span> <span class="tfont1">2006;33:98)</span></p></td>
<td class="bg0-br"><p class="tab">Busulfan</p></td>
<td class="bg0-b"><p class="tab">~8% fibrosis or DAH; if severe → steroids</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Bleomycin</b></p></td>
<td class="bg0-b"><p class="tab">~10% IPF; d/c drug, Rx: steroids</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">TKI (esp. dasatinib)</p></td>
<td class="bg0-b"><p class="tab">Pleural effusion</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Cyclophosphamide</p></td>
<td class="bg0-b"><p class="tab">Pneumonitis, progressive fibrosis; Rx: d/c</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Bevacizumab</b></p></td>
<td class="bg0-b"><p class="tab">Pulm hemorrhage (esp. NSCLC)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="3"><p class="tabc"><b class="calibre4">Nephrotoxicity/ urologic toxicity</b></p></td>
<td class="bg0-br"><p class="tab">Platinum Rx (<b class="calibre4">cisplatin</b>)</p></td>
<td class="bg0-b"><p class="tab">Esp. proximal tubule; pretreat w/ IV saline</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Methotrexate</p></td>
<td class="bg0-b"><p class="tab">Via deposition; Rx: alkalinize urine, IVF</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Cyclophosphamide</p></td>
<td class="bg0-b"><p class="tab">Hemorrhagic cystitis; Rx: Mesna</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="5"><p class="tabc"><b class="calibre4">Neurotoxicity</b></p>
<p class="tabc"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Sem Oncol</i></span> <span class="tfont1">2006;33:324)</span></p></td>
<td class="bg0-br"><p class="tab">Platinum Rx (<b class="calibre4">cisplatin</b>)</p></td>
<td class="bg0-b"><p class="tab">“Stocking-glove;” Ppx: vit E <span class="tfont">(</span><span class="tfont"><i class="calibre3">JCO</i></span> <span class="tfont">2003;2</span><span class="tfont">1</span><span class="tfont">:927)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Cytarabine</b></p></td>
<td class="bg0-b"><p class="tab">Cerebellar toxicity (irreversible 5–10%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Methotrexate (esp. intrathecal)</p></td>
<td class="bg0-b"><p class="tab">Late leukoenceph, meningitis; reverse w/ intrathecal glucarpidase, leucovorin</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Ifosfamide</p></td>
<td class="bg0-b"><p class="tab">Enceph; Rx: methylene blue, thiamine</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab"><b class="calibre4">Taxanes, vincristine</b></p></td>
<td class="bg0-b"><p class="tab">Sensorimotor long fiber neuropathy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2" rowspan="3"><p class="tabc"><b class="calibre4">Hepatotoxicity</b></p>
<p class="tabc"><span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Sem Oncol</i></span> <span class="tfont1">2006;33:50)</span></p></td>
<td class="bg0-br"><p class="tab">TKI (eg, imatinib, nilotinib)</p></td>
<td class="bg0-b"><p class="tab">↑ LFTs, rarely necrosis; Rx: d/c ± steroids</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Gemcitabine</p></td>
<td class="bg0-b"><p class="tab">Common ↑ ALT/AST; ↓ dose if ↑ bili</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tab">Methotrexate</p></td>
<td class="bg0-b"><p class="tab">↑ ALT/AST, rarely fibrosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tabc"><b class="calibre4">Dermatologic</b></p></td>
<td class="bg0-r"><p class="tab">TKI (eg, imatinib)</p></td>
<td class="bg"><p class="tab">Dermatitis, can be severe (eg SJS)</p></td>
</tr>
</table>
<p class="h2a">Immune checkpoint inhibitors <span class="s">(<i class="calibre3">ICI; Science</i> 2018;359:1350)</span></p>
<p class="bl"><span class="sbl">•</span> mAb against co-inhibitory signaling molecules, which cancers can use to prevent antitumor immunity</p>
<p class="bl"><span class="sbl">•</span> Targets &amp; drugs include</p>
<p class="bl1">Programmed cell death protein 1 (PD-1; T &amp; pro-B cells): nivolumab, pembrolizumab</p>
<p class="bl1">Prog. death-ligand 1 (PD-L1; tumor &amp; immune cells): atezolizumab, avelumab, durvalumab</p>
<p class="bl1">Cytotoxic T-lymphocyte-assoc. protein 4 (CTLA-4; T cells): ipilimumab</p>
<p class="bl"><span class="sbl">•</span> Toxicity <span class="s1r">(<i class="calibre3">NEJM</i> 2018; 378:158)</span>: increased w/ combination of CTLA-4 + PD-1/PD-L1</p>
<p class="bl1">Most commonly <b class="calibre4">colitis</b> (CTLA-4), <b class="calibre4">pneumonitis</b> (PD-1/PD-L1), <b class="calibre4">hepatitis</b> (CTLA-4), <b class="calibre4">dermatitis</b>, <b class="calibre4">hypothyroidism</b> (PD-1) / <b class="calibre4">hypophysitis</b> (CTLA-4)</p>
<p class="bl1">Rarely: myocarditis (can be fulminant), myositis, myelitis, uveitis, diabetes</p>
<p class="bl"><span class="sbl">•</span> Treatment: <i class="calibre3">multidisciplinary care</i>; hold ICI; give steroids, r/o infection. If severe, consider TNF-α inhibitor for colitis, mycophenolic acid for hepatitis, hormones for endocrinopathy</p>
<p class="h2a">Chimeric antigen receptor (CAR)-T cells <span class="s">(<i class="calibre3">Science</i> 2018;359:1350)</span></p>
<p class="bl"><span class="sbl">•</span> Autologous T cells w/ modified/chimeric receptor for Ag recognition and T cell activation w/o MHC or 2<sup class="calibre15">nd</sup> co-stim signal.</p>
<p class="bl"><span class="sbl">•</span> CD19 CAR-T cells targeting B-cell malig. most developed: tisagenlecleucel, axicabtagene ciloleucel</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre27"/>
<col class="calibre17"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabc"><b class="calibre4">CAR- T Toxicity</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Syndrome</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Mechanism &amp; Manifestations</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Treatment</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Cytokine release syndrome (CRS)</p></td>
<td class="bg0-br"><p class="tab">Due to proliferating CAR-T. Fevers to shock.</p></td>
<td class="bg0-b"><p class="tab">Anti-IL-6 (tocilizumab or siltuximab) + steroids if severe</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">CAR-T-cell-related encephalopathy syndrome (CRES)</p></td>
<td class="bg0-br"><p class="tab">Cerebral edema due to CAR-T in CNS. Delirium, aphasia, seizures, or death.</p></td>
<td class="bg0-b"><p class="tab">Steroids, ativan/keppra for seizures.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Hemophagocytic lymphohistiocytosis (HLH)</p></td>
<td class="bg0-r"><p class="tab">Rare hyper-inflammation. Ferritin &gt;10k &amp; liver/kidney/lung toxicity.</p></td>
<td class="bg"><p class="tab">CRS Rx, etoposide ± intrathecal cytarabine if not improving <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">Nat Rev Clin Onc</i></span> <span class="tfont1">20</span><span class="tfont">1</span><span class="tfont1">8;</span><span class="tfont">1</span><span class="tfont1">5:47)</span></p></td>
</tr>
</table>
<h2 class="ct"><a id="page_5-38" class="calibre7"></a>NOTES</h2>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0009.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0011.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
